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General Introduction
Congenital heart disease (CHD) has become a leading cause of neonatal
death since improved perinatal care has minimized other causes of neona-
tal mortality.1 In an effort to improve the outcome of the treatment of
these patients prenatal diagnosis of heart disease plays an increasing role.
Until the nineteen eighties physicians were confronted with undiagnosed
newborns with CHD. These neonates were often severely ill and in need of
urgent care. The development of sophisticated ultrasound equipment allo-
wed that situation to change. The first description by Wang and Xiao
almost 40 years ago formed the start of the development of fetal echocar-
diography.2
Initially, the discussion on fetal echocardiography was focused on the safe-
ty of the use of ultrasound before birth but this issue has gradually subsi-
ded. Ultrasound for clinical diagnosis uses sound waves of high frequency
(2 to 10 mHz) and low energy, and has proven to be harmless to human tis-
sues.3 In the meantime the image quality has improved dramatically and
the current generation of ultrasound equipment used for fetal echocardio-
graphy allows physicians to detect the majority of congenital heart anoma-
lies during fetal life. This provides an accurate definition of the fetal car-
diac structures as early as 16 weeks gestation.
Screening of the fetal heart has focused on the four-chamber view.
Identification of this view is relatively easy and 80% of patients with CHD
show abnormalities in the four-chamber view.4 Abnormal findings in this
view should initiate a thorough assessment by a specialized team of physi-
cians, since the four-chamber view by itself, is not sufficient to detect all
possible cardiac and associated abnormalities. A comprehensive cardiovas-
cular examination should therefore entail a segmental assessment of the
arrangement of the thoraco-abdominal organs and the entire fetal heart
and great vessels. Besides the four-chamber view, this evaluation of the
fetal heart should include views of the right and left ventricular outflow
tracts, the three-vessel view and the aortic arch view. The additional use of
M-mode and Doppler ultrasound extends the diagnostic yield beyond
morphological forms of fetal heart diseases. This allows the evaluation of
functional anomalies, such as arrhythmias and heart failure.
Prenatal diagnosis of a structural cardiac anomaly may yield important
consequences for the management of both mother and fetus. It requires
extensive counseling for the parents of the possible options, effects and
risks of the potential strategies. Once these implications are outlined and
understood a multi-disciplinary team including the obstetrician/perinato-
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logist, neonatologist, pediatric cardiologist and cardiac surgeon should be
involved in the elected management strategy. The broad spectrum of speci-
fic expertise of the participating physicians allows the team to provide
comprehensive parental counseling and planning of the pre- and postnatal
management of the patient.
It is very important to realize that despite all efforts to achieve the contra-
ry, a significant number of pregnancies may end in spontaneous intrauteri-
ne death. Furthermore the presence of incurable heart disease, or heart
disease which can preclude a reasonable quality of life for the patient, may
lead parents to opt for termination of pregnancy.
The most significant salutary effect of a prenatal diagnosis of congenital
heart malformations however is situated in those patients requiring imme-
diate surgical intervention postnatally. In these cases a prenatal diagnosis
of congenital heart disease should optimize perinatal care, guaranteeing
the best possible preoperative condition of the newborn patient by preven-
tion of postnatal deterioration. To achieve this goal, prenatal detection of
heart disease should result in a planned delivery in a tertiary level perina-
tal and cardiac center. In these centers rapid sequence of life sustaining
interventions are available. The importance of this strategy is that the
majority of the prenatally diagnosed severe forms of congenital heart
disease are dependent on a patent ductus arteriosus to guarantee the
maintenance of an adequate circulation and oxygen transport. During fetal
life the ductus arteriosus is a large channel with a diameter similar to that
of the descending aorta. Patency of the ductus in utero is maintained by
prostaglandins from the utero-placental site. The ductus arteriosus con-
stricts rapidly after birth and in most mature infants is functionally closed
within 10 to 15 hours. This mechanism is life threatening for the ductal-
dependent forms of congenital heart disease and these patients therefore
benefit from a timely infusion of prostaglandin E1 to maintain ductal
patency.5 Respiratory suppression however is an important side effect of
the administration of prostaglandin E1 and its therapeutic use frequently
provokes the need for immediate intubation and initiation of ventilatory
support in these patients.
Preoperative care is aimed at the maintenance of an adequate circulation
to facilitate oxygen transport, resulting in sufficient blood gas control and
prevention of acidosis. The importance of avoidance of severe metabolic
acidosis to prevent brain damage has been suggested in previous reports.6,7
Enhanced acidosis may exaggerate ischemic glial and vascular cell damage,
since it accelerates delocalization of protein-bound iron, with an ensuing
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free-radical damage to membrane lipids and proteins. Reports in the litera-
ture show that in the surviving patient group of neonates operated on for
congenital heart disease, a broad spectrum of developmental disorders is
found.8-11 This might to some extend be prevented by avoiding severe acido-
sis in the preoperative period.
Better surgical outcome in specific heart anomalies by the prevention of
metabolic acidosis, has been reported in prenatally diagnosed patients
with transposition of the great arteries12, hypoplastic left heart syndrome13
and coarctation of the aorta.14 This thesis outlines the impact of prenatal
diagnosis on the preoperative condition and outcome in a group of neona-
tes with severe congenital heart disease. In a step by step approach, first
the impact of prenatal diagnosis on acidosis in general is evaluated in a
large multi-center study, then the study focuses on a smaller group in
which the impact of prenatal diagnosis on serum lactates is highlighted
and finally the relationship between preoperative lactate and neurophysio-
logical outcome is studied.
The next chapters deal with two specific cardiac anomalies namely the
hypoplastic left heart syndrome and Ebstein’s anomaly, representing both
extremes of the spectrum of prenatally diagnosed types of congenital
heart disease. Although both types of congenital heart disease are increa-
singly surgically palliated, the longterm outcome and quality of life remain
doubtful. Early prenatal diagnosis in those cases frequently leads to termi-
nation of pregnancy.
Ultrasound screening for congenital malformations is currently not yet per-
formed on all pregnant women, and referral is primarily based on fetal and
maternal risk factors. The fetal risk factors include fetal arrhythmias, fetal
hydrops and/or hydramnion, chromosomal and structural anomalies and
more recently an increased nuchal translucency. Maternal risk factors inclu-
de congenital heart disease in mother or sibling, teratogenic exposure and
maternal diseases such as Sjögren’s syndrome, SLE and preexisting (type-1
or type-2) diabetes.
This last group, maternal diabetes, forms one of the largest referred group
of patients. These patients carry an increased risk of congenital abnormali-
ties in their offspring of which cardiac abnormalities form a large part.
While improved maternal care has reduced the incidence of perinatal loss,
infants of diabetic women remain at risk of developing congenital anoma-
lies. Major congenital malformations occur 2 to 4 times more frequently in
insulin dependent diabetic pregnancies than in infants born to nondiabetic
12
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women.15-19 Clinical observations indicate that poor control of maternal dia-
betes during the first trimester, the key period for fetal organogenesis, may
cause congenital anomalies. The increased risk of diabetic women having
children with congenital heart disease has prompted us to evaluate this
group specifically and focus on the pattern of heart disease encountered in
their offspring.
Even in the presence of a normal fetal cardiac anatomy, the fetus of the
diabetic mother is behaving differently. Differences in growth and in
placental development impose a significant effect on the fetal circulation
as is analyzed in a separate chapter in this thesis.
Finally this thesis discusses fetal rhythm disorders, which can be diagnosed
prenatally and if needed, treated by maternal administration of anti-
arrhythmic agents. The specific and well-defined group of fetal atrial flut-
ter is described, including the required pharmaco-therapeutic intervention
and eventual outcome.
Aim of the thesis
This thesis describes the possible advantages offered by prenatal diagnosis
of congenital heart disease. Both structural and functional anomalies have
been considered and benefits of prenatal detection on outcome have been
investigated. Examples of both kinds of anomalies are given with special
attention being paid to one of the largest referred groups, the fetus and
infant of the diabetic patient.
Outline of the thesis
In chapter 2 the effects of a prenatal diagnosis and maintenance of the
acid-base-equilibrium after birth have been investigated in a multi-center
study. Differences in the occurrence of severe preoperative acidosis have
been examined in groups with and without a prenatal diagnosis of conge-
nital heart disease. The whole spectrum of cardiac anomalies was conside-
red. Chapter 3 concerns a subpopulation of the study described in chapter
2. An in-depth investigation on the occurrence of lactacidosis in pre- and
postnatally diagnosed patient groups is presented. In chapter 4 we have
investigated the effects of prenatal diagnosis and prevention of acidosis on
developmental outcome. In chapter 5 the hypoplastic left heart syndrome
is explicitly investigated. Management and outcome have been considered
13
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in both prenatally and postnatally diagnosed patients. Also differences in
approach towards this anomaly between our clinic and centers in the
United Kingdom and United States are described. Chapter 6 deals with the
experience of prenatally diagnosed Ebstein’s anomaly. Management and
outcome are described. The incidence of prenatal detection of congenital
heart disease in the Utrecht area is described in chapter 7. Reasons for the
mismatch between the potency of ultrasound detection and the actual per-
centage of prenatally diagnosed cases are examined.
As an example of a functional cardiac anomaly we have examined atrial
flutter in chapter 8, a form of perinatal tachycardia. In this group a prena-
tal diagnosis is also possible and might have beneficial consequences.
To obtain a large study group, we performed a multi-center study over a
long period, since atrial flutter is only seldomly encountered. Diagnosis,
management and outcome of this heart rate anomaly were studied.
Chapter 9 provides a review of the literature on cardiac anomalies encoun-
tered in type-1 diabetic pregnancies. Furthermore a multi-center study was
performed in order to uncover the spectrum of cardiac anomalies associa-
ted with type-1 diabetes. In chapter 10 we have investigated fetal blood
flow in well-controlled type-1 diabetic pregnancies in comparison to a con-
trol group of normal pregnancies.
Chapter 11 is a general discussion and summary, and chapter 12 is a general
discussion and summary in Dutch.
The thesis concludes with the curriculum vitae of the authors and acknow-
ledgements of those who assisted in the research.
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Prenatal diagnosis of congenital heart
disease affects preoperative acidosis in the 
newborn patient
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Abstract
Objectives 
Congenital heart disease is the leading cause of death in the first year
after birth. Prenatal diagnosis of the disease can optimize the preoperative
condition of the patient and may help in the prevention of acidosis. In this
retrospective study we compared the occurrence of metabolic acidosis in
patients with and without prenatal diagnosis of a congenital heart disease.
Methods 
Data of 408 patients who needed an operation for congenital heart disease
within 31 days of life were analyzed retrospectively. Arterial blood gases at
fixed time intervals and worst blood gas of 81 patients with and 327
patients without a prenatal diagnosis were compared, categorizing the
patients on ductus-dependency, anticipated univentricular or biventricular
repair, and left-sided, right-sided or no heart obstruction.
Results 
In the overall group significant differences in lowest pH, lowest base
excess, and highest lactate level were found, with metabolic acidosis more
common among the patients with a postnatal diagnosis. In the group of
patients with ductus-dependent congenital heart disease, the difference
between patients receiving a prenatal diagnosis and those receiving a
postnatal diagnosis was more significant than in the group with non-duc-
tus-dependent lesions. Analyzing patients with right-sided, left-sided, and
no obstruction separately, significant differences where found in the group
with left-sided heart obstruction for lowest pH and base excess and in the
group with right-sided heart obstruction for lowest base excess.
Conclusions 
Prenatal diagnosis of congenital heart disease minimizes metabolic acido-
sis in patients with congenital heart disease and may be associated with
improved longterm outcome and prevention of cerebral damage among
this fragile group of patients, although no significant effect on direct surgi-
cal outcome was encountered.
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Introduction
Congenital heart disease remains the most important cause of death in the
first year after birth.1 Mortality occurs mainly in patients with severe forms
of congenital heart disease requiring immediate surgical intervention.
Secondary to the improvement of surgical techniques over the last years,
mortality has decreased dramatically, but important neurological sequelae
have been noted that may affect the quality of survival.2-4 Perfection of
operative techniques has resulted in only minimal operative mortality and
morbidity compared with the preoperative risk factors, as described by
Soongswang et al.5 Achieving a further decrease in mortality and morbidity
will predominantly require improved preoperative stabilization of the
patient.5,6 We hypothesize that the prenatal diagnosis of congenital heart
disease facilitates the initiation of therapeutic intervention immediately
after birth, including planned delivery at a cardiac center and immediate
postnatal stabilization, which may include the initiation of prostaglandin
therapy7 and intubation and ventilation if required. These measures may
prevent neonatal hypoxemia, hypoperfusion, and acidosis. A salutary effect
of prenatal cardiac diagnosis on neonatal survival has been proven for
transposition of the great arteries by Bonnet et al.8 This is the only paper in
the literature thus far that has the statistical power to show this effect.
Some studies suggest improved outcomes in some subgroups of patients
with prenatally diagnosed congenital heart disease.9-12 A significant effect
on the overall group of patients with structural heart disease has not been
shown. The purpose of this study was to evaluate retrospectively the effect
of prenatal diagnosis on the newborn with congenital heart disease, com-
paring the incidence of metabolic acidosis in prenatally and postnatally
diagnosed groups of patients with similar diagnoses.
Patients and Methods
This retrospective study included patients diagnosed with congenital heart
disease between January 1, 1991, and July 30, 1998, originating from three
institutions, Wilhelmina Children’s Hospital/University Medical Center,
Utrecht, the Netherlands; Yale-New Haven Children’s Hospital, USA; and
University of Maryland Medical System in Baltimore, USA. All patients who
required operations for structural heart disease in the first 31 days of life or
died before the operation could take place were included. Excluded were
patients with severe, life-threatening extracardiac or chromosomal anomalies.
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Two different groups of patients with structural heart disease were compa-
red, one in which the diagnosis was made prenatally and the other in
which the cardiac anomaly was discovered after birth. Both groups received
similar care at the same institutions.
The patients having a prenatal diagnosis were delivered within the
University Hospitals, where indicated prostaglandin was started immedia-
tely and infants were intubated and ventilated if needed. The other
patients were treated after congenital heart disease was suspected.
Outcome variables 
Medical records were reviewed for age at diagnosis, mode of delivery,
gestational age at delivery, Apgar scores, prostaglandin administration and
laboratory values, including arterial pH, base excess (BE), Pco2, Po2, and, if
measured, lactate values. Arterial blood gases were those reported at 1 and
4 to 6 hours postpartum and worst blood gas, regardless of postnatal age
in hours. These data were used to compare not only the two different
groups described above but also to compare several sets of subgroups,
including patients with and without ductus-dependent lesions, patients
with a future possibility of biventricular repair, and those with an anticipa-
ted single ventricular repair. The outcomes in patients with left ventricular
outflow tract obstruction, right ventricular outflow tract obstruction, and
without any obstruction were compared seperately.
Statistical Analysis
Data were analyzed by using SPSS software (SPSS Inc, Chicago, Ill, USA).
The Student’s t-test was used for comparing both groups for values of pH,
BE, Pco2, Po2, and lactate values. Chi-square testing was used for compari-
son of both groups with regard to univentricular or biventricular repair,
ductus-dependency, and mode of delivery.
Results
Between January 1, 1991, and June 30, 1998, 408 patients with congenital
heart disease requiring operations within 31 days of life were admitted to
the three participating institutions. Prenatal diagnosis in this group was
established in 81 (20%) patients at an average gestational age of 30.5
weeks, whereas 327 (80%) patients only had postnatal diagnosis of their
heart disease. Cesarean delivery was performed in 30.4% of the prenatal
cases and 21.8% of the postnatal cases (P=0.31). The gestational age at deli-
very was 37.5 ± 0.4 weeks (mean ± SEM) in the group with prenatal diagno-
sis, whereas the patients with a postnatal diagnosis were delivered signifi-
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cantly later (39.1 ± 0.2 weeks; P<0.001). Apgar scores were not different.
Prostaglandin administration was required in 71% of both the prenatal and
the postnatal patients. In the prenatal group prostaglandin was always star-
ted on the first day of life (SEM = 0), and this differed significantly from the
postnatal group, in which prostaglandin was started at 2.6 ± 0.6 days
(P< 0.001). No difference was found in the dosage or duration of prostaglandin
administration (Table 1).
Table 1. Gestational age at delivery, Apgar scores, and duration of prostaglandin E1 admini-
stration, prostaglandin E1 dose per minute, and total cumulative dosage of prostaglandin E1.
Prenatal
Diagnosis n Mean SEM P
Gestational age at Yes 44 37.45 0.40 <0.001
delivery (weeks) No 90 39.08 0.22
Apgar score, 1 min Yes 43 7.60 0.22 0.93
No 95 7.58 0.18
Apgar score, 5 min Yes 43 8.56 0.13 0.55
No 95 8.66 0.10
Prostaglandin E1 Yes 30 4.30 0.40 0.44
administration (days) No 55 4.89 0.52
Prostaglandin E1 dose/min Yes 36 0.044 0.009 0.16
(microg/kg.min) No 66 0.060 0.007
Prostaglandin E1 total Yes 29 0.282 0.071 0.24
dose (mg/kg) No 51 0.565 0.174
n = Number, SEM = Standard error of mean, P = Probabilty
Patients with a prenatal diagnosis stayed in the hospital a mean time of
15.4 days, and those with a postnatal diagnosis stayed 19.9 days (P=0.55).
The difference in outcome was not significant either. Of the prenatal
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group, 17% died within 31 days after birth compared with 19% in the post-
natal group (P=0.87).
Laboratory results
Significant differences were found in the lowest arterial pH (prenatal vs
postnatal, 7.31 ± 0.01 vs 7.28 ± 0.01; P=0.004) and the lowest preoperative
BE (prenatal vs postnatal, -4.90 ± 0.45 mEq/L vs -7.26 ± 0.35 mEq/L;
P<0.001), with acidosis more common among the postnatally diagnosed
group. Lactate was only measured in the patients seen in Utrecht because
this is not a standard procedure in the two American centers in this study.
The patients receiving prenatal and postnatal diagnosis had a highest lac-
tate value of 3.14 ± 0.57 mmol/L and 6.33 ± 0.58 mmol/L, respectively
(P<0.001). No significant differences were found in highest arterial Pco2
and lowest Po2 (Table 2).
Table 2. Arterial blood gases in the preoperative period.
Prenatal
Diagnosis n Mean SEM P
Lowest pH Yes 67 7.31 0.01 0.004
No 293 7.28 0.01
Lowest BE Yes 67 -4.90 0.45 <0.001
(mEq/L) No 291 -7.26 0.35
Highest Pco2 Yes 41 45.14 2.03 0.244
(mm Hg) No 88 48.72 1.86
Lowest Po2 Yes 41 42.90 2.46 0.956
(mm Hg) No 83 42.68 2.49
Highest lactate Yes 11 3.14 0.57 <0.001
(mmol/L) No 99 6.33 0.58
n = Number, SEM = Standard error of mean, P = Probabilty
24
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Because very few blood gases were obtained 1 and 4 to 6 hours postpartum
in the postnatal group, no significant differences were encountered for pH
or BE at these times. The only significant difference was found for Pco2
after 1 hour (prenatal vs postnatal, 45.4 ± 2.5 vs 34.1 ± 3.7 mm Hg; P=0.015;
Table 3).
Table 3. Arterial blood gases 1 hour and 4 to 6 hours post partum.
Prenatal
Diagnosis n Mean SEM P
PH, 1 h Yes 14 7.31 0.02 0.287
No 10 7.35 0.03
BE, 1 h Yes 14 -4.32 1.12 0.461
(mEq/L) No 9 -5.78 1.68
Pco2 ,1 h Yes 14 45.43 2.54 0.015
(mm Hg) No 10 34.10 3.67
Po2 ,1 h Yes 14 43.50 4.39 0.744
(mm Hg) No 10 45.90 6.01
PH, 4-6 h Yes 18 7.37 0.02 0.216
No 11 7.31 0.05
BE, 4-6 h Yes 18 -0.82 0.58 0.051
(mEq/L) No 12 -4.81 1.77
Pco2 ,4-6 h Yes 18 43.06 1.95 0.063
(mm Hg) No 12 37.08 2.40
Po2, 4-6 h Yes 18 44.39 2.95 0.840
(mm Hg) No 12 43.25 5.23
n = Number, SEM = Standard error of mean, P = Probabilty
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The percentage of patients with markedly abnormal labaratory results was
also compared. Lactate values over 7.5 mmol/L were found in none of the
patients in the prenatal group compared with 24.5% in the postnatal group
(P=0.29). The pH was lower than 7.20 in 8.8% of those having prenatal
diagnosis and 20.7% of those having postnatal diagnosis (P=0.02). Base
excess lower than –9.0 mEq/L was found in 11.8% in the prenatal group
and in 28.3% in the postnatal group (P=0.005).
Ductus-dependent lesions versus non-ductus-dependent lesions
In the same patient population, a difference was made between two groups,
those with (n=265) and those without (n=109) a circulation depending on
the persistence of a ductus arteriosus. When the same set of variables was
compared for these groups, lowest pH (prenatal vs postnatal, 7.32 ± 0.01 vs
7.27 ± 0.01; P=0.005) and lowest BE (prenatal vs postnatal, -5.15 ± 0.54 vs
-7.44 ± 0.45 mEq/L, P=0.002) differed significantly in the ductus-dependent
group, whereas only the lowest BE (prenatal vs postnatal, -4.08 ± 0.87 vs
-6.83 ± 0.58 mEq/L; P=0.027) differed in the non-ductus-dependent group.
Single ventricular repair versus biventricular repair
Differences found between patients in this population requiring a single
ventricular repair and those patients going for a biventricular repair were
the percentage of prenatal diagnosis made in these groups (univentricular
vs biventricular, 33% vs 14%; P<0.001) and lowest Po2 (univentricular vs
biventricular, 37.5 ± 1.8 vs 45.0 ± 2.5; P=0.018).
Right-sided heart obstruction: prenatal versus postnatal diagnosis
When comparing blood gases of prenatally and postnatally diagnosed
infants with a right ventricular outflow tract obstruction, a significant dif-
ference was found in lowest arterial BE (prenatal vs postnatal, -4.38 ±  0.69
vs –6.64 ± 0.59 mEq/L; P=0.024).
Left-sided heart obstruction: prenatal versus postnatal diagnosis
In the group with a left ventricular outflow tract obstruction, both lowest BE (pre-
natal vs postnatal, -5.03 ± 0.78 vs –7.80 ± 0.62 mEq/L; P=0.007) and lowest pH
(prenatal vs postnatal, 7.32 ± 0.02 vs 7.27 ± 0.02; P=0.027) differed significantly.
Prenatally diagnosed right-sided heart obstruction versus prenatally
diagnosed left-sided heart obstruction
In comparing patients with a prenatal diagnosis of right and left ventricu-
lar outflow tract obstruction, significant differences were found in lowest
arterial Po2 (right vs left, 37.2 ± 2.6 vs 48.7 ± 4.0 mmHg; P=0.038) and
highest arterial lactate (right vs left, 3.6 ± 0.4 vs 1.3 ± 0.3 mmol/L, P=0.024).
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Discussion
Prenatal diagnosis of congenital heart disease demands a high level of skill
but one that is achievable during routine obstetric ultrasonography.13 The
most convincing justification for such an effort would be to demonstrate
that patients with a prenatal diagnosis have a better chance on a good
outcome as a result of early initiation of therapy.
In 43% of the patients the diagnosis was made before 24 weeks gestation,
an age at which termination of pregnancy is still a legal option, but the
parents opted for continuation of the pregnancy with a planned delivery.
Although the number of cesarean deliveries was not significantly higher,
the gestational age at delivery was significantly lower in infants with a
prenatal diagnosis, probably because of the planned induction of the deli-
very to insure optimal postnatal care.
No difference was found in Apgar scores between both groups, which could
be expected because cardiac status in the delivery room rarely differed
between the two groups as a result of ductal patency and the absence of
significant left-to-right shunting before the postnatal drop in pulmonary
vascular resistance.
Total cumulative dosage of prostaglandin E1 was no different, and therefo-
re no difference in side effects is to be expected between the tw0 patient
groups.14-17 Prostaglandin E1 administration was, if required, always started
on the first day of life in the prenatal group, whereas administration was
started after 2.6 days in the postnatal group. This is likely due to the fact
that decreased ductal flow among the infants with a postnatal diagnosis
resulted in the symptoms leading to initial diagnosis.
Although hypoxemia or ischemia may result in metabolic acidosis, highest
Pco2 and lowest Po2 values were no different between the two patient
groups, suggesting that the predominant cause of acidosis is hypoperfu-
sion rather than hypoxemia with early prostaglandin E1 infusion affecting
systemic perfusion.
In our study prenatal diagnosis did lead to a significant prevention of dete-
rioration of the acid-base-equilibrium. A positive effect of prenatal detec-
tion on surgical outcome has been suggested in previous reports,8-12 but we
could not affirm such a direct effect. Eapen et al.12 analyzed a specific popu-
lation with left ventricular outflow tract obstruction and found a signifi-
cant difference in BE in first blood gases in favor of the prenatally
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diagnosed group. Our study covers the entire spectrum of congenital heart
disease and reports on representative information about the actual acido-
sis obtained at fixed time intervals after birth or by analyzing worst blood
gases and demonstrates a significant difference in the severity of acidosis
in favor of the group of patients with a prenatal diagnosis of congenital
heart disease. This outcome suggests that immediate management of
heart disease facilitated by the prenatal diagnosis of the disease dimini-
shes acidosis and allows immediate stabilization of the acid-base-equilibri-
um. Comparison of markedly abnormal laboratory values shows that a pre-
natal diagnosis helps in prevention of extreme acidosis.
The importance of avoidance of severe metabolic acidosis to prevent brain
damage has been suggested in previous reports. Enhanced acidosis may
exaggerate ischemic glial and vascular cell damage because it accelerates
delocalization of protein-bound iron, with an ensuing free-radical damage
to membrane lipids and proteins.18-21 Prevention of metabolic acidosis
might, in addition, lead to better surgical outcomes. Postoperative lactate
levels are higher for nonsurvivors and may be a useful predictor of
mortality in children less than 1 year of age.22-25  
The comparison of prenatally and postnatally diagnosed patients with duc-
tus-dependent lesions showed significant differences for lowest BE and
lowest pH, and in patients with non-ductus-dependent lesions, only lowest
BE differed significantly in favor of the prenatal group. This implicates that
especially the early initiation of prostaglandin E1 administration in the duc-
tus-dependent group prevents acidosis, whereas the difference in the non-
ductus-dependent group, although less significant, suggests that early ini-
tiation of medical care, other than prostaglandin therapy, is another positi-
ve factor of prenatal diagnosis. In most cases, however prostaglandin admi-
nistration can be delayed for 2 to 3 hours after birth because the ductus
arteriosus will normally stay widely patent in the first several hours.
Comparing patients with a future possibility of biventricular repair to
those with an anticipated single ventricular repair, the only statement to
be made is the obvious higher percentage of prenatal diagnosis in the last
group because of the presence of a distinctly abnormal four-chamber view,
which facilitates early diagnosis.
The separate analysis of patients with and without prenatal diagnosis of
right-sided heart obstruction, left-sided heart obstruction, or no obstruc-
tion, reveals a significant difference in lowest BE in favor of the prenatal
group for the right-sided heart obstruction, lowest BE and pH for left-sided
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heart obstruction, and no significant difference for the group without
obstruction. This indicates that also in the group with right-sided heart
obstruction, prenatal diagnosis has a positive effect on prevention of meta-
bolic acidosis.
The power of the numbers is small, especially when groups of patients are
separated out, which makes significance hard to reach in subgroups. This
includes the important group of transposition of the great arteries, where
Bonnet et al.8 showed that prenatal detection reduced neonatal mortality.
Our data did not allow such a conclusion, although the surgical outcomes
of all patients have been investigated. The number of influencing parame-
ters, such as different surgeons, different institutions, and different proto-
cols prevented a clean analysis.
In conclusion, prenatal diagnosis diminishes the development of metabolic
acidosis in the newborn patient with congenital heart disease without an
apparent effect on immediate surgical outcome. Although in this study the
differences are significant but small, they indicate a first step towards a
better-controlled preoperative approach, which will allow an optimization
of the preoperative condition of the patient with severe congenital heart
disease. We postulate that this improvement in preoperative condition may
lead to improved longterm outcome and prevention of cerebral damage
among this fragile group of patients.
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Lactacidosis in the neonate is minimized by 
prenatal detection of congenital heart disease
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Abstract
Objectives 
To investigate the impact of prenatal detection of congenital heart disease
on preventing severe preoperative lactacidosis.
Methods 
Patients operated upon for congenital heart disease during the first 31 days
of life (n=209) were studied retrospectively, 21 were diagnosed prenatally
and 188 patients had not been diagnosed prenatally. Preoperative lactate,
pH and base excess were evaluated.
Results 
Differences were noted in preoperative pH (7.28 ± 0.03 vs 7.24 ± 0.01;
P=0.29), base excess (-5.83 ± 0.64 vs -6.93 ± 0.46 mmol/L; P=0.10) and lac-
tate (3.05 ± 0.35 vs 6.08 ± 0.45 mmol/L; p<0.001), indicating a significant
difference in blood lactate values in favor of the prenatally diagnosed
group.
Conclusions 
Prenatal diagnosis of congenital heart disease and the resulting immediate
postnatal care prevent lactate increase in the preoperative period of these
patients. This may decrease the risk of cerebral damage and result in the
patient being in better condition at surgery.
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Introduction
Severe congenital heart disease may require urgent surgical intervention in
the first weeks of life. The improvement of surgical techniques and
increased surgical experience have diminished mortality in these patients
significantly. Due to the already low surgical mortality, a further improve-
ment should be located in the preoperative period.1,2 Prenatal detection of
congenital heart disease might be one way to achieve this improvement,
as it is supposed to improve and optimize care in the short postnatal and
preoperative period.3-7 Prenatal diagnosis facilitates planned delivery and
immediate prostaglandin administration8, which supposedly improves pre-
operative management and leads to better blood gas control, thus preven-
ting severe preoperative lactacidosis. In this study, two groups of patients
with and without a prenatal diagnosis of severe congenital heart disease
were compared. Both groups required comparable surgery in the neonatal
period. Our hypothesis is that prenatal diagnosis of congenital heart disea-
se and the resulting immediate postnatal care prevent lactate increase in
the preoperative period of these patients.
Methods
Patient population
This retrospective study included patients diagnosed with congenital heart
disease between January 1, 1991, and January 1, 2000, at the Wilhemina
Children’s Hospital/University Medical Center, Utrecht, the Netherlands.
All patients required surgery for congenital heart disease within the first
31 days of life. Medical records were studied retrospectively for diagnosis,
randomly obtained blood gas values and outcome. Two groups of patients
with structural heart disease were compared, one diagnosed prenatally and
the other in which the cardiac anomaly was only discovered after birth.
All prenatally diagnosed patients were delivered within the university hos-
pital, received low dose prostaglandin immediately when ductal-depen-
dent, and were intubated and ventilated if needed in our tertiary-level neo-
natal intensive care unit. The other patients were all born in outlying hos-
pitals or at home and were transported after congenital heart disease was
suspected. Both groups of patients received similar care, depending on the
kind and severity of the malformation once they were admitted.
35
Congenital heart disease and lactacidosis
Statistical Analysis
Data were analyzed by using SPSS software (SPSS Inc, Chicago, Ill, USA).
The Student’s t-test and Fisher's exact test were used for comparing both
groups for values of pH, base excess and lactate. All data are presented as
mean ± standard error of the mean.
Results
Patient population
Between January 1, 1991, and January 1, 2000, 209 patients with congenital
structural heart disease requiring surgery within 31 days of life were admit-
ted to this institution. In 21 patients (10%) prenatal diagnosis was esta-
blished, whereas 188 patients (90%) had only a postnatal diagnosis of their
structural heart disease. In the postnatal group, 80.2% had had general
ultrasound screening but congenital heart disease was not detected. A pre-
natal diagnosis could not be made in 32% of the patients because the
ultrasound investigation was performed at a gestational age when the
heart could not yet be properly evaluated. The four-chamber view was not
reported in 23% and was missed in 26% despite a four-chamber view being
visible at the right gestational age. Table 1 shows the distribution of conge-
nital defects in the two groups.
Postoperative intensive care duration was 4.40 ± 1.54 days in the prenatal
group vs 9.51 ± 2.29 days in the postnatal group (P=0.48). The prenatally
diagnosed neonates were operated on at a mean age of 5.38 ± 1.05 days,
which is significantly different from the postnatal group that was operated
on at 9.21 ± 0.50 days’ age (P=0.023). No difference in survival was found
between the two patient groups.
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Table 1. Distribution of congenital defects 
Prenatal (n) Postnatal (n) Surgery
Transposition of the 
great arteries 5 68 Switch
Coarctation of the aorta 4 42 End-end anastomosis
Hypoplastic left heart
syndrome 2 15 Norwood
Ventricular septum defect 0 4 VSD repair
Tetrology of Fallot 2 7 One stage/two 
stage-repair
Hypoplastic right heart
syndrome 0 1 Single ventricle repair
Pulmonary atresia 4 15 Unifocalization
Pulmonary stenosis 0 3 Valvulotomy
Aortic stenosis 0 2 Aortic valvulotomy
Tricuspid atresia 0 5 Single ventricle repair
Rhabdomyoma 1 0 Excision
Interrupted aortic arch 0 7 Arch repair
Total anomalous 
pulmonary venous 
connection 1 8 TAPVC-repair
Double outlet right ventricle 1 4 DORV-repair
Double inlet left ventricle 0 3 Single ventricle repair
Truncus arteriosus 1 4 Truncus repair
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Laboratory results
The values for worst preoperative arterial lactate of the prenatally diagno-
sed group were 3.05 ± 0.35 vs 6.08 ± 0.45 mmol/L in the postnatal group,
indicating a significant difference in worst preoperative blood lactate in
favor of the prenatally diagnosed group (P<0.001).
Worst preoperative pH of the prenatally diagnosed group was 7.28 ± 0.03
vs a preoperative pH of 7.24 ± 0.01 in the postnatally diagnosed group
(P=0.29). Worst base excess of the prenatal group was -5.83 ± 0.64 mEq/L,
while the value for the postnatal group was -6.93 ± 0.46 mEq/L (P=0.10)
(Figure 1).
Normalization of preoperative lactate values occurred after 21.5 h, normali-
zation of pH after 5.3 h and normalization of base excess after 0.41 h.
Figure 2 shows lactate values at different time points after admission.
A significant difference in favor of the group with a prenatal diagnosis was
found when the patients were divided into groups with a worst preoperati-
ve lactate greater or less than 7.5 mmol/L. Of the patients without a prena-
tal diagnosis 22.3% had a worst preoperative lactate greater than 7.5
mmol/L, whereas none of the patients with a prenatal diagnosis had a
worst lactate greater than 7.5 mmol/L (P=0.026).
Statistical analysis on the subgroup of ductal-dependent lesions also
shows a significant difference in worst lactate values in favor of the prena-
tal group supporting the null hypothesis in the highest-risk group. The pre-
natal group had a worst arterial lactate of 3.03 ± 0.39 vs 6.07 ± 0.49
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Figure 1
Worst values of preoperative lactate, base excess and pH in both prenatal 
and postnatal groups. * = P<0.001 for lactate difference between groups
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mmol/L in the postnatal group. In this subgroup the differences in base
excess (-5.88 ± 0.65 vs –6.89 ± 0.50 mEq/L; P=0.225) and pH (7.29 ± 0.04 vs
7.26 ± 0.01; P=0.32) were not significant.
Discussion
The purpose of this study was to investigate the impact of prenatal diag-
nosis on the preoperative condition of the neonate. This study showed a
significant prevention of lactate formation in the preoperative period in
the group with a prenatal diagnosis. This means the patient is in better
condition at surgery and might result in a decrease of the risk of cerebral
damage, as high lactate values are correlated with possible cerebral dama-
ge and complications.9-13 In our study none of the prenatally diagnosed
patients had a worst lactate greater than 7.5 mmol/L vs 22.3% of the group
with a postnatal diagnosis, a level that would threaten the neonatal brain.
This study demonstrates the positive effect of prenatal diagnosis on the
overall group of congenital heart disease in a small population. This
accords with previous publications of Bonnet et al.3 showing that prenatal
detection of transposition of the great arteries actually reduced neonatal
mortality and Chang et al.5 who reported a decrease in preoperative meta-
bolic acidosis and cardiopulmonary arrest in a group of neonates with left
ventricular outflow tract obstruction. These publications support the view
that prenatal detection may lead to a better preoperative condition and
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Figure 2
Arterial lactate values at different time points after admission: prenatal and postnatal
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possible improvement of surgical outcome. This is parti-cularly important
in neonates with ductus-dependent lesions, who receive constant prostag-
landin infusion to prevent unfavorable hemodynamic changes.14,15
Normalization of lactate values takes significantly more time than normali-
zation of either pH or base excess, as titration of bicarbonate will almost
immediately normalize pH and base excess. The extent of the hypoxia and
the severity of the resulting acidosis threatening the neonatal brain seem
therefore better reflected by lactate measurements.
Several studies have reported perinatal hypoxic ischemic injury as a signifi-
cant cause of neurodevelopmental impairment and neuronal damage.16-17
Hanrahan et al.18 investigated the relationship between elevated cerebral
lactate levels in children with birth asphyxia and their neurodevelopment
at one year of age. Elevated levels had a predictive value of 86% for adverse
outcome, i.e. death or neurodevelopmental impairment. Other studies also
showed the correlation between initial brain lactate levels measured and
adverse outcome in children experiencing perinatal asphyxia.19-21
Comparable information has surfaced in recent years on the outcome of
open-heart surgery in the pediatric age group. Prospective observational
studies have been published by Siegel et al.22 on the predictive value of
serum lactate measurement after pediatric open-heart surgery on outco-
me. These studies showed that nonsurvivors after open-heart surgery have
significantly higher serum lactate levels than the surviving group of
patients and that an initial lactate level greater than 4.5 mmol/L had a
positive predictive value for mortality of 100%. Cheifetz et al.23 also repor-
ted that an elevated level of serum lactate could be seen as an important
indicator of potential mortality in children less than 1 year of age under-
going surgery for complex congenital heart disease. These elevated lactate
levels reflect tissue hypoperfusion and hypoxemia. According to another
study the occurrence of metabolic acidosis and the need for preoperative
respiratory support were greater in the nonsurviving patients.1
A number of studies indicate the importance of lactate levels over arterial
pH or base excess.22,24,25 They support the finding that the anion gap and
arterial pH, often used to screen for hyperlactatemia, are poor predictors
for outcome after open-heart surgery and cannot replace serum lactate
measurements. Deshpande and Platt26 state that pH and negative base
excess are both insensitive indicators of raised lactate concentrations and
stress the importance of high lactate concentration as an early warning
signal and prognostic information in the critically ill infant. The lack of cor-
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relation of pH with hyperlactatemia is explained by the titration of bicar-
bonate to maintain the patient at normal pH.22
Progress in surgery for congenital heart disease has led to the successful
operation in infancy of complex heart lesions that were previously thought
to be inoperable. However, there is still an increasing disquiet about the
high incidence of acute neurological events in the immediate postoperative
period.27 Our study showed that the prenatal diagnosis of congenital heart
disease could have an important role in the prevention of neurological
sequelae by preventing lactate increase in the preoperative period. We sup-
port the opinion that the most significant contribution for a positive out-
come for the newborn patient after cardiothoracic surgery would be inter-
vention in the preoperative period. A diagnosis of the cardiac lesion before
birth allows physicians to initiate therapy immediately after birth and
helps prevent these problems.
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Predictive value of acidosis on developmental 
outcome in newborns with congenital 
heart disease
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Abstract
Objectives 
This study is aimed at the evaluation of parameters for acidosis and their
predictive value on developmental outcome in newborns with congenital
heart disease. Attempts have been made to identify indices that may pre-
dict outcome or morbidity, as mortality for congenital heart disease has
declined. Prenatal diagnosis has shown to decrease preoperative acidosis
and might prevent the occurrence of disturbed developmental outcome.
Methods 
117 patients, requiring surgery for structural heart disease in the first 31
days of life were included. Diagnosis was established either prenatally or
postnatally. Preoperative values of lactate, pH and base excess levels were
compared to the occurrence of disturbed developmental outcome, i.e. an
underperformance of more than 10% from the P90 on a standardized Dutch
developmental scale. Patients were divided into groups according to blood
levels of parameters of acidosis, using Receiver Operating Characteristics
curves for determining cut-off values for pH, base excess and lactate.
Results 
No significant difference in developmental outcome was found using valu-
es for pH or base excess as a cut-off level. Preoperative lactate values
exceeding 6.1 mmol/L resulted in a significant increase in impaired deve-
lopment: 40.9% as compared to 15.1% in infants with a preoperative lactate
lower than 6.1 mmol/L (P=0.03).
Conclusions
Preoperative lactate values have a prognostic value on developmental out-
come in newborns with a congenital heart disease. The limited prognostic
value of pH can be explained by the fact that pH can be easily corrected,
while lactate better reflects the total oxygen debt experienced by these
patients.
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Introduction
Congenital heart disease is the leading cause of neonatal death.1 Improved
surgical and cardiopulmonary bypass techniques and timing of surgery
however, have led to a substantial improvement of survival in patients
requiring surgery for their structural heart anomaly.2 Advances in surgical
and cardiopulmonary bypass techniques made it possible to correct the
majority of congenital heart diseases successfully in infancy or childhood.3
This shifted our research emphasis to the identification of indices that may
predict outcome or morbidity along with possible strategies to attenuate
adverse clinical responses2, since a broad spectrum of developmental disor-
ders has been reported in patients surviving heart surgery.3-6 PH, base
excess and lactate measurements have been proposed in numerous studies
as prognostic indicators to identify patients with a considerable risk to
experience substantial shortterm morbidity.7,8
Postoperative serum lactate levels have clearly shown to correlate with
outcome after pediatric open-heart surgery.9-11 The predictive value of pre-
operative measurements of acidosis in patients with congenital heart
disease, which is heavily influenced by prenatal diagnosis of the
anomaly12,13, is unclear.
Prenatal detection of congenital heart disease may lead to a better control
of the acid-base-equilibrium and thus prevent the development of severe
acidosis in the neonate with congenital heart disease.12,13 A decline in mor-
bidity and mortality has been shown after prenatal detection of transposi-
tion of the great arteries14 and left outflow tract obstruction.15,16 The long-
term developmental effects have never been evaluated for the overall
group of congenital heart disease.
In this study we have investigated the correlation between prenatal detec-
tion of congenital heart disease, preoperative measurements of acidosis
and outcome. We have studied the prognostic value of different parame-
ters of acidosis and have considered both shortterm and longterm outcome.
Methods
This retrospective study included 117 patients diagnosed with congenital
heart disease between December 1, 1994, and January 1, 2000, in the
Wilhelmina Children’s Hospital/University Medical Center Utrecht, the
Netherlands. All patients, requiring surgery for structural heart disease in
the first 31 days of life or who died before surgery could take place, were
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included. Excluded were patients with severe, life threatening extracardiac
or chromosomal anomalies.
Preoperative values of lactate, pH and base excess levels were retrieved of
all patients. These blood samples had been randomly obtained in the pre-
operative period, i.e. between admission for operative intervention and sur-
gery itself. In all patients several blood samples had been taken and in this
study the worst values obtained were used for studying relationships with
outcome.
Both shortterm and longterm outcome were investigated. Documented
were the occurrence of disturbed developmental outcome. Data on deve-
lopmental outcome were obtained retrospectively and extrapolated to a
standardized and validated Dutch developmental scale, the ‘Van Wiechen’
classification.17 Classification consisted of age-dependent assessment of
motoric behavior, speech, communication and social skills. In case patients
had been evaluated on more than one occasion, then the best (most opti-
mal) score was used to extrapolate to the developmental scale. The ‘Van
Wiechen’ classification indicates age-dependent skills that 90% of the
children of an average population should be able to perform. An underper-
formance of more than 10% from the P90 in one of the above mentioned
domains of the developmental scale was considered to indicate disturbed
development. Scores at developmental screening tests are in line with lear-
ning capacity in later life and these tests enable the detection of children
at risk of school achievement problems.18-20
Patients were split into groups with extreme values of parameters of
acidosis. Receiver Operating Characteristic (ROC) curves were used for
determining cut-off values for pH, base excess and lactate.
Using SPSS software (SPSS Inc, Chicago, Ill, USA) the correlation between
prenatal diagnosis of congenital heart disease, measurements of acidosis
and outcome parameters were tested.
Results
Between December 1, 1994, and January 1, 2000, 117 patients with congeni-
tal structural heart disease requiring surgery within 31 days of life were
admitted to this institution. In 15 cases (13%) prenatal diagnosis had been
established, while 102 patients (87%) only had a postnatal diagnosis of
their structural heart disease. No significant differences in lactate, base
excess and pH values were encountered in groups with and without deve-
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lopmental problems, with and without mortality within 31 days and with
and without longterm mortality (Table 1).
Table 1. No significant differences in parameters of acidosis are found comparing groups
with and without disturbed developmental outcome and with or without longterm or
shortterm mortality.
Disturbed 
developmental 
outcome Value ± SEM P-value
Lactate Yes 8.94 ± 2.33 mmol/L 0.123
No 5.05 ± 0.49 mmol/L
Base excess Yes -9.60 ± 1.86 mEq/L 0.333
No -7.66 ± 0.57 mEq/L
pH Yes 7.19 ± 0.16 0.239
No 7.24 ± 0.11
Mortality 
< 31 days Value ± SEM P-value
Lactate Yes 4.61 ± 1.18 mmol/L 0.388
No 6.20 ± 0.58 mmol/L
Base excess Yes -7.51 ± 1.18 mEq/L 0.745
No -8.04 ± 0.58 mEq/L
pH Yes 7.25 ± 0.03 0.832
No 7.24 ± 0.01
Mortality 
> 31 days Value ± SEM P-value
Lactate Yes 7.59 ± 2.54 mmol/L 0.388
No 5.87 ± 0.54 mmol/L
Base excess Yes -8.13 ± 2.47 mEq/L 0.928
No -7.97 ± 0.53 mEql/L
pH Yes 7.26 ± 0.03 0.609
No 7.24 ± 0.01
49
Acidosis and developmental outcome 
Patients were split into groups with extreme values of parameters of acido-
sis. Receiver Operating Characteristic curves were used for determining cut-
off values for pH, base excess and lactate. The cut-off values with the best
combination of sensitivity and specificity were 7.25 for pH, -9.6 mEq/L for
base excess and 6.1 mmol/L for lactate (Figure 1). These groups were com-
pared using chi-square testing on differences in developmental outcome
and longterm and shortterm mortality. No significant differences were
found using values for pH or base excess as a cut-off level, although signifi-
cance is almost reached using values of base excess (P=0.057). However,
preoperative lactate values exceeding 6.1 mmol/L resulted in a significant
difference in disturbed developmental outcome. Of the children with a pre-
operative lactate lower than 6.1 mmol/L, 15.1% had disturbed developmen-
tal outcome in later life, compared to 40.9% of the children with a lactate
exceeding 6.1 mmol/L (P=0.03; OR=3.88; 95%-CI= 1.47-10.24) (Table 2).
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Figure 1
1.1  ROC Curve for lactate
Lactate Sensitivity Specificity
(mmol/L)
1.3 1.00 0.02
3.1 0.56 0.35
5.2 0.56 0.64
6.1 0.56 0.78
7.2 0.44 0.83
8.4 0.38 0.88
11.4 0.31 0.91
15.6 0.19 0.97
18.5 0.06 0.98
26.6 0.06 1.00
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1.2  ROC Curve for base excess
Base excess Sensitivity Specificity
(mEq/L)
-1.2 0.88 0.03
-5.1 0.75 0.24
-6.8 0.56 0.55
-8.0 0.56 0.64
-9.6 0.50 0.79
-10.8 0.38 0.81
-12.2 0.31 0.85
-15.1 0.19 0.91
-19.4 0.06 0.97
-22.7 0.00 0.98
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1.3  ROC Curve for pH
pH Sensitivity Specificity
7.37 1.00 0.05
7.32 0.75 0.16
7.29 0.56 0.45
7.25 0.5 0.59
7.24 0.44 0.62
7.22 0.38 0.69
7.19 0.31 0.74
7.11 0.25 0.91
7.05 0.19 0.97
6.86 0.00 0.98
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Table 2. Prognostic value of lactate, base excess and pH for developmental outcome.
Disturbed developmental outcome is defined as an underperformance of more than 10%
from the P90 on the Van Wiechen developmental scale. (*P<0.05)
Disturbed 
developmental Odds
outcome P-value ratio 95% CI
Lactate Yes 40.9% 0.031* 3.88 1.47 - 10.24
> 6.1 mmol/L No 15.1%
Base excess Yes 40.0% 0.057 3.37 1.25 - 9.03
< -9.6 mEq/L No 16.1%
pH < 7.25 Yes 26.7% 0.578 1.45 0.58 - 3.62
No 20.0%
No significant differences in shortterm and longterm survival between the
prenatally and the postnatally diagnosed group were found. In the group
with a prenatal diagnosis 19.0% died within 31 days after birth compared to
7.4% of the newborns without a prenatal diagnosis (P=0.11). In the first
group 6.7% died beyond the neonatal period, while in the second group
9.4% died more than 31 days after birth (P=1.0). Disturbed developmental
outcome was encountered in 25.4% of the children in the postnatal group
compared to 13.3% in the prenatal group (P=0.50).
Worst preoperative arterial lactate of the prenatally diagnosed group was
3.03 ± 0.40 versus 6.39 ± 0.59 mmol/L in the postnatally diagnosed group
(P<0.001). Worst preoperative pH of the prenatally diagnosed group was
7.26 ± 0.02 versus 7.24 ± 0.01 in the postnatally diagnosed group (P=0.62).
Worst base excess of the prenatal group was –6.87 ± 0.71 mEq/L, and this
value for the postnatal group was –7.84 ± 0.59 mEq/l (P=0.30).
In Table 3 a breakdown of cardiac diagnoses in the study cohort is descri-
bed. The relations of different cardiac diagnoses to preoperative lactate,
base excess and pH values and outcome are given.
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Table 3 Breakdown of cardiac diagnoses in the study cohort and relations of different car-
diac diagnoses to preoperative lactate, base excess and pH values and outcome.
AS 1 0 7.31 -3.0 5.2 0 1 0
AS + VSD 1 0 7.23 -17.2 18.3 0 1 0
CoA 16 1 7.29 -5.1 4.7 0 15 1
CoA + AVSD 3 0 7.31 -2.9 4.8 2 1 0
CoA + VSD 7 0 7.16 -12.3 8.4 3 3 1
CoA/VSD/MS 1 0 7.37 0.2 2.2 0 1 0
DILV/TGA/VSD 1 0 7.36 1.8 1.7 1 0 0
DIRV/CoA 1 1 7.36 -0.8 1.0 0 0 1
TOF 8 1 7.34 -6.2 3.4 2 6 0
DORV 1 0 7.30 -5.0 2.5 0 0 1
DORV/TGA 1 1 7.38 -4.0 2.1 0 1 0
DORV/TGA/PA 1 1 7.29 -5.5 2.5 0 0 1
HLHS 13 2 7.25 -9.6 8.4 1 3 9
Borderline HLHS 3 2 7.22 -6.8 3.2 0 2 1
HRHS 1 0 6.90 -19.9 5.3 0 1 0
PA 6 1 7.19 -8.7 5.8 2 4 0
PA +VSD 1 1 7.04 -18.6 17.6 1 0 0
PS 1 0 7.26 -10.0 3.5 0 1 0
TA 2 0 7.30 -6.5 3.1 0 1 1
TA/CoA/TGA 1 0 7.33 -0.7 1.9 1 0 0
TAPVC 2 1 7.00 -12.3 6.2 0 1 1
TGA 28 2 7.21 -9.1 6.9 4 24 0
TGA + VSD 11 1 7.23 -8.5 5.5 3 8 0
TGA/PS/VSD 1 0 7.34 -3.4 1.2 0 0 1
Truncus Arteriosus 2 0 7.24 -4.0 5.2 0 0 2
VSD 3 0 7.32 -3.7 2.5 0 3 0
AS = Aortic stenosis, VSD = Ventricular septal defect, CoA = Coarctation of the aorta, AVSD = Atrioventricular septal
defect, DILV = Double inlet left ventricle, TGA = Transposition of the great arteries, HRH = Hypoplastic right heart, DIRV =
Double inlet right ventricle, DORV = Double outlet right ventricle, PA = Pulmonary atresia, HLHS = Hypoplastic left heart
syndrome, HRHS = Hypoplastic right heart syndrome, MS = Mitral stenosis, PAPVC/ TAPVC = Partial/Total anomalous  pul-
monary venous connection, MA =Mitral atresia, PS = Pulmonary stenosis, TOF = Tetralogy of Fallot, TA = Tricuspid atresia
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Discussion
The purpose of this study was to investigate the prognostic value of diffe-
rent preoperative parameters in patients with congenital heart disease
requiring surgery. Longterm, shortterm and developmental outcome were
considered.
Worst preoperative lactate values appeared to be of prognostic significance
for the occurrence of disturbed developmental outcome. Forty-one percent
of the patients with a lactate over 6.1 mmol/L had a disturbed developmen-
tal outcome in later life. PH and base excess did not show a significant
relation with developmental outcome. The limited prognostic value of pH
can be explained by the fact that pH is easily and rapidly corrected with
bicarbonate infusion, while lactate better reflects the total oxygen debt
experienced by the patient with congenital heart disease. Base excess is
also not as good a marker of tissue hypoxia as lactate, since its value is
also dependent on the Pco2, thus exaggerating any metabolic acidosis.21,22
In sick, ventilated, newborn infants no correlation between lactate and
base deficit was shown.23 Lactate on the other hand is the end product of
anaerobic metabolism and represents a better measure of hypoxia.24
No significant differences in shortterm or longterm mortality were found
in the groups with and without a prenatal diagnosis. Death within 31 days
occurred more often, although not significant, in the prenatal group. This
can be explained by the higher incidence of severe cardiac malformations
in this group.25,26 Especially the significant presence of hypoplastic left heart
syndrome in the prenatal group has a considerable influence on early
demise.27
Conclusion
In this study a significant correlation between preoperative lactate values
and disturbed developmental outcome was shown. PH and base excess did
not show such a correlation. Lactate therefore seems to be the most suita-
ble parameter when trying to relate the preoperative condition of the new-
born to outcome. Because of the small numbers of patients in this study no
significant relation between prenatal diagnoses and developmental outco-
me was found. Since previous publications have shown that prenatal diag-
nosis of congenital heart disease does help in the prevention of severe aci-
dosis,12,13 a positive effect of prenatal diagnosis on developmental outcome
might be expected if larger numbers will be analyzed.
54
Chapter 4
References
1 Centers for Disease Control. Contribution of birth defects to infants’ mortality -
United States 1986. MMWR 1989;38:633-5.
2 Laussen PC. Neonates with congenital heart disease. Curr Opin Pediatr 2001;13:220-6.
3 Kirkham FJ. Recognition and prevention of neurological complications in pediatric
cardiac surgery. Pediatr Cardiol 1998;19:331-45.
4 Kern JH, Hinton VJ, Nereo NE, Hayes CJ, Gersony WM. Early developmental outcome
after the Norwood procedure for hypoplastic left heart syndrome. Pediatrics
1998;102:1148-52.
5 Du Plessis AJ. Neurologic complications of cardiac disease in the newborn. Clin
Perinatol 1997;24:807-26.
6 Samango-Sprouse C, Suddaby EC. Developmental concerns in children with conge-
nital heart disease. Curr Opin Cardiol 1997;12:91-8.
7 Smith I, Kumar P, Molloy S, Rhodes A, Newman PJ, Grounds RM, Bennet ED. Base
excess and lactate as prognostic indicators for patients admitted to intensive care.
Intensive Care Med 2001;27:74-83.
8 Nagel HT, Vandenbussche FP, Oepkes D, Jennekens-Schinkel A, Laan LA, Gravenhorst
JB. Follow-up of children born with an umbilical arterial blood pH < 7. Am J Obstet
Gynecol 1995;173:1758-64.
9 Siegel LB, Dalton HJ, Hertzog JH, Hopkins RA, Hannan RL, Hauser GJ. Initial postope-
rative serum lactate levels predict survival in children after open heart surgery.
Intensive Care Med 1996;22:1418-23.
10 Cheifetz IM, Kern FH, Schulman SR, Greeley WJ, Ungerleider RM, Meliones JN.
Serum lactates correlate with mortality after operations for complex congenital
heart disease. Ann Thorac Surg 1997;64:735-8.
11 Charpie JR, Dekeon MK, Goldberg CS, Mosca RS, Bove EL, Kulik TJ. Serial blood lacta-
te measurements predict early outcome after neonatal repair or palliation for com-
plex congenital heart disease. J Thorac Cardiovasc Surg 2000;120:73-80.
12 Verheijen PM, Lisowski LA, Stoutenbeek P, Hitchcock JF, Brenner JI, Copel JA,
Kleinman CS, Meijboom EJ, Bennink GBWE. Prenatal diagnosis of congenital heart
disease affects preoperative acidosis in the newborn patient. J Thorac Cardiovasc
Surg. 2001;121:798-803.
13 Verheijen PM, Lisowski LA, Stoutenbeek  P, Hitchcock JF, Bennink GBWE, Meijboom
EJ. Lactacidosis in the neonate is minimized by prenatal detection of congenital
heart disease. Ultrasound Obstet Gynecol 2002;19:552-5.
14 Bonnet D, Coltri A, Butera G et al. Detection of transposition of the great arteries in
fetuses reduces neonatal morbidity and mortality. Circulation 1999;99:916-8.
15 Chang AC, Huhta JC, Yoon GY et al. Diagnosis, transport, and outcome in fetuses
with left ventricular outflow tract obstruction. J Thorac Cardiovasc Surg
1991;102:841-8.
55
Acidosis and developmental outcome 
16 Eapen RS, Rowland DG, Franklin WH. Effect of prenatal diagnosis of critical left
heart obstruction on perinatal morbidity and mortality. Am J Perinatol 1998; 15:237-42.
17 Van Wiechen, HJ. Early detection of handicapped infants. Huisarts en Wetensch
1972;15:351-4.
18 Conn P. The relations between Griffiths scales assessments in the pre-school period
and educational outcome s at 7+ years. Child Care Health Dev 1993;19:275-89.
19 Claeys V, Calame A, Fawer CL, Ducret S, Arrazola L, Jaunin L. Neurodevelopmental
abnormalities in preschool children with high perinatal risk. Prognostic value and
consequences on education at 8 years of age. Helv Paediatr Acta 1984;39:293-306.
20 Klackenberg G. What happens to children with retarded speech at 3? Longitudinal
study of a sample of normal infants up to 20 years of age. Acta Paediatr Scand
1980;69:681-5.
21 Rooth G. Acid-base and electrolyte balance. Lund: Studentlitteratur, 1975.
22 Rooth G. Perinatal acid-base balance. Studentlitteratur, Lund, 1988.
23 Dephande SA, Ward Platt MP. Association between blood lactate and acid-base sta-
tus and mortality in ventilated babies. Arch Dis Child 1997;76;F15-20.
24 Saugstad OD. Is lactate a reliable indicator of tissue hypoxia in the neonatal
period? Acta Paediatr 2002;91:17-9.
25 Sharland GK, Lockhart SM, Chita SK, Allan LD. Factors influencing the outcome of
congenital heart disease detected prenatally. Arch Dis Child 1991;66:284-7.
26 Allan LD. The outcome of fetal congenital heart disease. Semin Perinatol
2000;24:380-4.
27 Plantinga RF, Frohn-Mulder IME, Takkenberg HJM, Bennink GBWE, Meijboom EJ,
Bogers AJJC. De operatieve behandeling van het hypoplastisch linker hartsyn-
droom; beperkt succes. Ned Tijdschr Geneeskd 2001;145:85-90.
56
Chapter 4
57
Acidosis and developmental outcome 
prenatal cardiac pathology
58
P.M. Verheijen, L.A. Lisowski, R.F. Plantinga, J.F. Hitchcock, G.B.W.E. Bennink,
Ph. Stoutenbeek, E.J. Meijboom
Submitted
Chapter 5
Prenatal diagnosis of the fetus with a 
hypoplastic left heart syndrome:
management and outcome
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Abstract
Objectives 
To review our 13 year experience with prenatally detected hypoplastic left
heart syndrome (HLHS) which management remains controversial.
Methods 
A retrospective study on the management and outcome of HLHS, diagno-
sed prenatally in a tertiary level referral center for pediatric cardiology and
cardiac surgery between January 1988 and July 2001.
Results 
The diagnosis of HLHS was made in 32 fetuses. One mother had two preg-
nancies associated with HLHS. In 16 cases parents opted for termination of
pregnancy and in five for compassionate care. Four fetuses died in utero
and seven patients received a palliative Norwood procedure. In seven fetu-
ses associated anomalies were detected: three chromosomal and structural
and four only structural. In six fetuses other associated intracardiac ano-
malies were detected. Of seven operated infants, six had no associated
anomalies and only one is alive at an age of 17 months.
Conclusions 
The low percentage of intention to treat among patients in our center
(34%) is in accordance with the percentage found in another study from
the United Kingdom (36%), but differs significantly from reported series in
the US (67%). Prenatal diagnosis of the HLHS provides opportunities not
only for getting patients in optimal preoperative condition when surgery is
offered, but also for in-depth counseling of the parents on this severe mal-
formation. Parents faced with the difficult decision of possible termination
of pregnancy, compassionate care or the Norwood strategy, choose in a
minority for surgical treatment which might be based on the socioreligious
differences and in the interpretation of the longterm quality of life.
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Introduction
The hypoplastic left heart syndrome (HLHS) encompasses a spectrum of
structural cardiac malformations that are characterized by severe underde-
velopment of the structures in the heart-aorta complex, including the left
ventricular cavity and mass.1-3 This syndrome ranges from operable lesions
to lesions associated with other anomalies not compatible with life. At an
estimated prevalence of 1 to 4 per 10.000 life births, the hypoplastic left
heart syndrome accounts for 7 to 8% of congenital heart disease (CHD) and
is the most common cause of death due to heart disease in the newborn
period. The introduction of the palliative Norwood procedure in 1985 has
led to an increasing number of infants operated for a HLHS.4-7
The HLHS is readily detectable before 20 weeks gestation by echocardio-
graphic examination of the four-chamber view of the fetal heart and is
one of the most common abnormalities detected in utero.8,9 Before surgical
treatment options were introduced, no treatment was available and com-
passionate care therefore was the only option available for the infant.10
Although surgical options are available, the results reported so far are
encouraging but not yet comparable to the results of other types of neona-
tal cardiac surgery. The neurological outcome and the longterm quality of
life are until now still questionable.7,11-14 
Management of the HLHS remains controversial. Some centers favor the
palliative Norwood procedure or cardiac transplantation,15,16 while others
continue to withhold from surgery.3 At our institution the palliative
Norwood procedure is currently offered as the primarily surgical treatment
option to patients with HLHS as neonatal heart transplantation is not yet
performed in the Netherlands. This descriptive paper aims to review the
management and outcome of prenatally diagnosed HLHS in a single center
over 13 years and to compare it with the management strategy and out-
come in the United Kingdom (UK) and United States (US).
Materials and Methods
In this retrospective study we reviewed the medical records of 31 mothers
whose children had a HLHS diagnosed in utero by fetal echocardiographic
examination at the University Medical Center Utrecht in the Netherlands
between January 1, 1988, and June 30, 2001. Management, intervention,
outcome, fetal karyotyping and other possible intra- and extracardiac
anomalies were documented. The diagnosis of HLHS was based on
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two-dimensional echocardiographic evidence of a diminutive ascending
aorta, aortic atresia or stenosis and a hypoplastic left ventricle.17
The anomalies varied from a classic HLHS18 to a HLHS associated with
other intracardiac, extracardiac or chromosomal anomalies. Data on the
management of postnatally detected cases were obtained from a previous
study from our center.7 Data were analyzed using SPSS software (SPSS Inc,
Chicago, Ill, USA). Data were compared using the chi-square test.
Associations with P<0.05 were considered statistically significant.
Results
In this study one mother had two HLHS associated pregnancies. Of the 32
cases 16 sets of parents opted for termination of pregnancy, five sets of
parents chose not to treat the infant surgically after delivery and chose for
compassionate care. Four fetuses died in utero and seven patients received
a palliative Norwood procedure (Table 1).
Extracardiac anomalies
In this present study in seven patients extracardiac anomalies were detec-
ted in utero. One hydropic fetus with bilateral agenesis of the kidneys died
in utero at 22 weeks gestation. In four cases parents opted for termination
of pregnancy at 19, 22, 23 and 24 weeks gestation. These fetuses were found
to have syndrome of Patau, Turner syndrome with associated congenital
defects, Pierre Robin syndrome and Edwards Syndrome. Parents opted for
compassionate care in two fetuses of which one had an intracranial cyst
and the other microencephaly and severe growth retardation with hypopla-
sia of the lungs and kidneys. These patients died at day one and day 10
respectively.
Intracardiac anomalies
In six fetuses associated intracardiac anomalies were prenatally detected.
Three pregnancies, two with endocardial fibroelastosis and one with fetal
bradycardia, were terminated. One hydropic fetus with endocardial fibro-
elastosis died in utero at 26 weeks gestation. The three fetuses with endo-
cardial fibroelastosis were all found to have aortic atresia associated with a
hypoplastic left ventricle. One other fetus with complex associated lesions,
including ventricular inversion, died postoperatively on day 2. Finally
parents opted for compassionate care in one fetus with significant tricus-
pid valve insufficiency.
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Table 1 Outcome and associated anomalies in prenatally diagnosed patients with HLHS.
Category of Associated Age of death
Patient Outcome associated anomaly anomaly (weeks GA)
1 TOP Extracardial/ Patau Syndrome  19 
Chromosomal (Trisomy 13)
2 TOP Extracardial/ Turner syndrome 22 
Chromosomal
3 TOP Extracardial Pierre Robin syndrome 23 
4 TOP Extracardial/ Edwards Syndrome 24 
Chromosomal (Trisomy 18)
5 TOP Intracardial Endocardial fibroelastosis 24 
6 TOP Intracardial Endocardial fibroelastosis 24
7 TOP Intracardial Fetal bradycardia 22 
8 - 16 TOP None None 19,20,22,22,
23,23,23,23,24 
17 CC Extracardial Intracranial cyst Day 1
18 CC Extracardial Microcephaly/Lung-/ Day 10
kidneyhypoplasia
19 CC None None Day 2
20 CC Intracardial Tricuspid valve Day 4
insufficiency
21 CC None None Day 10
22 IUD Extracardial Kidney agenesis/Hydrops  22 
23 IUD Intracardial Endocardial fibroelastosis/ 26 
hydrops
24 IUD None None 35 
25 IUD None None 35 
26 N Intracardial Ventricle inversion Day 2
27 N None None Day 4 (PO)
28 N None None Day 4 (PO)
29 N None None Day 13
30 N None None Day 77
31 N None None Day 240
32 PCPC None None Alive at
17 months
TOP = Termination of pregnancy, CC = Compassionate care, IUD = Intrauterine death,
GA = Gestational age, N = Norwood procedure, PCPC  = Partial cavopulmonary connection,
PO = peroperatively
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Surgical outcome 
Of the seven patients who received surgical intervention, one had severe
associated cardiac pathology including ventricle inversion. Two patients
deceased peroperatively at an age of 4 days following the palliative
Norwood procedure. Four patients died between the palliative Norwood
procedure and the partial cavopulmonary connection at an age of 2, 13, 77
and 240 days and one patient is alive at an age of 17 months, after the pal-
liative Norwood procedure on day 2 and partial cavopulmonary connection
(PCPC) at 4 months. All deceased patients died of cardiac dysfunction.
Management of postnatal cases 
In the same time period 45 cases of HLHS were only discovered postnatally.
In 27 cases (60%) parents opted for compassionate care. In 18 cases (40%)
parents chose for surgical treatment. Of these 18 patients 17 patients
underwent a palliative Norwood procedure. Of these patients six died per-
operatively and four before the partial cavopulmonary connection could
take place. Five patients underwent the PCPC procedure and two are still
awaiting this procedure. One patient having received a PCPC died post-
operatively and three are still awaiting a total cavopulmonary connection
(TCPC). One patient received a TCPC and this infant is alive at an age of
10 years.
Discussion
There is a noteworthy difference in the management of prenatally detec-
ted HLHS between centers in Europe and those in the US. Although our
numbers are small, the management of the HLHS in our institution is com-
parable with the management seen in a study performed by Andrews et al.
in the UK. The percentages of the intention-to-treat group are 34% (our
study) versus 36% (Andrews et al.). However, there is a slight difference in
the choice of termination of pregnancy (50% vs 60%) and compassionate
care (16% vs 3.5%) between our and Andrews’ study respectively. If we com-
pare these above mentioned studies with the study performed by Allan et
al. from the US, a striking significant difference (P<0.05) is encountered in
the choice of all treatment options. As the intention-to-treat group consti-
tutes 67% of all patients (Allan et al.), we may conclude that this center in
the United States favors a surgical treatment policy. The group of parents
that opt for termination of pregnancy constitutes only 13%, and in 20% of
all cases parents declined treatment and chose for compassionate care
(Figure 1).
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TOP = Termination of pregnancy, CC = Compassionate care, IUD = intrauterine death,
ITT = Intention-to-treat
The different approach to this structural cardiac anomaly may be attribu-
ted to different socioreligious opinions on the management of this type of
lesion. We might carefully state that clinicians and parents in Europe are
more concerned with the longterm psychoneurological outcome and even-
tual quality of life of these infants and therefore chose for a less aggressive
management venue, i.e. no surgical treatment in the prenatal group.
This might well change in the future as survival rates of the palliative
Norwood procedure improve, the shortterm neurological deficit seems to
decrease and as more documented information on the longterm neurologi-
cal outcome and quality of life for these infants will become available.
Since the Netherlands have no pediatric heart transplantation programme
parents of patients with a HLHS are exclusively offered the staged palliati-
ve Norwood strategy21-26 and no palliative Norwood procedures are offered
with the intention of performing a cardiac transplantation at a later stage.
Because of the short history of the palliative Norwood procedure no data
are available on the consequences of the procedure on the longterm condi-
tion of the right ventricle, which serves as the systemic ventricle.
Figure 1
Management of prenatally detected HLHS: comparison of three centers 
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In our surgery group of seven patients, one patient was found to have
another associated malformation. Of the six patients without associated
anomalies one is alive at an age of 17 months, and three out of six patients
(50%) have survived the first stage of the palliative Norwood procedure.
This is in accordance with the study reported by Allan et al. in which an
early survival rate of 50% (7/14) after the first stage is described.8 Andrews
et al. reported on the outcome of staged reconstructive surgery and
showed an early survival of 52%.20 More recently however, Tworetzky et al.
showed an improved early survival of 100% (14/14) after the first stage pal-
liative procedure in prenatally diagnosed patients. Unfortunately we did
not see an apparent better outcome of staged reconstructive surgery for
HLHS following prenatal diagnosis. This might be due to the small numbers
we describe in our series.
The above mentioned studies and our study are dealing with early survival
of patients with an in utero diagnosis of the HLHS, where a palliative
Norwood procedure is successfully performed and patients are discharged
home in good condition. Tworetzky also described the management of
postnatally detected cases. Reviewing his excellent results for the prenatal
group we have to take into consideration that because of prenatal diagno-
sis these patients probably arrive in an optimal condition at surgery, pre-
venting lactates to increase, which opens a brighter future with a better
neurophysiologic outcome.27 Tworetzky even states that the difference in
early survival between the surgical groups with and without a prenatal
diagnosis of the anomaly, is likely based on the more stable preoperative
clinical condition of the prenatally diagnosed patients. This is most proba-
bly the determining factor in the difference in improved survival between
the two groups.19 This corresponds with Verheijen et al. who showed a sig-
nificant improvement of the preoperative metabolic condition of the neo-
nate with a prenatal diagnosis of the heart defect due to the possibility of
ideal perinatal care.27-29 This study included the whole range of structural
cardiac anomalies.
A study by Plantinga et al.7 on the surgical treatment of HLHS in our center
included 45 patients with a postnatal diagnosis of the anomaly. Parents
opted for surgical treatment in 18 cases (40%) and for compassionate care
in 27 (60%). In the intention-to-treat group one patient died before the
first stage of the Norwood procedure could be performed. These numbers
are significantly different compared to the results Tworetzky et al. showed
for their postnatal population: intention-to-treat was 69% and the choice
for compassionate care 31%. Remarkable is that in the postnatal group
parents make a different choice in the US than in the Netherlands despite
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the comparable numbers for early survival after first stage palliation: our
postnatal population undergoing the palliative Norwood procedure had an
early survival rate of 65% (11/17) compared to 66% in Tworetzky’s popula-
tion.19 This different approach to postnatally detected cases may again be
attributed to different socioreligious opinions on the management of this
type of lesion, on the emphasis on the eventual quality of life in the
Netherlands and on the impact of a more defensive type of medicine in the
US (Figure 2).
CC  = Compassionate care, ITT = Intention-to-treat
As the HLHS is associated with a high incidence of extracardiac or other
intracardiac anomalies (in our series 13 out of 32 infants: 41%), its manage-
ment is complicated. As mentioned earlier this cardiac anomaly is readily
detectable before 20 weeks gestation by echocardiographic examination.8,9
Although the detection of major malformations seen in the four-chamber
view is still not 100%, the pick-up rate of HLHS is reported to be
improving.8 Eapen et al.30 reported a sensitivity of 25% for the prenatal
detection of critical left heart obstructive lesions whereas Buskens et al.31
reported a sensitivity of 43% for structural cardiac anomalies. In our popu-
lation we found a prenatal: postnatal ratio of patients with a HLHS of 0.71.
Once a HLHS is diagnosed in utero parents have several options to choose
from. It is our policy to inform parents on all the current and future aspects
Figure 2
Management of postnatally detected HLHS: comparison of two centers 
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of the HLHS and provide them with a Patient Information Document (PID),
which describes in detail the various possibilities for management of this
anomaly, surgical results, and surgical and neurological hazards. In this
PID, the results are described of the study by Plantinga et al. Although
these surgical results are relatively poor, the technique and operative
results are still improving. After this extensive counseling, it is made clear
that parents will be fully supported in their decision.
The largest group of parents chose to terminate the pregnancy. This choice
was based on the presence of associated lesions or the need for multiple
operative procedures for their young infant combined with a questionable
longterm quality of life. In the Netherlands parents may opt for TOP if the
lesion is detected before a gestational age of 24 weeks. Termination of
pregnancy after 24 weeks gestation is only a possible option when it is cer-
tain that the structural or chromosomal lesions encountered are not com-
patible with life.
Parents may opt for compassionate care after delivery for reasons mentio-
ned above. Advanced gestational age or socioreligious reasons usually
exclude a TOP in this group. Parents will be counseled and supported
during this difficult period and the infant cared for by their general practi-
tioner in the home situation, while stress or discomfort of the infant will
be prevented medically.
The longterm effect on neurodevelopmental outcome, as a potential
advantage of in utero diagnosis, has not been clarified yet.6 Although no
consensus exists on the occurrence of neurological complications in infants
with a HLHS, some authors have reported data on the neurological deve-
lopment of these infants. They most often function in the low-normal
range of intelligence and adaptive behaviour.13,18,32-34 Mahle and Rogers evalu-
ated the neurodevelopmental outcome in infants with HLHS who under-
went staged surgical repair and reported varying degrees of mental retar-
dation and severe cerebral palsy.6,12 The surgical procedure in infancy may
have contributed to these neurological hazards, as they might be attributa-
ble to cardiopulmonary bypass and deep hypothermic cardiac arrest neces-
sary during open-heart surgery.11,35
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Conclusion
This descriptive paper aims to review the management and outcome of the
HLHS diagnosed prenatally in a single center over 13 years and to compare
its management with other centers. The management at our center is in
accordance with the management in another center from the UK. However,
our data show a significant difference in the prenatally diagnosed group as
far as intention to treat and rates of termination of pregnancy are concer-
ned, when we compare our series with that in the United States. The
management of postnatally diagnosed patients also shows a significant
difference, but the percentages of early survival after the palliative
Norwood procedure do not differ between the reported series. Although
our numbers are small compared to reports of other recently published
reports show that prenatal diagnosis allows informed decisions about
management options, and facilitates preoperative care. Mortality following
the palliative Norwood procedure is high, but medium term outcome for
survivors is good.
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Abstract
Objectives 
A meta-analysis of the literature on Ebstein’s anomaly and a comparison of
the results in a tertiary level referral center for pediatric cardiology and
cardiac surgery. Included is a review of the diagnosis, management and
outcome in cases of Ebstein’s anomaly.
Methods 
A diagnosis of tricuspid valve anomaly was made in 14 fetuses. Isolated
Ebstein’s anomaly occurred in 4 patients. One patient had Ebstein’s anoma-
ly associated with discordance of the great arteries, congenitally corrected
transposition of the great arteries. Tricuspid valve dysplasia was encoun-
tered in 10 fetuses.
Results 
In the group with Ebstein’s anomaly (n=4) two fetuses died in utero at a
gestational age of 29 and 36 weeks. Parents opted for compassionate care
in one fetus that died at an age of 2 days. One patient with congenital cor-
rected transposition of the great arteries is alive at an age of 9 years after
receiving pulmonary artery banding, a partial cavopulmonal connection
and a Damus-Kay-Stansel operation. In this group two fetuses had hypopla-
sia of the lungs, of which one had a chromosomal anomaly (trisomy 18).
Conclusion 
Patients with a prenatal diagnosis of Ebstein’s anomaly or dysplasia of the
tricuspid valve represent the most serious component of the spectrum of
Ebstein’s malformation. The very poor outcome is representative for this
selected population and cannot be compared to patients in which the ano-
maly is detected in later life. Parental counseling of these patients can
therefore not be based upon the natural history of these older patients.
Prenatal diagnosis provides opportunities for in-depth counseling of the
parents before the medical and emotional complexities associated with the
neonatal intensive care setting are encountered. Surgical procedures of tri-
cuspid valve repair or replacement are offered for this anomaly, but this
option is almost exclusively provided for patients with a diagnosis in later
life, as very few patients survive the neonatal period.
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Introduction
Anatomy
Dysplastic malformations of the tricuspid valve (TV) include a wide range
of morphologic features.1 The pathological spectrum of dysplasia of the tri-
cuspid valve starts with deformation of the leaflets and the tension appa-
ratus, but without downward displacement, an arrangement primarily
described as dysplasia, and ranges to lesions in which the primary lesion is
downward displacement of the proximal attachment of the posterior and
septal leaflets, known as Ebstein’s anomaly (EA). Although the anatomical
spectrum varies, the clinical expression is similar and the outcome depends
primarily on the severity of the tricuspid insufficiency, rather than the ana-
tomical substrate.2-7
Prevalence
The prevalence of Ebstein’s anomaly and tricuspid valve dysplasia (TVD) is
approximately 0.5-1.0 % of patients with congenital heart disease.8,9
Patients with Ebstein’s anomaly may present at any age, including the pre-
natal period. Most cases are sporadic, but familial occurrence has been
documented. Fetal echocardiography is a very sensitive (91.6%) and specific
(99.9%) tool for antenatal diagnosis of congenital heart disease in high-
risk pregnancies.10,11 The experience with prenatal detection of structural
congenital heart defects is still increasing and the methods of prenatal
examination become more sensitive.12 Therefore more lesions of this kind,
even the milder cases, will be detected in utero which might improve the
overall outcome and will raise questions about the management of the
fetus during pregnancy and in immediate postnatal life.
Indications for intrauterine evaluation
Fetal factors 
Fetal factors for reference include fetal arrhythmias, fetal hydrops and/or
hydramnion, but most patients with an in utero diagnosis are referred
because of an abnormal four-chamber view on a routine prenatal ultra-
sound.13,14 This abnormal four-chamber view is not infrequently associated
with the existence of non-immune hydrops fetalis and associated arrhyth-
mias.
Maternal factors 
Maternal factors for referral include: a history of congenital heart disease
in the previous offspring of the mother, gestational diabetes and teratoge-
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nic exposure to drugs, mostly lithium therapy, during pregnancy.6,15-17
The latter forms a special indication for referral. A direct teratogenic effect
of lithium on the atrioventricular junction is thought to facilitate the deve-
lopment of Ebstein’s anomaly.18 While initial information regarding the
teratogenic risk of lithium treatment was derived from retrospective
reports, more recent epidemiological data indicate that the teratogenic risk
of first trimester lithium exposure is lower than previously suggested. An
incidence of 2-8% of the occurrence of Ebstein’s anomaly has been repor-
ted with lithium use during pregnancy, whereas the normal incidence of EA
is 1 in 20.000 births.19 Finally, one study reported that the development of
polyhydramnios in the last trimester could be explained by lithium
crossing the placenta and causing fetal polyuria, which results in the detec-
ted polyhydramnios.20 As a general rule most authors state that the admi-
nistration of lithium should be avoided during pregnancy at least during
the first trimester and, if used, the patients should definitely have a timely
fetal echocardiographic investigation.
Echocardiographic features
As cardiac structural anomalies and functional problems in the fetus can
be detected by prenatal echocardiography from 16 weeks gestation, a sys-
temic assessment of the four-chamber view can pick up more than half of
the intracardiac abnormalities such as Ebstein’s anomaly and tricuspid
valve dysplasia.21-23 The echocardiographical examination is dominated by
the enlarged right atrium and the dilated atrioventricular annulus. In
Ebstein’s anomaly the degree of the tricuspid valve displacement divides
the right ventricle in a proximal or inlet portion, which is atrialized, and
the distal trabecular portion, which makes up the remaining functional
ventricle. The wall of the atrialized portion is usually thinner than that of
the functional right ventricle.24,25 Early presentation is more frequently asso-
ciated with cardiac lesions, usually pulmonary stenosis or atresia. Serious
underdevelopment of pulmonary tissue, caused by either primary pulmo-
nary hypoplasia or secondary pulmonary dysplasia is frequently encountered.
Associated abnormalities
Intracardiac abnormalities
Other intracardiac malformations reported in Ebstein’s anomaly are atrial
septal defects, ventricular septal defect, pulmonary stenosis or atresia,
mitral valve prolapse, endocardial fibroelastosis and less frequently the
rare combination of Ebstein's anomaly with ventricular L-loop, corrected
transposition of the great arteries.26-28 One study reported cardiac rhabdo-
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myomata.29 Fetal rhythm disorders such as supraventricular tachycardia
(SVT) and atrial flutter (AF) are also frequently encountered.30
Extracardiac abnormalities
Other extracardiac malformations reported in Ebstein’s anomaly are
hydrops fetalis associated with the presence of SVT or AF.30 The presence 
of tuberous sclerosis was seen in one case-report.31
Other anomalies described associated with Ebstein’s anomaly are the Holt-
Oram syndrome, a dominantly inherited syndrome of skeletal abnormali-
ties.32 The association of Ebstein’s anomaly and chromosomal abnormali-
ties, such as Down syndrome, is extremely unusual.33,34
Pathophysiology
The pathophysiology is similar in both groups of the anomaly of the tricus-
pid valve. The natural history depends on the varying degrees of severity of
incompetence of the tricuspid valve, the presence or absence of an atrial
septal defect, the degree of impairment of right ventricle function and
associated clinical findings. Although the right ventricular abnormalities
might be explained by hemodynamic stress in utero, abnormalities of the
left ventricular free wall, which are also sometimes encountered, suggest
that either genetic or non-hemodynamic environmental factors are invol-
ved in the morphogenesis of this condition.35,36
The fetal and neonatal period however are dominated by the extent and
pathophysiology of the pulmonary hypoplasia. Once the crucial neonatal
phase is survived and pulmonary problems prove to be surmountable, the
outlook becomes more comparable to that of older children and adults and
is usually associated with an excellent outcome.3,13,24,25
Intrauterine course and mode of delivery
Spontaneous intrauterine death is reported, as high as 48%, and 35% of
those who were live-born died despite vigorous medical and, when neces-
sary, surgical management, of a combination of hypoxia and severe con-
gestive heart failure.31 Early detection of tricuspid valve disease has led
parents to the option of termination of pregnancy in view of the poor post-
natal course of the anomaly. For those deciding to continue the pregnancy
no advantage of a cesarean section has been proven and a normal delivery
is therefore suggested.
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Postnatal interventions and outcome
The diagnostic potential and importance of fetal echocardiography during
prenatal evaluation of cardiac malformations allows for adequate perinatal
planning and management, with an obvious impact on morbidity and mor-
tality.30 Some report a policy of induction at term and immediate surgical
intervention when Ebstein's anomaly was diagnosed prenatally.37
Despite these efforts most patients with a prenatal diagnosis surviving the
fetal period die of a combination of pulmonary and cardiac insufficiency
shortly after birth. The prognosis of Ebstein's anomaly during fetal life is
not influenced by criteria described for postnatal life but is primarily rela-
ted to the hypoplastic lungs and to factors that control the volume load of
the left ventricle. Previous studies have indicated that in cases with dila-
tion of the chambers of the right heart, pulmonary atresia and an intact
ventricular septum the prognosis is even worse. The degree of cardiomega-
ly may provide useful information about secondary lung compression or
cardiac failure and therefore assists in giving an accurate prognosis for
postnatal survival.38 When surgical intervention becomes necessary, it is
essential to make a detailed assessment of both valvular and ventricular
abnormalities (Figure 1 and 2).
Experience
Prenatal diagnosis of Ebstein’s anomaly or tricuspid valve dysplasia was
established in 14 patients at the University Medical Center Utrecht in the
Netherlands between January 1, 1988, and July 31, 2001. The diagnosis of EA
was based on two-dimensional echocardiographic evidence of a downward
displacement of the septal leaflet of the TV, as seen in the apical four-
chamber view. If the TV inserts on the ventricular septum more than 8
mm/m2 below the insertion of the mitral valve, the diagnosis can be
made.24 In case of TVD only an abnormal thickened and irregular TV but no
apparent downward displacement is seen on echocardiography.16
In these 14 patients with a dysplastic tricuspid valve Ebstein’s anomaly was
only documented in four. One fetus with Ebstein’s anomaly died in utero at
a gestational age (GA) of 29 weeks and another with associated hypoplasia
of the lungs and trisomy 18 died at a GA of 36 weeks. Parents opted for
compassionate care in one fetus that died at an age of 2 days. In another
fetus parents chose for surgery in which Ebstein’s anomaly was associated
with a congenitally corrected transposition of the great arteries. This
patient received a pulmonary artery banding at one week of life, later a
partial cavopulmonary connection (PCPC), and at a later stage a Damus-
Kay-Stansel operation. This patient is still alive at an age of 9 years.
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Figure 1 
Figure 2 
[A] Fetal chest with enlarged heart. 
LA = Left atrium, LV = Left ventricle, RA = Right 
atrium, RV = Right ventricle.
[B] Fetal chest with Ebstein’s anomaly and the 
typical downward displacement of the tricuspid 
valve. 
[C] Fetal chest with Ebstein’s anomaly and 
hypoplastic lungs.
[A] Ebstein’s anomaly with downward 
displacement of the tricuspid valve and 
enlarged right atrium compressing the left 
atrium.
[B] Dysplastic tricuspid valve syndrome with 
downward displacement of the tricuspid valve 
but with enlarged right atrium compressing 
the left atrium.
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Discussion
Patients with Ebstein’s anomaly may present at any age, including the pre-
natal period. Patients with an in utero diagnosis were most commonly
referred because of an abnormal routine prenatal ultrasound.13,14 Fetuses
may also be referred for an associated arrhythmia, gestational diabetes, a
history of maternal lithium ingestion, and a history of congenital heart dis-
ease in the offspring.16,17,30
Ebstein’s anomaly and dysplasia of the tricuspid valve can both be easily
recognized during routine prenatal ultrasonography, since it tends to pro-
duce significant cardiomegaly and regurgitation. These structural abnor-
malities should prompt the need for an in-depth fetal echocardiographic
evaluation and search for associated malformations.39, 40
The clinical presentation of Ebstein’s anomaly varies for the different age
groups. In utero patients may develop significant right ventricular outflow
tract obstruction, congestive heart failure, cardiomegaly, pulmonary hypo-
plasia and hydrops fetalis. Presentation in utero is associated with a signifi-
cant risk of death, which can be predicted by the echocardiographic
appearance and presence of associated lesions. Early presentation was fre-
quently associated with other cardiac lesions, usually pulmonary stenosis
or atresia. The high incidence of intrauterine death in our series is in accor-
dance with other studies.13 Neonatal survivors mostly present with cyanosis
and heart failure.9 
The poor prognosis of the fetus is mainly due to the incompetence of the
tricuspid valve, leading to right atrial enlargement and subsequently pul-
monary hypoplasia or cardiac failure.13,38 Some authors have suggested that
a myocardial problem and not pulmonary artery atresia or stenosis is the
leading pathologic factor for the incompetence of the tricuspid valve. The
dominating problem in the perinatal age group, the reduction in size of the
lungs, may simply be a consequence of the dilation of the chambers of the
heart. During the crucial fetal period of development, the lungs have no
space to grow since the heart occupies the larger part of the thoracic cavi-
ty.3 The possibility exists that if cardiac dilation could be avoided by thera-
peutic measures during fetal life, the lungs would grow normally, giving a
much better prognosis.40 
Patients presented with Ebstein’s anomaly in utero should be monitored on
a regular basis for the development of arrhythmias and effusions. Some
fetal arrhythmias can be managed by maternal administration of antiar-
rhythmic agents.41 The presence of enlarging effusions and hydrops are
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poor prognostic signs and may be an indication for premature delivery
after administration of steroids to maximize lung maturity.
Once a fetus survives the perinatal period, further management depends
on the severity of the tricuspid valve anomaly. If it is technically possible,
the preferred surgical procedure is repair rather than replacement of the
tricuspid valve and closure of the atrial septal defect under cardiopulmona-
ry bypass. Variations on this theme have been proposed by others.4,42,43
In milder cases the full-term neonate presenting with cyanosis might
benefit from treatment with prostaglandine E1 to maintain ductal patency.
Conclusion
Ebstein’s anomaly remains a severe and frequently fatal disorder in the
fetus, with gross echocardiographic abnormalities, readily detectable by
routine obstetrical ultrasound.14  In Ebstein’s anomaly visualization of an
apical displaced septal tricuspid leaflet has been shown to be the most
diagnostic feature. There is much overlap between valvular dysplasia and
Ebstein’s anomaly, and therefore the two conditions can be readily confu-
sed with each other on the echocardiogram. Differentiation is very impor-
tant, but sometimes difficult. Knowledge of the natural history and the
observed poor outcome in continuing pregnancies, allows us to counsel
parents on the course of the disease in the fetus and possible management
during fetal life. In general, the earlier the patient presents with the mal-
formation, the poorer the prognosis. Fetal and neonatal presentation is
typically associated with a dismal outcome secondary to the almost always
occurring pulmonary hypoplasia.24,44
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Prenatale diagnostiek bij structurele congenitale 
hartafwijkingen; effectiviteit en gevolgen
87
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Nederlandse samenvatting
Inleiding 
De zorg voor patiënten met een congenitale hartafwijking lijkt door een
prenatale diagnose geoptimaliseerd te kunnen worden. Deze retrospectieve
studie analyseert aan de ene kant de groep met een prenatale diagnose
van een structurele hartafwijking en aan de andere kant de groep die in de
neonatale periode chirurgie nodig had voor een hartafwijking.
Methode 
Binnen de prenatale groep werd gekeken naar management en follow-up
en bij de chirurgie groep werd er gekeken in hoeverre er prenatale diagnos-
tiek had plaatsgevonden en of een prenatale diagnose invloed had op de
mate van verzuring.
Resultaten
Prenatale echogroep: Van de 170 prenataal gediagnosticeerde hartpatiëntjes
overleed 64% tijdens of kort na de zwangerschap of werd de zwangerschap
beëindigd, terwijl 14% binnen 31 dagen post partum werd geopereerd. Deze
vormen dus een overlap met de chirurgie-groep.
Chirurgie-groep: Chirurgie in de neonatale periode werd bij 191 patiënten
uitgevoerd, inclusief de 24 uit de prenatale groep. 87% was prenataal niet
gediagnosticeerd. Significant betere preoperatieve lactaatwaarden werden
gevonden bij de groep met een prenatale diagnose.
Conclusie 
Slechts 13% van de patiënten uit de chirurgiegroep werd prenataal gedetec-
teerd, ondanks dat dit technisch mogelijk was bij 46%. Een verbetering van
dit percentage is van belang voor het maken van een weloverwogen keuze
tussen zwangerschapsbeëindiging, conservatieve therapie of spoedchirur-
gie, waarbij prenatale diagnostiek voor een verbetering wat betreft morta-
liteit en morbiditeit zou kunnen zorgen.
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Abstract
Objectives
Prenatal diagnosis of congenital heart disease (CHD) is likely to contribute
positively to the care of patients with a CHD. This retrospective study
analyzes data from one group, whose cardiac anomaly was diagnosed
prenatally and another group, who required surgery for their CHD in the
neonatal period.
Methods 
In the prenatal group management and follow-up were analyzed while in
the surgery group the percentage in which ultrasound investigations were
performed, the efficacy of prenatal ultrasound and the influence of a pre-
natal diagnosis on the severity of acidosis were analyzed.
Results 
Prenatal group: 64% of the prenatally diagnosed patients died before or
right after birth, while 14% needed surgery in the neonatal period.
These patients are also included in the surgery group.
Surgery group: Surgery in the neonatal period was required in 191 patients,
including the 24 from the prenatal group. 87% had no prenatal diagnosis of
their heart disease. In the group with a prenatal diagnosis preoperative lac-
tate values were significantly better.
Conclusions 
Only 13% of the patients from the surgery group were prenatally detected,
while this was technically feasible in 46%. A larger percentage of prenatal-
ly diagnosed CHD could contribute to a better counseling of parents in
their choice between termination, conservative treatment or emergency
surgery with prenatal detection hopefully leading to a decrease in morbidi-
ty and mortality.
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Inleiding
Er zijn in toenemende mate aanwijzingen dat prenatale diagnostiek een
positieve invloed heeft op de uitkomst van congenitale hartafwijkingen,
zowel in relatie tot de morbiditeit1,2 als tot de mortaliteit.3,4 
Prenatale diagnostiek van hartafwijkingen gebeurt door middel van foetale
echocardiografie. Indicaties voor deze foetale echocardiografie zijn beperkt
tot de bekende maternale en foetale risicogroepen.5,6 Deze vormen echter
ondanks hun verhoogde risico slechts een zeer klein deel van de totale hoe-
veelheid patiënten met een congenitaal hartdefect.7 De overgrote meerder-
heid wordt geboren uit gezonde moeders zonder enige indicatie voor een
verhoogd risico. Het opsporen van deze patiënten middels routine echocar-
diografische screening is een arbeidsintensieve en daardoor kostbare zaak.
In deze studie is gekeken naar de resultaten van prenatale diagnostiek van
structurele congenitale hartafwijkingen en de impact ervan op beleid en
behandeling. Daarnaast wordt de effectiviteit van de huidige prenatale
screening in kaart gebracht met als doel een eventuele discrepantie tussen
de vermeende potentie van screenende prenatale echografie van aangebo-
ren hartafwijkingen enerzijds en de huidige situatie in de praktijk in
Nederland anderzijds op het spoor te komen.
Methode
In deze retrospectieve studie zijn twee verschillende, deels overlappende,
groepen patiënten betrokken afkomstig uit dezelfde regio in de periode
januari 1991- juli 1999. De eerste groep bestaat uit patiëntjes met een
structurele congenitale hartafwijking, die prenataal gediagnosticeerd is
door middel van foetale echocardiografie. De tweede groep bestaat uit
patiëntjes die in de neonatale periode geopereerd werden aan een conge-
nitale hartafwijking.
Prenatale echogroep
Tussen 1 januari 1991 en 1 juli 1999 werden 3086 zwangere vrouwen naar
het foetale cardiologie programma van het UMC Utrecht verwezen voor
specifieke cardiale evaluatie van de foetus, welke wordt verricht door een
echografist onder supervisie van een kindercardioloog. In deze regio
bestaat geen routine echocardiografische screening voor alle zwangeren
maar wordt een prenatale hartecho pas gemaakt op indicatie na verwij-
zing. Indicaties voor verwijzing waren maternale en foetale risicofactoren.
Onder maternale risicofactoren worden hartafwijkingen bij eerste of twee-
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degraads familieleden, maternale diabetes mellitus, maternale leeftijd en
maternale teratogeen expositie verstaan. Foetale risicofactoren zijn elders
gediagnosticeerde extracardiale anomalieën, hydrops foetalis en foetale
aritmieën. Daarnaast vond verwijzing in 53% van de gevallen plaats op
basis van verdenking op een abnormaal vierkamerbeeld bij tweedelijns
echografisch onderzoek.
In totaal werd bij 170 patiënten (5,5%) een congenitale hartafwijking
gediagnosticeerd. Bij deze patiënten werd behalve naar de indicatie voor de
echo ook gekeken naar de echodiagnose, het gevoerde beleid, follow-up tot
juli 1999, eventuele geassocieerde chromosoomafwijkingen en de uitkomst
van de obductie. De prenataal gestelde diagnose werd vergeleken met de
diagnose bij postnatale echografie. De ouders werd in het kader van de
opsporing van vals negatieve echo-uitslagen verzocht bij eventuele postna-
tale cardiale problematiek contact op te nemen.
Chirurgie-groep
In dezelfde periode werden 191 patiëntjes in het kinderhartcentrum van het
Wilhelmina Kinderziekenhuis binnen de neonatale periode geopereerd aan
een congenitale structurele hartafwijking. Er is gekeken welke patiëntjes
uit de prenatale echogroep van het UMC Utrecht kwamen. Middels infor-
matie van huisartsen, verloskundigen, kinderartsen en gynaecologen werd
verder nagegaan of er bij de overige patiënten een prenatale echo gemaakt
was, wat de indicatie was, of er een vierkamerbeeld gemaakt was en wat
de echodiagnose was. Bij deze patiëntjes zijn tevens middels statusonder-
zoek de at random afgenomen bloedgaswaarden geanalyseerd. Waarden
voor base excess, lactaat en pH werden in de analyse meegenomen.
Resultaten
Prenatale echogroep
Bij 5,5% (170) van de zwangere vrouwen, waarbij echocardiografie plaats-
vond, werd een structurele congenitale hartafwijking geconstateerd.
Chromosoom analyse werd 125 maal uitgevoerd, waarbij bij 55 patiënten
een anomalie geconstateerd werd.
Spontane intra-uteriene vruchtdood trad bij 23/170 patiënten op. Bij negen
van deze 23 patiënten werd door de ouders toestemming tot obductie
gegeven. Zeven van deze negen patiënten hadden bij obductie dezelfde
diagnose als prenataal. Een patiënt waarbij prenataal een hydrops en een
klein inlet VSD  werd gezien bleek bij obductie het syndroom van Turner te
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hebben en geen VSD meer. Tenslotte werd bij een patiënt, prenataal gedia-
gnosticeerd met een milde hypertrofie van de ventrikels naast een prune-
belly, bij obductie geen hartafwijking gevonden.
Tot beëindiging van de zwangerschap werd in 56/170 gevallen besloten
(Tabel 1).
Tabel 1 Hartafwijkingen en overige malformaties bij de 56 afgebroken zwangerschappen uit
de prenatale echogroep.
Cardiaal en overige afwijkingen 36 patiënten
Hartafwijking Geassocieerde afwijking
Single ventricle (4 patiënten) Trisomie 13/18, 68 XX, aangezichtsschisis,
nierpathologie
Malalignment VSD (6 patiënten) Trisomie 13/18, hernia diafragmatica,
verwijde hersenventrikels, anus agenesie,
darm malrotatie
AVSD (11 patiënten) Trisomie 18/21, T12-T19 translocatie,
omfalocèle
VSD (8 patiënten) Trisomie 18, omfalocèle, encefalocèle,
hygroma colli
AVSD, TAPVC (2 patiënten) Heterotaxie
Ectopia cordis (2 patiënten) Gastroschisis, omfalocèle, buikwanddefect,
anencephalie
RV hypertrofie, fibro-elastose Cerebrale AV-malformatie
Gefuseerd hart Conjoined twin
Twin transfusion syndroom
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Enkel cardiale afwijkingen 20 patiënten
Hartafwijking
Malalignment VSD met extreme 
pulmonaal arterie hypoplasie (4 patiënten)
Single ventricle (4 TA en 11 HLHS)
PA
AVSD = Atrioventriculair septum defect, HLHS = Hypoplastisch linker hart syndroom,
PA = Pulmonalis atresie, RV = Rechter ventrikel, TA = Tricuspidaal atresie, TAPVC = Totaal
abnormale pulmonale veneuze connectie, VSD = Ventrikel septum defect
Bij 36 van deze 56 patiënten werd door de ouders toestemming tot obduc-
tie gegeven. Vijfendertig van deze 36 patiënten hadden na obductie dezelf-
de diagnose als prenataal. Een patiënt met een trisomie 18 bleek postna-
taal een VSD te hebben in plaats van een AVSD. Ruim de helft van de prena-
taal gediagnosticeerde patiënten, 91 in totaal, werd levend geboren. Bij 29
van deze 91 zuigelingen werd gekozen voor abstinentie van elke vorm van
therapie vanwege de infauste prognose van de hartafwijking (Tabel 2).8
Van deze 29 patiëntjes overleden er 14 ten gevolge van cardiale afwijkin-
gen, de overigen ten gevolge van andere geassocieerde afwijkingen. Bij 12
van deze 29 patiëntjes werd door de ouders toestemming gegeven tot
obductie. Bij alle 12 was er geen verschil tussen de prenatale diagnose en
het resultaat van de obductie. Bij de overige 17 patiënten werd de diagnose
in alle gevallen bevestigd door middel van postnatale echografie. Bij 24 van
de levend geboren kinderen vond chirurgie plaats in de eerste 31 dagen
post partum. De overige 38 levend geboren kinderen hadden geen spoed-
operatie nodig, maar ondergingen ofwel electieve chirurgie op een later
tijdstip of hadden geen chirurgie voor hun hartafwijkingen nodig. Zie voor
een overzicht Figuur 1. Bij de levendgeborenen werd de diagnose bevestigd
door postnatale echografie. Veertien maal was er een verschil tussen de
gestelde diagnose pre- en postnataal (Tabel 3). Tenslotte werd twaalf keer
een klein VSD gezien, dat later niet meer aanwezig bleek te zijn. Mogelijk ging
het hier om defecten die intra-uterien dichtgegaan zijn en derhalve worden de
desbetreffende diagnoses in deze studie niet als vals positief beschouwd.
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Tabel 2 Hartafwijkingen en overige malformaties bij de 29 patiënten uit de prenatale
echogroep waarbij tot een abstinerend beleid is besloten.
Cardiaal en overige afwijkingen 16 patiënten
Hartafwijking Geassocieerde afwijking
Malalignment VSD (3 patiënten) Longhypoplasie/nieragenesie/Trisomie 18
AVSD (7 patiënten) Trisomie 18/21/Arnold Chiari
Ebstein’s anomalie,
ASD, PS Trisomie 21
VSD (3 patiënten) Trisomie 18, hernia diafragmatica/buik-
wanddeffect/multipele cong. afwijkingen
LVOTO (2 patiënten) 22q11 translocatie/hydrops
Enkel cardiale afwijkingen 13 patiënten
Hartafwijking
ASD, hydrops, bradycardie,
cardiomyopathie
Single ventricle (9 patiënten)
Tetralogie van Fallot
TAPVC
Ebstein’s anomalie, PA
ASD = Atrium septum defect, AVSD = Atrioventriculair septum defect, LVOTO = Left ventri-
cular outflow tract obstruction, PA = Pulmonalis atresie, PS = Pulmonalis stenose,
TAPVC = Totaal abnormale pulmonale veneuze connectie, VSD = Ventrikel septum defect
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Verwijzing vond bij 18/170 patiënten plaats op basis van maternale facto-
ren, bij 43/170 patiënten op basis van foetale risicofactoren, bij 5/170
patiënten op basis van andere factoren (eigen verzoek, maternale leeftijd,
IVF zwangerschap) en bij 91/170 patiënten naar aanleiding van een afwij-
kend vierkamerbeeld bij echografie elders.
Chirurgie-groep
In totaal werden in de periode tussen januari 1991 en juli 1999 191 patiën-
tjes binnen 31 dagen (gem. 9 ± 3 dagen) na de geboorte geopereerd.
Prenatale echografie was bij 158/191 uitgevoerd. Vierentwintig van de 191
patiëntjes (13%) vormen een overlap met de prenatale echogroep (Figuur 2).
Bij 43/191 patiënten werd een vierkamerbeeld vervaardigd op een tijdsstip
dat het hart goed te beoordelen was en als normaal geïnterpreteerd.
Tenminste 17 van deze 43 patiënten hadden malformaties, die een verande-
ring in het vierkamerbeeld  tot gevolg hebben. Bij 38/191 patiënten werd
een echo gemaakt bij een zwangerschapsduur > 17 weken, maar werd de
anatomie van het hart niet geëvalueerd of werd er geen verslag van
gedaan. Bij 53 patiënten werd de prenatale echo te vroeg in de zwanger-
schap gemaakt om het hart te kunnen beoordelen.
Figuur 1  
Prenatale echogroep
Levend geboren
91
Totaal
170
Spontane IUVD
23
Geen spoedchirurgie 
38
Chirurgie <31 dgn
24
Terminatie 
56
Abstinentie 
29
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Tabel 3 Veertien maal een verschil tussen de diagnose pre- en postnataal.
Vals negatief (8 patiënten)
Aortaklep atresie met VSD en pulmonalisklep dysplasie 
Pulmonalisatresie met een klein VSD
Multipele musculeuze VSD’s
Abnormale inmonding van de longvenen
Coarctatio aortae met een VSD
Klein VSD (3 patiënten)
Diagnose onvolledig (2 patiënten)
Prenataal Postnataal
LV hypertrofie LV hypertrofie, uitstroom-obstructie,
apicaal VSD
AVSD Eisenmenger VSD 
Vals positief (4 patiënten)
Mogelijke coarctatio aortae
Mogelijke dubbele aortaboog, coarctatio niet uit te sluiten
Cardiomegalie
RV>LV, mogelijk coarctatio aortae
Negenentwintig van de patiëntjes die binnen een maand chirurgie moes-
ten ondergaan waren prenataal niet echografisch geëvalueerd. Tenslotte
bleef de antenatale geschiedenis van 4/191 patiënten onbekend.
Gemiddeld is de slechtste lactaatwaarde bij de groep zonder prenatale
diagnose 6.08 ± 0.45 mmol/L t.o.v. 3.05 ± 0.45 mmol/L bij de groep met een
prenatale diagnose (P<0.001). De slechtste preoperatieve pH is 7.28 ± 0.03
in de prenatale en 7.24 ± 0.01 in de postnatale groep (P=0.29). Slechtste
preoperatieve base excess is –5.83  ± 0.64 mEql/L voor de prenatale en
–6.93 ± 0.46 mEq/L voor de postnatale groep (P=0.10). Ook in de risico-
groep van patiënten met ductus-afhankelijke laesies zien we een signifi-
cant verschil in slechtste preoperatieve lactaatwaarde in het voordeel van
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de groep met een prenatale diagnose, 3.03 ± 0.39 versus 6.07 ± 0.49
mmol/L (P<0.05).
Discussie
Het opvallend hoge percentage kinderen met een structurele congenitale
hartafwijking binnen de prenatale echogroep kan verklaard worden door
het feit dat we hier te maken hebben met een door tweedelijns echografie
geselecteerde populatie. Daarom kan het gevonden percentage niet verge-
leken worden met percentages die gevonden worden in screeningspro-
gramma’s voor de hele bevolking.7,9
Het primaire doel van de prenatale diagnostiek van hartafwijkingen is
gelegen in het scheppen van betere voorwaarden voor de behandeling van
deze patiënten in het directe postnatale traject. Het belangrijkste voordeel
van een prenatale diagnose valt wellicht dan ook te behalen bij de
Chirurgie-groep 191
Prenatale echogroep 170
Onbekend 4
4-kamerbeeld 43
Geen 4-kamerbeeld 38
Echografie < 17 wkn 53
Geen echografie 29
Prenataal gediagnostiseerde chirurgische patiënten 24
Intra uteriene vruchtdood 23
Zwangerschaps beëindiging 56
Geen OK <31 dgn 38
Abstinentie 29
Figuur 2 
Overlap tussen chirurgie-groep en prenatale echogroep
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patiënten die in de neonatale periode geopereerd dienen te worden voor
hun hartafwijking. Door een prenatale diagnose kan het patiëntje in een
hartcentrum geboren en direct gestabiliseerd worden, waardoor stabilisa-
tie van het zuur-base evenwicht mogelijk is.
Bij een niet onaanzienlijk deel van deze diagnoses blijken de ouders echter
te besluiten tot de beëindiging van de zwangerschap of af te zien van
behandeling na de geboorte, omdat een voor de ouders acceptabele kwali-
teit van leven voor het kind niet bereikbaar lijkt. In 34% van de gevallen
werd besloten de zwangerschap af te breken. In de helft van de gevallen
gaat het om geïsoleerde, zeer ernstige en moeilijk corrigeerbare hartafwij-
kingen en bij de andere helft is sprake van congenitale hartafwijkingen
gecombineerd met chromosomale en/of orgaanafwijkingen. Bij 29 levend
geboren patiëntjes werd tot een abstinerend beleid besloten.8 In deze
groep ging het om zeer ernstige aandoeningen die echter pas na de 24ste
zwangerschapsweek gediagnosticeerd werden, zodat beëindiging van de
zwangerschap vanuit juridisch perspectief niet in aanmerking kwam of om
gevallen, waarbij de ouders vanwege socio-religieuze gronden geen zwan-
gerschapsbeëindiging verkozen. Prenatale diagnostiek bood in deze geval-
len de mogelijkheid tot het voorkomen van postnataal lijden voor de
patiënt door snelle pijnstilling en sedatie in goed overleg met de ouders.
Aangezien een groot aantal harten niet pathologisch-anatomisch kon wor-
den onderzocht en er de mogelijkheid bestaat dat binnen het gebruikte
studie-ontwerp een aantal vals-negatieve diagnosen postnataal onopge-
merkt blijven is een harde uitspraak over de daadwerkelijke effectiviteit moeilijk.
Binnen de chirurgie-groep zien we een discrepantie tussen de pogingen om
een groot gedeelte van de hartafwijkingen prenataal te diagnosticeren en
de mate waarin prenatale diagnostiek heeft plaatsgevonden in de groep
waarbij een spoedoperatie is uitgevoerd. Zevenenentachtig procent van de
patiëntjes had geen cardiale evaluatie ondergaan in de derde lijn. Bij 43%
was geen echo of een echo voor de zeventiende zwangerschapsweek
gemaakt en kon er dus ook geen sprake zijn van een eventuele vroegtijdige
herkenning van het hartgebrek. Bij 42% was echter wel een echo gemaakt,
maar het vierkamerbeeld niet of als niet afwijkend beoordeeld. Deze inade-
quate echografie beoordeling verminderde het aantal patiëntjes dat prena-
taal gediagnosticeerd had kunnen worden, zorgde voor een aanzienlijk
behandelingsdelay en verminderde daarmee de kansen voor deze patiën-
tjes. Daarnaast gaf deze situatie vaak aanleiding tot een groot onbegrip bij
de ouders, die na vaak diverse echo’s begrepen hadden dat alles met hun
kind in orde was.
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Het feit dat er wel een verschil in lactaatwaarden en niet in pH of BE-waar-
den gevonden wordt kan verklaard worden door het feit dat een verhoging
van lactaat veel langer meetbaar blijft terwijl pH en BE zeer snel door
bicarbonaat-toediening genormaliseerd kunnen worden. Het at random
afnemen van bloedmonsters zou wel eventueel de mogelijkheid van een
bias met zich mee kunnen brengen.
Conclusie
Aangezien in de regio Utrecht slechts 13% (24/191) van de congenitale hart-
afwijkingen, die ‘emergency chirurgie’ nodig hebben, prenataal wordt
gediagnosticeerd, blijft er een grote ruimte voor verbetering. Aangezien er
steeds meer aanwijzingen komen dat prenatale diagnostiek een positieve
invloed heeft op uiteindelijke morbiditeit en mortaliteit en in de onder-
zochte populatie een positief effect van prenatale diagnostiek op het voor-
komen van metabole acidose wordt gevonden, lijkt een hogere detectie-
graad ook in Nederland wenselijk.1-3,10 Adequate en laagdrempelige trai-
ningsmogelijkheden zouden de basis moeten vormen om dit doel te berei-
ken, waarbij een betere training noodzakelijk lijkt aangezien alleen uitbrei-
ding van het aantal ‘views’ onvoldoende blijkt te zijn. Een prenatale diag-
nose blijft te vaak achterwege ten gevolge van misinterpretatie of tech-
nisch onjuist verrichte echografie.
Als conclusie kan gesteld worden dat er een grote discrepantie bestaat tus-
sen de vermeende potentie van screenende prenatale echografie van aan-
geboren hartafwijkingen enerzijds en anderzijds de huidige situatie in de
praktijk in Nederland.
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Abstract
Objectives 
The aim of this retrospective study was to evaluate perinatal atrial flutter
(AF) and the efficacy of maternally administered antiarrhythmic agents,
postpartum management and outcome. Perinatal AF is a potentially lethal
arrhythmia and management of this disorder is difficult and controversial.
Methods 
Forty-five patients with documented AF were studied retrospectively.
Results 
Atrial flutter was diagnosed prenatally in 44 fetuses and immediately post-
natally in 1 neonate. Fetal hydrops was seen in 20 patients, 17 received
maternal therapy, 2 were delivered and 1 was not treated because it had a
severe nontreatable cardiac malformation. In the nonhydropic group of 24
patients, 18 were treated and the remaining 6 were delivered immediately.
In the hydropic group, 10 received single-drug therapy (digoxin or sotalol)
and 7 received multi-drug therapy. In the nonhydropic group, 13 received a
single drug (digoxin or sotalol) and 5 received multiple drugs. One patient
with rapid 1:1 atrioventricular conduction (heart rate 480 beats/min) died
in utero and another died due to a combination of severe hydrops because
of the AF, sotalol medication, stenosis of the venous duct and hypoplastic
placenta. Of the 43 live-born infants, 12 were in AF at birth. Electrical car-
dioversion was successful in eight of nine patients. No recurrences in AF
have occurred beyond the neonatal period. Four patients with fetal flutter
and hydrops showed significant neurological pathology immediately after
birth.
Conclusions 
Fetal AF is a serious and threatening rhythm disorder; particularly when it
causes hydrops, it may be associated with fetal death or neurological
damage. Treatment is required and primarily aimed at reaching an ade-
quate ventricular rate and preferably conversion to sinus rhythm. Digoxin
failed in prevention of recurrence at time of delivery in a quarter of our
patients, whereas with sotalol no recurrence of AF has been reported, sug-
gesting that class III agents may be the future therapy. Once fetuses with
AF survive without neurological pathology, their future is good and prophy-
laxis beyond the neonatal period is unnecessary.
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Introduction
Atrial flutter (AF) is an uncommon form of tachycardia in infancy and child-
hood, the management and particularly the pharmacological treatment of
which continue to pose a challenge to clinicians and electrophysiologists.
This pertains even more to perinatal AF, a rhythm disorder in which the
rate differs from that seen in adult patients and of which underlying etio-
logy and pathophysiology (in the presence or absence of structural heart
disease and secondary atrial dilation) still need to be determined in
humans. The description of intrauterine AF by Carr and McLure1 in 1931 is
probably the first published report; Blumenthal et al.2 documented intra-
uterine AF with the use of fetal electrocardiography in 1968. Currently, fetal
echocardiography is the best method and remains the cornerstone for in
utero diagnosis.
Observations from the early reports1-5 of atrial flutter in the fetus and new-
born infant include a rapid intrauterine heart rate and an abrupt irregular
rhythm. Postnatal electrocardiograms (ECGs) show typical AF waves type I,
the common form of AF. In 1965, Hassenruck et al.6 were the first to report
successful direct current cardioversion (DCC) of a newborn with AF. The
next successful outcome was not published until 1972 by Barclay and Barr.7
The purpose of our retrospective study was to present our experience with
45 fetuses with AF, 44 diagnosed in utero. The course, management and
outcome are analyzed.
Patients and Methods
Our retrospective multi-center study comprised 45 patients, 44 fetuses
with AF diagnosed in utero and one neonate with longstanding AF (proba-
bly from 24 weeks gestation) diagnosed only at birth. The review includes
patients with AF referred from obstetrical units because of an irregular or
fast fetal heart rate from January 1984 to December 1998.
Cross-sectional echocardiography, M-mode and echo-Doppler were used for
diagnosis. Conventional fetal echocardiographic views of the heart were
obtained to exclude structural heart malformation. Atrial rate was deter-
mined using M-mode echocardiography, while ventricular rate was deter-
mined with the use of M-mode and/or echo-Doppler. A complete fetal scan
was simultaneously performed to determine indices of fetal growth, the
presence of hydrops, hydramnion or associated anomalies.
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The decision to institute maternofetal therapy was related to gestational
age at presentation, state of lung maturity and the presence of hydrops.
Mode of delivery was decided based upon the fetal condition and the fur-
ther stress that vaginal delivery might impose.
Results
Forty-four fetuses with in utero AF were diagnosed at a median gestational
age of 31.5 weeks, range 19 to 40 weeks. At time of presentation, mean
atrial rate was 450 beats/min (median 440, SD 42.8) and mean ventricular
rate was 224 beats/min (median 220, SD 21.8). At time of diagnosis, 20 out
of 44 fetuses were hydropic.
Maternofetal therapy
As outlined in Figure 1, 17 out of 20 hydropic fetuses received therapy. Nine
of these received single-drug therapy with digoxin (loading dose of 1.5 mg
and maintenance dose of 0.25 mg twice daily) and one with sotalol (80 mg
q 8 hrs). In this group, one patient died in utero shortly after diagnosis and
2 hours after maternal loading with intravenous (IV) digoxin. The AF was
associated with 1:1 atrioventricular (AV) conduction, with a ventricular rate
of 480 beats/min. This ventricular rate, and not the initiation of digoxin
therapy, probably caused the demise of this fetus. Another patient was tre-
ated with sotalol and died abruptly intrauterine at 38 weeks gestation wit-
hin 24 hours after the oral sotalol medication was increased to 160 mg q 12
hrs, because of persisting AF. This could very well be a pro-arrhythmic
effect, but in this hydropic patient an associated hypoplastic ductus veno-
sus was found at autopsy. Of the remaining eight patients, one was in AF at
time of birth.
Seven of the 20 hydropic fetuses received more than one drug, digoxin as
the drug of first choice in each. Drug combinations included digoxin and
procainamide, quinidine, flecainide, propaphenone and sotalol. One of
these patients received direct umbilical vein digoxin and procainamide.
Of these seven patients, three (including the latter) were born in AF. Of the
24 nonhydropic patients, 18 were treated. Thirteen of them had single-drug
therapy, five with digoxin and eight with sotalol. The remaining five
patients received a combination of digoxin and sotalol.
Surveillance of mother and fetus occurred twice weekly. Fetal heart rate
was examined, and the mother was questioned on subjective maternal 
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Figure 1
Allocation of fetal patients with atrial flutter into two study groups at time 
of recognition: hydropic and nonhydropic. Patients are further subdivided 
into treated and nontreated for each group.
HLHS = Hypoplastic left heart syndrome, proc/flec/quin/prop = procainamide/quinidine/flecainide/propaphenone
The bottom boxes describe the number of cases with atrial flutter at birth per number of infants born alive.
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complaints; however, no maternal problems other than slight dizziness
occurred. All mothers had an ECG made before therapy initiation, but no
irregular heart rates were found. No blood levels were measured during the
period of this review, but recently this policy has been changed, and blood
levels are monitored. Before a second drug was introduced, the initial the-
rapy was maximized (sotalol 160 mg q 8 hrs and digoxin 0.25 mg q 8 hrs).
Table 1 contains a summary of clinical data, and dosages for the different
drugs are indicated in Table 2.
Table 1 Summary of clinical data
1 40 - no cs 40 yes DCC 12
2 36 - yes nvd 40 no no 1,25
3 33 + yes cs 33 yes DCC 7,5
4 37 - no cs 37 yes DCC 6
5 34 - yes cs 35 yes DCC 7
6 39 - no nvd 40 no no no
7 34 - yes nvd 36 no no 9
8 37 - no nvd 38 no no no
9 35 - no cs 35 yes TVAOP 12
10 19 + yes nvd 38 no no 12
11 29 + yes cs 30 yes yes 6
12 35 + no cs 35 yes DCC 3
13 24 + yes nvd 39 yes yes 6
14 19 + no nvd 29 no HLHS no
15 28 + yes nvd 38 yes yes 12
16 36 - yes nvd 40 no no no
17 37 - no nvd 37 yes DCC 9
18 37 - yes nvd 42 yes DCC 12
19 34 - yes cs 38 no no 12
20 34 - yes nvd 38 no no 12
21 - + no nvd 39 yes DCC died day 2
Pa
tie
nt
GA
 a
tr
ec
og
ni
tio
n 
(w
ee
ks
)
Hy
dr
op
s
In
 u
te
ro
 tr
ea
tm
en
t
De
liv
er
y m
od
e
GA
 (w
ee
ks
)
AF
 a
tb
irt
h
Tr
ea
tm
en
ta
tb
irt
h
Du
ra
tio
n 
of
 p
ro
ph
yl
ax
is
(m
on
th
s)
Chapter 8
109
22 32 + yes nvd 37 no no 3
23 33 + yes nvd 38 no no 12
24 36 + yes nvd 38 no no 6
25 36 - yes nvd 38 no no no
26 34 + yes nvd 37 no no 3
27 34 + yes nvd 37 no no 6
28 35 + yes nvd 39 no no 3
29 28 + yes nvd 36 no no no
30 31 + yes nvd 38 died in died in died in 
utero utero utero
31 36 + yes nvd 38 no no no
32 38 + yes nvd 39 no no no
33 - + yes nvd 36 no yes yes
34 31 + no cs 35 no no no
35 - - yes nvd 34 no no no
36 35 - yes cs 39 no no no
37 36 - yes nvd - no no no
38 30 - yes nvd - no no no
39 21 - yes nvd 40 no no no
40 31 - yes nvd 39 no no no
41 34 - yes nvd 34 no no no
42 - - yes nvd 36 no yes 0.75
43 30 - yes nvd - no no no
44 36 - yes nvd 39 no yes yes
45 33 + yes nvd 39 died in died in died in 
utero utero utero
GA = Gestational age, Cs =Cesarean section, nvd = Normal vaginal delivery, DCC = Direct
current cardioversion, AF = Atrial flutter, TVAOP = Transvenous atrial overdrive pacing,
HLHS = Hypoplastic left heart syndrome
Pa
tie
nt
GA
 a
tr
ec
og
ni
tio
n 
(w
ee
ks
)
Hy
dr
op
s
In
 u
te
ro
 tr
ea
tm
en
t
De
liv
er
y m
od
e
GA
 (w
ee
ks
)
AF
 a
tb
irt
h
Tr
ea
tm
en
ta
tb
irt
h
Du
ra
tio
n 
of
 p
ro
ph
yl
ax
is
(m
on
th
s)
Atrial flutter
110
Table 2 Drugs used for control of fetal atrial flutter
Drug Dose Maternal Fetal: Maternal
therapeutic concentration ratio
concentration
Digoxin Loading:
iv  3 dd 0.5 mg 1 - 2 mg/ml 0.6
Maintenance:
po 0.25 - 1.0 mg/24h
Flecainide Loading:
po 2dd 150 mg 0.2 - 1 mcg/ml 0.86
Maintenance:
po 2dd 100mg 
Sotalol Maintenance:
po 160-320 mg/24 h 2 - 7 mcg/ml 1.05 
Amiodarone Loading: Amiodarone:
po 1200 mg/24 h 1 - 2.5 mcg/ml 0.1 - 0.3 
Maintenance: Desethylamiodarone 
po 400-600 mg/24 h 0.2 - 2.6 mcg/ml 
iv = Intravenous, po = Per os
Nontreated fetuses
Three of the 20 hydropic patients were not treated, one due to an associa-
ted hypoplastic left heart syndrome (HLHS) and the other two were deliver-
ed soon after diagnosis because they were near term. Six of the 24 nonhy-
dropic fetuses received no medication, as they were delivered within a
week of diagnosis and beyond 35 weeks gestation (when the lungs were
assumed to be mature).
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Structural heart disease
Only one of the 44 fetuses was found to have a cardiac malformation.
Atrial flutter in this fetus was detected at 19 weeks gestation, and a HLHS
was diagnosed. In light of the prognosis a decision was made not to treat,
and spontaneous delivery occurred at 29 weeks gestation.
Mode of delivery
Delivery through means of a cesarean section was deemed necessary in 10
of the 44 fetuses (median gestational age 37 weeks, range 30 to 40 weeks)
as normal vaginal delivery was considered to impose further stress on an
already compromised heart. Cesarean section was performed soon after
presentation and diagnosis of AF in five cases, which were not treated. A
hydropic fetus diagnosed at 33 weeks gestation was treated with digoxin
for 24 hours with no improvement and was therefore delivered by cesarean
section. In another fetus presenting at 34 weeks gestation, maternofetal
digoxin was administered for four weeks before cesarean section delivery.
In a third patient, presented at 35 weeks gestation, sotalol and digoxin fail-
ed to establish normal sinus rhythm, and delivery was performed at 39
weeks gestation by cesarean section. Two other fetuses with AF diagnosed
at a gestational age of 29 and 34 weeks were delivered by cesarean section.
Atrial flutter at birth
Of the original 45 patients, two patients died in utero, and 12 out of the 43
live-born infants were in AF at birth. Twelve-lead ECG confirmed AF with
monomorphic undulating negative flutter waves in leads II, III and avF
(common type). Flutter waves were commonly seen in lead V1. No sign of
aberrant conduction was noted on these ECGs. Three infants were in
serious trouble with poor Apgar scores at birth.
Nine of the 12 patients in AF received DCC as initial treatment. Eight of
these converted to sinus rhythm. One patient remained in AF despite
undergoing subsequent transvenous atrial overdrive pacing (TVAOP). This
baby received a multitude of medications including IV digoxin and proca-
inamide. Loading with IV amiodarone and repeat of TVAOP were successful
in conversion to sinus rhythm. One other patient born with AF initially
underwent unsuccessful TVAOP and reverted to sinus rhythm after electro-
cardioversion.
Two patients were treated medically, one with digoxin alone, the other
with digoxin and quinidine. Both reverted to sinus rhythm on medication.
In one other patient, AF had not been diagnosed before birth. At 26 weeks 
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Figure 2  
Outcome for the entire study group and treatment strategies
DCC = Direct current cardioversion, TVAOP = Transvenous atrial overdrive pacing, 
Death/neuro = Death due to a neurological cause
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gestation polyhydramnion had been detected, and an irregular CTG (cardio-
tonography) suggested a possible existence of AF, but this was not recogni-
zed and no further investigations or treatment were performed. Delivery at
39 weeks gestation revealed a hydropic and acidotic baby with an extreme-
ly poor Apgar score requiring immediate resuscitation and artificial ventila-
tion. On referral, the pulse was irregular, between 120 and 140 beats/min.
Blood pressure was low, 40/22, mean 29 mm Hg. A narrow QRS rhythm
could be seen on ECG, but no detectable P waves. Twelve-lead ECG confir-
med AF at a rate of 480 to 540 beats/min with varying AV block. On cross-
sectional echocardiography the atria were markedly dilated and seen to
flutter, while the ventricles were dilated. Synchronized electrocardioversion
was successful. The infant was digitalized. Over the ensuing 4 hours the
rhythm changed from AF with varying block to AV-re-entry supraventricular
tachycardia with ventricular rates of up to 300 beats/min. Six hours later
the infant was in sinus rhythm with a good blood pressure and improved
peripheral perfusion. Ultrasound of the head showed evidence of cortical
necrosis most likely on the basis of longstanding cerebral hypoperfusion.
Two days later the child died from cerebral inactivity. Figure 2 indicates
outcome and treatment strategy after birth for the whole study group.
Neurological complications
In four of the 45 patients, including the one described above, neurological
morbidity was documented immediately postnatally, suggesting an asso-
ciation with the prenatally existing arrhythmia. The neurological damage
ranged from severe cerebral hypoxic-ischemic lesions to intraventricular
hemorrhage, resulting in a hydrocephalus. One patient had a small periven-
tricular infarction that is resolving.
Management and follow-up
Prophylactic antiarrhythmic medication was given to 25 of the infants.
Median duration of prophylaxis was 7.25 months and ranged from 3 weeks
to 12 months. Prophylactic antiarrhythmic drugs included digoxin alone in
17 patients, digoxin and quinidine in one patient, digoxin and sotalol in one
patient and sotalol alone in six patients.
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Recurrence of AF after initial conversion to sinus rhythm did not occur in
any of the patients. Longterm follow-up for the group ranges between 6
months to 10 years and 3 months, median 5 years and 2 months.
Discussion
Early reports
Atrial flutter is a primary atrial tachyarrhythmia confined solely to the
atrium. The specialized AV conduction system does not participate in the
primary mechanism. Early reports1-5,8 of AF in the fetus and newborn stres-
sed that the intrauterine heart rate was rapid, and the rhythm was abrupt-
ly irregular. Digoxin did not seem to be effective in converting the rhythm
to sinus and after birth the ECG showed typical flutter waves. Furthermore,
if the infant had a cardiac malformation, the prognosis was poor. Even in
the absence of associated structural heart disease, the prognosis has been
reported to be poor.
Our series
In our series of 45 patients with perinatal AF, the mortality and neurologi-
cal morbidity were each 9% and were confined to the subgroup of hydropic
fetuses. One patient died postnatally from severe associated structural
heart disease (hypoplastic left heart syndrome) and another intrauterine
after treatment with digoxin. We do not consider this patient’s death a
consequence of digoxin therapy, because under ideal circumstances, trans-
placental passage of this drug is slow (up to a few days) in order to achieve
an adequate therapeutic level in the fetus. In this patient with a hydropic
placenta, the transplacental transfer of digoxin was further hampered. At
autopsy an accessory AV connection was identified, which we contend was
responsible for the 1:1 AV conduction.
In the third severely hydropic patient, AF had been missed before birth, but
was present immediately after birth. Despite successful DCC after birth, the
patient ultimately died from cerebral damage probably due to longstan-
ding and/or fluctuating cerebral hypoperfusion as a result of intrauterine
AF.
Potential mortality and morbidity
The potentially lethal outcome in perinatal AF is not to be underestimated.
In 1969 Moller et al.5 were the first to report increased birth weight, which
suggested to them the presence of anasarca from intrauterine cardiac fai-
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lure secondary to arrhythmia. They reviewed the outcomes of 36 infants
with AF. Nine infants died, of whom six had received digoxin but failed to
respond. In 1970 van der Horst9 reported a case of fetal hydrops secondary
to intrauterine AF.
Even more worrisome were the four patients in the present study with
neurological damage. In a previous publication we reported the assump-
tion that AF was responsible for the disturbance of the maintenance of
adequate cerebral perfusion.10 This causes loss of cerebrovascular autoregu-
lation and will result in a pressure-passive phenomenon, whereby a reduc-
tion or increase in mean arterial blood pressure is accompanied by a conco-
mitant reduction or increase in cerebral blood flow. In the distressed new-
born, cerebral autoregulation is lost, exposing the brain to ischemia in even
moderate hypotension and to an increased pressure gradient across the
capillary wall in even moderate hypertension, with increased risk of intra-
cranial hemorrhage.11 Experimental studies in the fetal lamb have shown
that this certainly applies to the distressed fetus in utero; a period of
intrauterine distress causes abolition of cerebral autoregulation leading to
severe impairment of the maintenance of constant cerebral perfusion.12,13
A fetus presenting with hemodynamic compromise and hydrops secondary
to fetal tacharrhythmia is therefore at increased risk of development of a
pressure-passive cerebral circulation and the cerebral complications that
may result from this.
Intrauterine treatment
In light of these findings, we have opted for a policy to treat all fetuses
with AF at time of presentation, unless immediate delivery is possible.
Despite active treatment, we were confronted with AF at birth in six out of
33 medically treated live-born patients (18%). Conversion to sinus rhythm in
our patients while receiving maternofetal therapy is a debatable issue. Was
this indeed a result of the antiarrhythmic medication or was it part and
parcel of the natural history of AF in these patients? One may postulate
that both a paroxysmal and sustained form of AF exist in the fetus and
newborn infant, as is seen with adult patients. Alternatively, we are unsure
whether the stress of delivery and release of catecholamines may have an
influence on retriggering the onset of AF, as seen in fetuses with supraven-
tricular tachycardia.14
Digoxin may be useful through its action in slowing ventricular rate,
allowing more ventricular filling, and improving cardiac output. Its inability
in breaking or converting AF to sinus rhythm in pediatric and adult
patients has been well documented.14-16 In the collaborative study reported
by Garson et al.17, digoxin used alone was successful in preventing
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recurrences of AF in only 44% of patients. Wellens and Durrer18 stress that
digoxin is contraindicated in the presence of an accessory pathway, which
conducts anterogradely. This is most likely to have been the case in our
fetus with 1:1 AV conduction.
These studies suggest that although digoxin has been used for treatment
in the past, it might have lost some of its attraction for treatment of AF.
Alternatively, antiarrhythmic drug treatment with class I drugs is often
unsuccessful in the conversion of AF to sinus rhythm, possibly explained by
experimental data, suggesting that prolongation of the atrial-effective
refractory period is more critical than slowing conduction in the termina-
tion of re-entrant atrial flutter.19 Action potential prolongation in the
absence of conduction slowing seems more effective in terminating human
AF than depression of the excitability.19
Current literature in adult patients advocates the use of class III agents
such as sotalol. Sotalol appears to be an effective agent in the treatment of
AF, seems suitable in treating the fetus, and has excellent transplacental
passage in a dosage regimen of 160 mg twice daily.20,21 Monitoring of the
maternal QT-interval is essential in excluding maternal pro-arrhythmia;
fetal pro-arrhythmia, however, is a troublesome aspect of this therapy and
might force the fetal cardiologist eventually to abandon this agent.
Amiodarone, also a class III agent, has been used for fetal arrhythmias but
has many side effects and does not cross the placenta as readily as does
sotalol.22
Dophitilide, a new class III agent, may be even more promising in the futu-
re for both in utero treatment and in the newborn infant. Although current
data on the use of dophitilide in the fetus and neonate are lacking, dophiti-
lide is found to be more effective than flecainide in the conversion of AF to
sinus rhythm in adult patients, yet flecainide produces a more prolonged
flutter cycle length.19
Although both digoxin and sotalol are effective drugs in the treatment of
fetal AF, we use sotalol as the drug of choice because digoxin transplacen-
tal passage is slower, relapse into AF occurs more often at birth and subjec-
tive maternal complaints are more prominent than with sotalol.
Postnatal flutter and treatment
The relapse of patients at birth into AF remains a troublesome issue and
requires intensive-care admission of these fragile patients. Synchronized
DCC (eight out of nine patients) was useful in the conversion of AF to sinus
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rhythm6,7, and TVAOP was successful in one of two patients, and only after
loading with amiodarone. Esophageal or TVAOP has been used in children
to terminate atrial flutter.23,24
Once AF is converted to sinus rhythm, one may elect to wait and observe if
flutter recurs.25 Alternatively, one may elect to treat for six months to a
year, although it appears from this review that recurrence of AF is excee-
dingly rare beyond the neonatal period. This questions the need for prophy-
laxis; our current policy is not to treat prophylactically.
Conclusion
Finally, we can state that AF is a serious and life-threatening rhythm disor-
der of the human fetus. Specifically, when it causes hydrops it is associated
with fetal death or neurological damage. Treatment therefore is required,
primarily aiming at reaching an adequate ventricular rate and preferably
conversion to sinus rhythm. It seems important that relapses back and
forth and in and out of flutter should be prevented at all cost to protect
the fetal brain. Once fetuses with AF survive, their future is bright, and pro-
phylaxis beyond the neonatal period is unnecessary.
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Congenital heart disease in pregnancies 
complicated by maternal diabetes mellitus:
an international clinical collaboration,
literature review and meta-analysis
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Abstract
Objectives 
To investigate the incidence and distribution of congenital heart disease in
the offspring of type-1 diabetic mothers and the influence of periconcep-
tional glycemic control reflected by glycosylated hemoglobin (HbA1c) levels.
Methods 
A multi-center retrospective clinical study, literature review and meta-ana-
lysis. The incidence and pattern of CHD in our study populations and in the
literature in offspring of type-1 diabetic mothers were compared with
those in the offspring of nondiabetic mothers registered by EUROCAT
Northern Netherlands. Medical records were reviewed for HbA1c during the
first trimester.
Results 
The distribution of CHD in our diabetic study population was in accordance
with reports in the literature. This distribution differed considerably from
that in the nondiabetic population. Approximately half the CHD were
conotruncal anomalies (persistent truncus arteriosus (PTA), tetralogy of
Fallot (TOF) and transposition of the great arteries (TGA)). In our series TGA
was the single most frequently encountered conotruncal abnormality, and
no cases of double-outlet right ventricle (DORV) were detected. Our study
demonstrated an increased likelihood of visceral heterotaxia and single
ventricle. Elevated first trimester HbA1c values were associated with fetal
CVD.
Conclusions 
This study shows an increased likelihood of transposition of the great arte-
ries, persistent truncus arteriosus, visceral heterotaxia and single ventricle
among offspring of diabetic mothers. This suggests a profound teratogenic
effect at a very early stage in cardiogenesis, with overlap between malfor-
mations that relate to single gene defects versus teratogenic exposure.
Our study emphasizes the frequency with which the offspring of diabetes-
complicated pregnancies suffer from complex forms of CHD.
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Introduction
Maternal type-1 diabetes mellitus is a relatively common illness that com-
plicates pregnancy and results in an increased incidence of congenital mal-
formations.1-5 Offspring of diabetic mothers have a fivefold incidence of
congenital malformations compared to pregnancies in the general healthy
population. Major congenital malformations, of which congenital heart dis-
ease (CHD) constitutes a significant part, are the most important single
cause of perinatal mortality amongst the offspring of diabetic mothers.6-13
In general, the pattern of CHD encountered among offspring of diabetic
mothers, with an emphasis on abnormalities of laterality, looping and
conotruncal septation, suggests that the maternal metabolic state affects
cardiogenesis at a very early stage of the developmental period, prior to 7
weeks’ gestation.14,15 
It was the aim of this investigation to study the pattern of cardiac anoma-
lies among offspring of pregnancies complicated by type-1 diabetes melli-
tus and to assess the importance of periconceptional glycemic control,
reflected by HbA1c levels, during the first trimester. Our working hypothe-
sis was that detection of CHD among the fetuses of diabetic mothers
would uncover a high incidence of complex anomalies of laterality, looping
and conotruncal malformations that are ductal-dependent for sustained
pulmonary and systemic blood flow. Such abnormalities are particularly
amenable to early medical and surgical intervention.16
Methods
We studied the incidence and the spectrum of congenital cardiac malfor-
mations among fetuses and neonates born to mothers with type-1 diabetes
mellitus in three populations and compared our data with those reported
in the literature.
Study population
We studied the incidence of congenital cardiac malformations in three
populations:
1 Yale New Haven Medical Center: this population consisted of the 
offspring of mothers with type-1 diabetes mellitus undergoing routine fetal
echocardiography at the Yale Fetal Cardiovascular Center during the inter-
val between 1988 and 1998. Medical records were reviewed retrospectively.
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2 Retrospective review in the Netherlands: a retrospective study in which
data were obtained from a review of medical records from pregnancies 
(> 16 weeks in women with type-1 diabetes) at the University Medical
Center Utrecht, University Hospital Groningen, and Isala Clinics Zwolle, the
Netherlands, between 1988 and 1998.
3 Prospective nationwide study in the Netherlands: data were obtained from
a nationwide prospective cohort-based study on type-1 diabetes and preg-
nancy, in which all (n=118) hospitals in the Netherlands participated
between April 1999 and April 2000.
Literature review
A systematic review of published articles, in English, concerning maternal
insulin-dependent diabetes mellitus (IDDM) and congenital malformations
was conducted using the Medline (1970-April 2002) and Pubmed databa-
ses. The incidence and the detailed diagnosis of congenital cardiac malfor-
mations in the literature were extracted only from reports in which the
anomalies could be assigned to a well-defined diagnosis. Various anoma-
lies were grouped, in order to make meaningful comparisons. Conotruncal
malformations included persistent truncus arteriosus (PTA), double-outlet
right ventricle (DORV), tetralogy of Fallot (TOF) and complete transposition
of the great arteries (TGA). Other major categories included visceral hetero-
taxia, atrioventricular septal defect (AVSD), atrial septal defect (ASD), ven-
tricular septal defect (VSD), patent ductus arteriosus (PDA), coarctation of
the aorta (CoA), anomalies of the aorta or pulmonary artery, single ventri-
cle (SV), hypoplastic left heart syndrome (HLHS), Ebstein’s anomaly, anoma-
lies of the tricuspid, mitral, pulmonic or aortic valve, total (TAPVC) or par-
tial anomalous pulmonary venous connection (PAPVC) and other anomalies
of the great veins.
The incidence and spectrum of congenital heart disease in our population
and in the literature among offspring of type-1 diabetic mothers were com-
pared with those in the offspring of nondiabetic mothers registered by
EUROCAT (European registration of congenital anomalies and twins)
Northern Netherlands. In this registry obstetricians, pediatricians, clinical
geneticists, surgeons, general practitioners, midwives, well-baby clinics,
pathologists and the national obstetric registry provided data from 1989 to 1999.
Hemoglobin A1c measurement
HbA1c determination was performed by high-pressure liquid chromatogra-
phy (HPLC) at Yale and at the centers in the Netherlands (normal reference
value: 4.0–6.3 %). HbA1c values of diabetic pregnancies complicated by
CHD were compared with those resulting in the birth of a healthy infant.
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Statistical analysis 
Data were analyzed using SPSS software (SPSS Inc., Chicago, Ill, USA). Data
are presented as mean and standard error of the mean (SEM) or percenta-
ges. Continuous data were compared using the Student’s t-test and catego-
rical data were compared using the chi-square test or the Fisher’s exact
test. Associations with p<0.05 were considered statistically significant.
Odds ratios (OR) for incidences and their 95% confidence intervals (CI) were
calculated.
Results
At the Yale New Haven Medical Center 624 fetal echocardiographic scans
were performed on 557 pregnant women with type-1 diabetes mellitus.
Congenital heart disease was diagnosed in 19 pregnancies (3.0%). These
cases were all confirmed postnatally, with no false-negative or false-positi-
ve diagnoses encountered. In the retrospective study in the Netherlands 172
type-1 diabetic women had 220 (212 single and 8 twin) pregnancies and a
total of 14 (out of 228 infants; 6.1%) cases of CHD were encountered post-
natally. In the prospective cohort-based study in the Netherlands, in which
324 infants (from 305 singleton pregnancies, 8 twins and 1 triplet pregnan-
cy) were born after 24 weeks’ gestation, a total of 8 (2.5%) cases of CHD
were encountered. Details are shown in Table 1.
Initial hemoglobin A1c
The 19 patients whose fetuses had CHD in the study group from Yale were
diagnosed at a mean gestational age of 27.9 ± 1.2 weeks. First trimester
HbA1c concentration in this subgroup of 19 patients (CHD; 9.8 ± 0.7%) were
significantly higher than those in mothers with unaffected infants (con-
trols; 8.1 ± 0.3%; P<0.05). The mean age of the mothers was 30.7 ± 0.9
(CHD) versus 29.1 ± 0.8 years (controls; P=0.212). The mean duration of dia-
betes was 11.5 ± 2.2 (CHD) versus 10.9 ± 1.1 years (controls; P=0.791).
The 14 patients in the retrospective study group and the 8 patients in the
prospective study group from the Netherlands had initial HbA1c values of
6.4 ± 1.4%   and 7.4 ± 1.2% respectively. The HbA1c values in the control
groups were 6.3 ± 1.3 % (P=0.361) and 6.5 ± 1.0 % (P=0.009) respectively.
Literature review versus study population
The literature review of studies of CHD among the offspring of IDDM
uncovered a total of 26 reports. 4,10,11,13-15,17-35 The incidence and distribution of
malformations in this series is shown in Table 1; there was no statistically 
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Table 1 Incidence and spectrum of cardiovascular malformations in fetuses and infants of
women with type-1 diabetes in study population and literature.
CHD Our study Literature review Combined studies P -value
n (%) n (%) n (%)
PTA 3 (7.3) 9 (3.4) 12 (3.9) 0.224
TGA 9 (22) 30 (11.2) 39 (12.7) 0.054
DORV 0 (0) 7 (2.6) 7 (2.3) -
T4F 1 (2.4) 15 (5.6) 16 (5.2) 0.393
Conotruncal 13 (31.7) 61 (22.8) 74 (24.0) 0.149
SV 4 (9.8) 13 (4.9) 17 (5.5) 0.202
VSD 8 (19.5) 80 (30.0) 88 (28.6) 0.114
AVSD 2 (4.9) 9 (3.4) 11 (3.6) 0.628
ASD 3 (7.3) 17 (6.4) 20 (6.5) 0.818
PDA 2 (4.9) 15 (5.6) 17 (5.5) 0.847
HLHS 1 (2.4) 8 (3.0) 9 (2.9) 0.844
CoA 3 (7.3) 12 (4.5) 15 (4.9) 0.434
Other anom. Aorta 1 (2.4) 5 (1.9) 6 (1.9) 0.807
Anom. Pulm. artery1 (2.4) 15 (5.6) 16 (5.2) 0.393
Heterotaxia 2 (4.9) 5 (1.9) 7 (2.3) 0.229
TAPVR 1 (2.4) 1 (0.4) 2 (0.6) 0.125
PAPVR 0 (0) 1 (0.4) 1 (0.3) -
Anom. Ao. valve 0 (0) 2 (0.7) 2 (0.6) -
Anom. Mi. valve 0 (0) 4 (1.5) 4 (1.3) -
Anom. Pulm. valve 0 0) 15 (5.6) 15 (4.9) -
Anom. Tric. valve 0 (0) 1 (0.4) 1 (0.3) -
Ebstein 0 (0) 0 (0) 0 (0.0) -
Unspec. anom. 0 (0) 3 (1.1) 3 (1.0) -
Total 41 (100) 267 (100) 308 (100)
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significant difference in incidence of the malformations between the lite-
rature and our study groups. Thirty percent of patients in the literature
review were reported to have ventricular septal defects and 23 percent had
conotruncal malformations (CTM). Approximately half (49%) of the
patients with CTM were reported to have TGA, followed by a smaller num-
ber of patients with TOF (25%) or PTA (15%). Only 2.6 percent of offspring
with cardiac anomalies were reported to have DORV. AVSD (3,4%), while
less common than conotruncal malformations, was more prevalent than
double-outlet right ventricle. Visceral heterotaxia was reported in 3.0% of
the cases.
EUROCAT Registry
In Table 2, we compare the distribution of specific cardiovascular defects in
our study population and literature on diabetes taken together, with that
in the nondiabetic population (EUROCAT Registry). For each diagnostic sub-
group, the number of cases and the risks of these specific cardiac disorders
in the offspring of diabetic mothers are shown. Conotruncal malformations
(persistent truncus arteriosus: OR 4.72, transposition of the great arteries:
OR 2.85), single ventricle: OR 18.24, and visceral heterotaxia: OR 6.22, are
most highly associated with pregestational diabetes (all P<0.05).
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Table 2 Distribution  and relative risk of specific cardiovascular defects in offspring of
women with pregestational diabetes in comparison with that in a large nondiabetic popu-
lation (EUROCAT). (Combined studies = Our study population and literature on diabetic
grouped together)(*P<0.05)
CHD EUROCAT Combined P-value OR 95% CI 
studies
n (%) n (%)
PTA 16 (0.9) 12 (3.9) <0.05* 4.72 2.21 – 10.08
TGA 91 (4.8) 39 (12.7) <0.05* 2.85 1.92 – 4.23 
DORV 35 (1.9) 7 (2.3) 0.652 1.23 0.54 - 2.78
T4F 59 (3.1) 16 (5.2) 0.088 1.69 0.96 – 2.98
Conotruncal 201 (10.7) 74 (24.0) <0.05* 2.64 1.96 – 3.56
SV 6 (0.3) 17 (5.5) <0.05* 18.24 7.13 – 46.63
VSD 552 (29.4) 88 (28.6) 0.839 0.96 0.74 – 1.26
AVSD 85 (4.5) 11 (3.6) 0.549 0.78 0.41 – 1.48
ASD 211 (11.2) 20 (6.5) 0.012* 0.55 0.34 – 0.88
PDA 116 (6.2) 17 (5.5) 0.797 0.89 0.53 – 1.50
HLHS 44 (2.3) 9 (2.9) 0.547 1.26 0.61 – 2.60
CoA 87 (4.6) 15 (4.9) 0.884 1.05 0.60 – 1.85
Other anom. Aorta 91 (4.8) 6 (1.9) 0.024* 0.39 0.17 – 0.90
Anom. Pulm artery 40 (2.1) 16 (5.2) 0.005* 2.52 1.39 – 4.56
Heterotaxia 7 (0.4) 7 (2.3) <0.05* 6.22 2.17 – 17.86
TAPVR 11 (0.6) 2 (0.6) 0.892 1.11 0.25 – 5.03
PAPVR 15 (0.8) 1 (0.3) 0.366 0.41 0.05 – 3.08
Other anom. veins 38 (2.0) 0 (0) - - -
Anom. Ao. valve 62 (3.3) 2 (0.6) 0.006* 0.19 0.05 – 0.79
Anom. Mi. valve 36 (1.9) 4 (1.3) 0.646 0.67 0.24 – 1.91
Anom. Pulm. valve 151 (8.0) 15 (4.9) 0.062 0.59 0.34 – 1.01
Anom. Tric. valve 36 (1.9) 1 (0.3) 0.052 0.17 0.02 – 1.22
Ebstein 6 (0.3) 0 (0.0) - - -
Other spec. anom. 71 (3.8) 0 (0.0) - - -
Unspec. anom. 13 (0.7) 3 (1.0) 0.590 1.41 0.40 – 4.98
Total 1879 (100) 308 (100)
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Discussion
Congenital malformations emerged as a leading cause of infant mortality
in the western world during the past two decades, accounting for 22.1% of
US infant mortality in 1997 vs 15.1% in 1970.36 During that period malforma-
tions of the nervous, cardiovascular and respiratory systems accounted for
60% of that mortality
The frequency with which type-1 diabetes is encountered among pregnant
women (0.1–0.3%)37 and the high frequency (3-6%), with which congenital
cardiac anomalies are encountered during these pregnancies, account for
the interest in the diabetic pregnancy. Although perinatal mortality has
declined dramatically in diabetic pregnancies during the latest decades,
most studies of large populations continue to encounter a higher mortality
among these patients than in control populations.5,38 Studies from the
United Kingdom have shown that there is a persistently high level of non-
attendance of preconceptional care, late registration for prenatal care and
poor glycemic control in diabetic pregnancies. However, the Dutch popula-
tions show that there is still a significantly increased occurrence of conge-
nital malformations among the offspring of women with type-1 diabetes
who planned their pregnancy, with good periconceptional glycemic control
and adequate use of folic-acid supplementation. In both Dutch studies 70
percent of women had a HbA1c less than 7 % during the first trimester.39,40
The potential for cardiac abnormalities among offspring of pregnancies
complicated by maternal diabetes mellitus has been recognized for over 50
years. In 1937 Hurwitz and Irving described cardiomegaly in such a concep-
tus.41 In 1946 Miller reported two cardiac malformations (i.e. cor biloculare
with aortic hypoplasia and bicuspid pulmonic valve) among a series of 19
autopsies.42
Our study shows an increased absolute and relative incidence of transposi-
tion of the great arteries, persistent truncus arteriosus, visceral hetero-
taxia, and single ventricle when compared to the nondiabetic population
(EUROCAT), suggesting teratogenesis at an early stage in heart develop-
ment (during cardiac looping and conotruncal septation). Our series was
compatible with the previous literature concerning the predilection for
infants of diabetic mothers to have offspring with particularly complex car-
diovascular malformations, but differed (p<0.05) from the Baltimore
Washington Infant Study (BWIS) in the rarity with which we encountered
cases of double-outlet right ventricle, which was the most frequent asso-
ciation found by Ferencz and Loffredo et al. 22,43
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The increased prevalence of abnormalities of bulboventricular looping,
conotruncal septation, and migration of the atrioventricular canal among
infants of IDDMs clearly relates to a teratogenic impact at a very early
point in heart development. Between weeks 5 and 8 the primitive heart
tube undergoes a process of folding, remodeling and septation that trans-
forms its single lumen into the four chambers of the definitive heart. The
cephalad end of the bulbus cordis will form the distal outflow regions of
the left and right ventricles, including the conus cordis and truncus arterio-
sus. Finishing by the 9th gestational week, the cardiac outflow pathway is
divided into two by ridges that grow from opposite walls of the conus cor-
dis and truncus arteriosus to fuse and twist counter clockwise. The latter
may relate to tensile stress, hemodynamic changes and migration of neural
crest-derived cells.44 Animal models of transposition of the great arteries
have shown that retinoic acid has effects on the neural crest cells, thus
altering the development of the downstream structures of the heart.45
Experimental embryogenesis in high glucose concentrations shows a simi-
lar effect on neural crest cellular migration and proliferative capacity, pos-
sibly partially explaining the pathogenesis of conotruncal anomalies in dia-
betic pregnancies.46 A variety of outflow tract malformations result from
errors in conotruncal septation, ranging from a persistent truncus arterio-
sus, with a common outflow tract, to tetralogy of Fallot and double-outlet
right ventricle, through transposition of the great arteries.
Goldmuntz et al.47,48 demonstrated that abnormalities of chromosome 22
(microdeletion at q11) may be associated with such abnormalities, and
with DiGeorge syndrome. These findings suggest that conotruncal septa-
tion and abnormalities of the thymus and parathyroid glands may result
from a single gene defect. On the other hand, two cases of infants born to
diabetic mothers, with DiGeorge syndrome and normal chromosome 22q11,
have been reported, suggesting that maternal diabetes may be a primary
pathogenic factor in this anomaly.49 
Similarly, while there has been significant progress in deciphering the
genetic control of ventricular looping,50,51 there is circumstantial evidence
that the diabetic environment may alter this fundamental step in cardiac
development. Slavotinek et al. reported three infants of diabetic mothers
with abnormal left-right laterality, including one with the unusual associa-
tion of left atrial isomerism with asplenia (usually associated with right
atrial isomerism).52 Strong associations between IDDM and left atrial iso-
merism and transposition of the great arteries have been reported.53,54
The tendency among offspring of IDDM toward multiple malformations in
various organ systems suggests a teratogenic exposure during early embry-
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ogenesis.55,56 It appears likely that there is a genetic and environmental
interaction that renders some embryologic pathways particularly suscepti-
ble to disruption by one or another metabolic perturbation associated with
maternal diabetes mellitus. It is possible that specific fetuses are genetical-
ly predisposed to the teratogenic effect of specific metabolic fuels that
may accumulate in IDDM-complicated pregnancies. Teratogenic agents are
thought to act by causing embryonic cell death or altered cell growth or
differentiation.57 It is unclear which substances in the fetus of the IDDM are
the specific teratogens, and it is unclear whether these are acting by alte-
ring nucleic acid chemistry, enzyme function, or through direct impact on
cellular function (metabolic or cell membrane), resulting in cellular death,
impaired cell-cell interaction, or abnormal cell migration. The overlap
between the spectrum of congenital cardiac abnormalities among the
offspring of diabetic mothers and those cardiac lesions at the foundation
of our emerging understanding of the genetics of left-right asymmetry,
cardiac looping, and conotruncal septation provides us with added insight,
and raises important questions surrounding the developmental biology of
the heart, and emphasizes the overlap between genetic and environmental
influences in the causation of congenital heart disease.7,58
The initial HbA1c levels of patients in the prospective were above the nor-
mal range of 4.0–6.3% and emphasize the difficulty in obtaining adequate
glycemic control. The significantly higher initial HbA1c levels in cases with
cardiac malformations support the association between sub-optimal
glycemic control and the occurrence of CHD.1,4,59 Recent reports showed
decreased dysmorphogenesis in experimental diabetic pregnancy in the rat
using a combined treatment strategy of vitamin E and C to decrease oxida-
tive stress.60
Despite the intuitively obvious recommendation that glucose metabolism
in these patients should be strictly controlled during the preconceptual
period and through embryogenesis, in many countries these patients may
not register for obstetrical care until well into pregnancy. The data for the
Netherlands show an increased incidence of CHD, even with only slightly
increased HbA1c values. Such findings emphasize the continued importance
of prenatal diagnosis in these patients. Previous studies from our centers
have demonstrated that prenatal diagnosis of congenital heart disease
may alter the postnatal course of affected neonates, by avoiding lactacido-
sis, and enhancing survival among patients with cardiac malformations
reparable into a two-ventricular physiology.16,61 Others have reported that
prenatal cardiac diagnosis improves surgical morbidity and mortality
among offspring with complete transposition of the great arteries62 , in
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patients with hypoplastic left heart syndrome63 and coarctation of the
aorta.64 Hence, the predilection of offspring of IDDM’s for conotruncal mal-
formations, including complete transposition of the great arteries, and
lesions associated with ductal-dependent pulmonary or systemic blood
flow, underscores the clear-cut role of detailed fetal echocardiography in
the management of these pregnancies. Fetal echocardiography, therefore,
should be included as a routine component in the management of such
pregnancies.
Conclusions
Our study emphasizes the frequency with which the offspring of IDDM-
complicated pregnancies suffer from complex forms of congenital heart
disease. Pregnancies with poor first trimester glycemic control are more
prone to the presence of fetal heart disease. The high incidence of cono-
truncal septation and bulboventricular looping abnormalities among these
patients suggests a profound teratogenic effect during the first weeks of
gestation. The perturbed maternal metabolic state appears to result in an
accumulation of metabolic fuels that alter the expression of genes that
control the most fundamental aspects of cardiac development. The predi-
lection of these fetuses to have complex congenital cardiac malformations
such as persistent truncus arteriosus, complete transpositon of the great
arteries, visceral heterotaxia, and single ventricular complexes, emphasizes
the crucial role that detailed fetal echocardiographic studies occupy in the
perinatal management of these patients.
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Altered fetal circulation in type-1 diabetic 
pregnancies
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Abstract
Objectives 
Type-1 diabetic pregnancies (tIDP) are associated with congenital cardiac
malformations, fetal cardiomyopathy, venous thrombosis and altered
placental vascularization, even with tight maternal glucose control. It was
the aim of this study to investigate if with good glucose control, achieved
with continuous subcutaneous insulin infusion (CSII), normal blood flow
over the fetal heart can be achieved.
Methods 
Seventeen fetuses of women with well-controlled type-1 diabetes were stu-
died longitudinally to evaluate effects on the fetal circulation. Doppler fre-
quency shift tracings, valve diameters and intercept angles were measured
at right and left atrioventricular valve (AVV) orifices at 4-week intervals
starting at 15 weeks gestation. AVV flow was calculated and compared to
normal fetal data obtained in previous studies.
Results 
Maximal and mean temporal velocities (Vmax and MTV) increased in both
groups during gestation but significantly more in fetuses of tIDP’s.
Combined ventricular output, absolute and per kg estimated fetal weight,
were also greater in these fetuses. In the normal group the ratio of the
right/left ventricular output decreased significantly during gestation (from
1.34 ± 0.28 to 1.08 ± 0.28), but in tIDP’s this decrease did not occur (1.20 ±
0.26 to 1.25 ± 0.29).
Conclusions 
These data indicate significant differences in the fetal circulation between
normal pregnancy and well controlled tIDP, suggesting the existence of a
compensatory mechanism that increases cardiac output and causes cardiac
hypertrophy.
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Introduction
Maternal type-1 diabetes is, among other complications, associated with
congenital cardiac malformations and diabetic cardiomyopathy in the
newborn infant. Offspring of diabetic mothers have a fivefold increase in
incidence of congenital heart malformations compared to infants of non-
diabetic women.1 Diabetic cardiomyopathy occurs in 30% of the newborns
of diabetic mothers.2,3 Furthermore, thrombosis in fetal veins is known to
occur4,5, vascularization in the placental villi is abnormal, even with good
glucose control6, and pathologic fetal heart rates have been observed.7
Using Doppler ultrasound, flow and flow velocity waveforms can be meas-
ured in various fetal vessels and over the atrioventricular (AV) orifices of
the fetal heart. In the present study, longitudinal data are presented on
blood flow over the AV orifices of 17 fetuses of type-1 diabetic women.
It was the aim of this study to investigate if with good glucose control,
achieved with continuous subcutaneous insulin infusion (CSII), normal
blood flow over the fetal heart can be achieved.
Methods
Seventeen pregnant women with type-1 diabetes, who attended the outpa-
tient clinic were asked to participate in this study. A detailed explanation
of the investigation was given before informed consent was obtained.
Initial Doppler recordings were attempted between 15 and 18 weeks gesta-
tion. Subsequent examinations were performed every 4 weeks until deli-
very. Blood flow velocities through mitral and tricuspid valve orifices and
diameters of these orifices were measured. Blood flow volumes through
the atrioventricular valve orifices were calculated using the equation:
Mean temporal flow velocity  x  A
Blood flow =
Cos q
In which A is the estimated area of the atrioventricular orifices and q is the
angle between the Doppler beam and the estimated direction of the blood
flow.
Flow over the atrioventricular valves was compared to normal fetal data
obtained in 28 control fetuses. Data of these control fetuses have been
published previously.8 All ultrasound studies were performed following the
same protocol as in an earlier study in normal fetuses by Reed et al.9
141
Diabetes mellitus and fetal circulation
Fetal weight percentile was estimated from abdominal area measurements
by two-dimensional ultrasound.
Maximal and mean temporal velocities, areas of AV orifices, ventricular
output and combined ventricular output corrected for estimated fetal
weight were evaluated. Ninety percent confidence intervals were calcula-
ted. Differences between fetuses of women with type-1 diabetes and con-
trol fetuses were analyzed. A normal distribution was present; therefore
paired t-test could be performed.
The mean duration of diabetes was 11 years with a range of 2-20 years.
According to the modified White classification two women had class B, five
class C and ten class D diabetes. In six patients tight metabolic control
with continuous subcutaneous insulin infusion had been started before
conception. In nine CSII treatment was started between 7 and 14 weeks of
gestation. Two women were well-controlled with conventional injections
and remained on this regimen during pregnancy. Eighty-five percent of the
women had a glycosylated Hb percentage (HbA1c) less than four standard
deviations above the mean at early gestation, whereas HbA1c was less than
2 SD above the mean in all cases at the end of gestation. Average HbA1c at
9 to 12 weeks gestation was 5.6 ± 0.4% (1SD), at 17 to 28 weeks 5.1 ± 0.4%
and at delivery 4.8 ± 0.6% with normal values of 4.0 to 6.3%.
Results
None of the newborns had a structural heart defect on two-dimensional
real time ultrasound. Five infants had a birth weight above the 90th percen-
tile (29%).
The control group consisted of 28 normal fetuses.8 Mean and maximal
temporal velocities were higher in fetuses of women with diabetes than in
controls throughout gestation and these differences were significant at
most ages. With increasing gestation the mean and maximum temporal
velocities of the AV orifices increased in both groups during gestation.
Maximal and mean temporal velocities however increased more with
increasing gestational age in fetuses of diabetic women than in the control
group (Table 1, Figure 1).
Until a gestational age of 32 weeks areas of mitral and tricuspid valves
were significantly larger in the diabetic group. Later in pregnancy these dif-
ferences disappeared (Table 1).
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Table 1
15-20 weeks
Maternal diabetes Control group p-value
MTV       L 10.7 +/- 1.2 9.8 +/- 1.8 NS
R 11.7 +/- 1.5 11.1 +/- 1.7 NS
V max     L 39.5 +/- 4.7 38.3 +/- 6.5 NS
R 43.5+/- 5.1 43.0 +/- 6.7 NS
Area     MO 0.197 +/- 0.134 0.086 +/- 0.034 0.001<2p<0.01
TO 0.198 +/- 0.120 0.100 +/- 0.040 0.001<2p<0.01
Output L 131.8 +/- 88.2 53.7 +/- 21.4 0.001<2p<0.01
R 141.3 +/- 77.9 66.7 +/- 25.2 0.001<2p<0.01
20-24 weeks
Maternal diabetes Control group p-value
MTV       L 13.2 +/- 1.7 11.2 +/- 2.0 0.001<2p<0.01
R 13.7 +/- 2.8 12.0 +/- 1.5 0.01<2p<0.05
V max   L 45.8 +/- 7.5 41.5 +/- 6.0 NS
R 47.3 +/- 8.0 44.7 +/- 6.3 NS
Area     MO 0.284 +/- 0.144 0.163 +/- 0.043 2p<0.001
TO 0.297 +/- 0.188 0.190 +/- 0.044 0.01<2p<0.05
Output L 232.7 +/- 99.5 112.1 +/- 33.2 2p<0.001
R 249.2 +/- 128.3 141.4 +/- 32.8 2p<0.001
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24-28 weeks
Maternal diabetes Control group p-value
MTV       L 14.2 +/- 2.5 13.1 +/- 2.0 NS
R 15.4 +/- 2.0 13.8 +/- 2.1 0.01<2p<0.05
V max     L 46.1 +/- 7.9 42.4 +/- 7.8 NS
R 50.8 +/- 5.0 46.2 +/- 8.4 0.01<2p<0.05
Area     MO 0.381 +/- 0.177 0.253 +/- 0.057 0.001<2p<0.01
TO 0.410 +/- 0.209 0.272 +/- 0.065 0.001<2p<0.01
Output L 347.9 +/- 119.9 199.7 +/- 56.4 2p<0.001
R 395.5 +/- 191.4 230.5 +/- 67.4 0.001<2p<0.01
28-32 weeks
Maternal diabetes Control group p-value
MTV       L 16.3 +/- 2.4 14.4 +/- 2.5 0.001<2p<0.01
R 16.2 +/- 2.5 14.6 +/- 2.8 0.01<2p<0.05
V max     L 48.6 +/- 7.3 44.9 +/- 8.3 NS
R 50.0 +/- 10.1 48.0 +/- 8.3 NS
Area     MO 0.555 +/- 0.222 0.388 +/- 0.079 0.001<2p<0.01
TO 0.644 +/- 0.234 0.425 +/- 0.077 2p<0.001
Output L 547.6 +/- 226.1 329.6 +/- 74.7 2p<0.001
R 611.9 +/- 218.3 372.5 +/- 86.1 2p<0.001
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32-36 weeks
Maternal diabetes Control group p-value
MTV      L 16.8 +/- 3.1 15.5 +/- 2.7 NS
R 17.4 +/- 2.9 15.8 +/- 2.0 0.01<2p<0.05
V max   L 49.0 +/- 10.2 45.3 +/- 8.7 NS
R 54.0 +/- 9.9 50.1 +/- 7.0 NS
Area     MO 0.691 +/- 0.313 0.557 +/- 0.074 NS
TO 0.700 +/- 0.258 0.653 +/- 0.238 NS
Output L 700.6 +/- 339.6 518.2 +/- 114.1 0.01<2p<0.05
R 730.3 +/- 260.8 605.5 +/- 184.7 NS
36-40 weeks
Maternal diabetes Control group p-value
MTV    L 18.8 +/- 4.7 15.2 +/- 2.3 0.001<2p<0.01
R 20.7 +/- 3.7 16.0 +/- 3.1 2p<0.001
V max     L 53.4 +/- 12.8 43.1 +/- 7.0 0.001<2p<0.01
R 62.1 +/- 9.5 49.4 +/- 7.7 2p<0.001
Area     MO 0.754 +/- 0.440 0.923 +/- 0.164 NS
TO 0.977 +/- 0.428 0.995 +/- 0.202 NS
Output L 708.7 +/- 329.4 820.4 +/- 164.4 NS
R 1102.9 +/- 395.2 915.1 +/- 229.3 NS
MTV in cm/s, Vmax in cm/s, Area in cm2, Output in ml/min
MO = Mitral orifice, TO = Tricuspid orifice, L = Left, R = Right
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Temporal velocities in diabetic and control fetuses
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Both the higher blood flow velocities and the greater AV orifices resulted in
an increased combined cardiac output in the fetuses of diabetic women,
absolute and per kilogram (kg) estimated fetal weight. Per kilogram esti-
mated fetal weight the mean total cardiac output was also greater, with an
average of 823 ± 308 ml/min/kg. In the case of diabetes the mean cardiac
output decreased during gestation. This in contrast to control fetuses in
which mean total cardiac output per kilogram estimated fetal weight
remained constant throughout gestation, with an average of 553 ± 153
ml/min/kg. In the control group the ratio of right to left ventricular output
decreased from 1.34 ± 0.28 at 15 weeks to 1.08 ± 0.28 at 40 weeks.8 This
decrease did not occur in the diabetic group and the ratios at 15 and 40
weeks were 1.2 ± 0.26 and 1.25 ± 0.29 respectively (Figure 2).
There was a positive relationship between the blood flow velocities obtai-
ned within two weeks before delivery and birth weight percentiles, and
three of the five infants weighing more than the 90th percentile had a
mean temporal velocity exceeding the normal range. Average birth weight
and distribution of weight percentiles were not different between the two
groups. The birth weights ranged from 2,590 to 5,250 g (mean 3,526 ± 587
g) in the control group and from 2,460 to 4,500 g (mean 3,296 ±  677 g) in
diabetic pregnancies.
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Discussion
Our data show that even in well-controlled diabetic pregnancies mean and
maximum temporal velocities over the fetal AV orifices were significantly
higher and increased more with advancing gestational age than those in
normal pregnancies. Also the combined ventricular output, absolute and
per kg estimated fetal weight, was greater in the fetuses of diabetic
women. These changes in fetal circulation might be a compensatory reac-
tion to the existence of a chronic hypoxemic situation. Such an existence is
suggested by the higher hemoglobin levels in newborns of diabetic
mothers as described in earlier publications10-12 and also by the elevated
number of nucleated red blood cells in well-controlled diabetic pregnan-
cies.10,13 Moreover, hypoxemia has been found at cordocentesis, especially in
case of increased maternal and fetal glucose levels.14 
Fetal hypoxemia may occur because of a relative immaturity of the placen-
ta, with an increased distance over which oxygen diffusion has to occur
from maternal to fetal side.6,15 
Our results are different from those found by Jaeggi et al. who found no
differences in indices of diastolic and systolic function between fetuses of
diabetic pregnancies and an age-matched control group.16
In the diabetic group a decrease of the ratio of the right to left ventricular
output did not occur. This indicates that there is a dominant role for the
right ventricle until the end of pregnancy, whereas in normal pregnancy
right and left ventricle transport both half of the cardiac output at the end
of gestation. The reason for this right ventricle dominance is to be found in
the fact that the head of the fetuses of women with diabetes is relatively
smaller than the body.17-19 Furthermore, as a result of the placental immatu-
rity more blood has to be transported to the placenta and the right ventri-
cle is responsible for delivery of blood to the placenta.
The control group of normal fetuses is from a population studied in 1987.
This group was chosen because the techniques used and validation imple-
mented were exactly comparable to the current study and measurements
were performed by the same observers. Recent flow measurements on
similar but updated ultrasound equipment show the same normal values,
although a coherent longitudinal study on a normal population has not
been undertaken.
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Two sites for fetal ventricular output are available, i.e. the AV orifices and
the great arteries. We performed measurements at the AV level since
Doppler frequency shift tracings at the AV orifices are more easily obtained
and have a lower velocity9, avoiding the problems in velocity aliasing. In
addition, the AV orifice has margins clearly defined by the bright echoden-
se spots of the fibrous AV annulus tissue and has a larger diameter than
the great artery orifices. The echodense spots allow an accurate diameter
measurement, whereas the large diameter reduces the relative impact of
errors of diameter measurement on the calculation of blood flow.20, 21
To minimize the variability of the method we calculated the mean tempor-
al velocity by integrating the Doppler frequency shift on three consecutive
cardiac cycles and performed these measurements three times. The diame-
ter of the AV orifices was measured five times, averaging the results. This
method was extensively validated in a previous study of which the results
were published earlier.21 We did not study the reproducibility of the ultra-
sound parameters regarding fetal weight estimation, nor did we study the
reliability of fetal weight estimation in type-1 diabetic pregnancies.
However, McLaren et al. found that the accuracy of predicting birth weight
among diabetic women is similar to that among women without diabetes,
regardless of the sonographic model used.22
Many publications have reported an abnormal ventricular filling pattern in
fetuses of type-1 diabetic mothers. The ratio between early and active ven-
tricular filling at the level of the ventricular valves is lower than in control
fetuses caused by an interventricular septal hypertrophy affecting cardiac
diastolic function and by differences in hematocrit and heart rate.23-28
A ventricular hypertrophy might enable the increased cardiac output
necessary in these fetuses. Rizzo et al. also showed that despite an ade-
quate metabolic control an interventricular septal hypertrophy occurs,
which affects cardiac diastolic function.23
We conclude that these data indicate significant differences in the fetal cir-
culation between normal pregnancy and well controlled type-1 diabetic
pregnancies and suggest the existence of a compensatory mechanism
which increases cardiac output and causes cardiac hypertrophy.
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Structural heart defects
Over the years there has been a steady increase in the number of patients
with a prenatally detected structural congenital heart disease. Despite
efforts to achieve the contrary, some pregnancies will end in intrauterine
death. In these patients the sole advantage of the prenatal diagnosis is to
facilitate thorough parental counseling concerning future pregnancies.
Another group consists of those patients, in whom prenatal diagnosis
detects severe fetal heart disease, precluding a reasonable quality of life.
In such circumstances parents may opt for termination of pregnancy or
choose for compassionate care. Compassionate care is generally opted for
if termination of pregnancy is not considered an option, based on the
socioreligious background, or if the heart defect has been detected after 24
weeks gestation. Prenatal diagnosis in this situation enables physicians to
prevent intensive, traumatic and lengthy treatment.
The primary goal of prenatal detection of cardiac defects is better care in
the immediate postnatal period. The most convincing justification for the
efforts taken would be to demonstrate that prenatally diagnosed patients
have a better chance of a good outcome. We therefore studied in chapter 2
the impact of prenatal diagnosis on management and outcome of new-
borns with congenital heart disease in a retrospective multi-center study.
In this study the incidence of metabolic acidosis in prenatally and postna-
tally diagnosed groups of patients with similar diagnoses was compared.
Although previous reports suggest a direct positive effect of prenatal
detection on immediate surgical outcome, our study did not allow such a
conclusion, most likely due to confounding factors such as different surge-
ons, different institutions and different protocols. Prenatal diagnosis howe-
ver, proved to prevent deterioration of the acid-base-equilibrium.
Significant differences were found for the worst arterial pH and for the
lowest preoperative base excess with severe acidosis being more common
among the postnatally diagnosed group. The study covers the entire spec-
trum of congenital heart disease and suggests that immediate manage-
ment of heart disease, facilitated by the prenatal diagnosis of the disease,
reduces the incidence and degree of acidosis and allows immediate stabili-
zation of the acid-base-equilibrium. Our study covered the subgroups with
and without ductal-dependent lesions. Significant differences for lowest
base excess and lowest pH in favor of the prenatal group were found in the
ductal-dependent group, while in patients with non-ductal-dependent
heart disease only lowest base excess differed significantly. This indicates
that especially the early initiation of Prostaglandin E1 (PGE1) administration
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in the ductal-dependent group may prevent acidosis. The difference in the
non-ductal-dependent group, although less significant, suggests that early
medical care other than PGE1 therapy is also a positive effect of prenatal
diagnosis. In conclusion, chapter 2 shows that a prenatal diagnosis reduces
the development of metabolic acidosis in the newborn patient with conge-
nital heart disease. Although no apparent positive effects on immediate
surgical outcome could be found optimization of the preoperative condi-
tion of the patient with severe congenital heart disease can be expected to
lead to improved longterm outcome and prevention of cerebral damage in
this fragile group of patients.
A subpopulation of the study group of chapter 2 is used in chapter 3. An in-
depth analysis of the occurrence of lactacidosis was performed and para-
meters of acidosis were more thoroughly investigated. This study was only
conducted in the Dutch patient groups since lactate measurements were
not a standard procedure in the two American centers participating in the
previous study. Two-hundred-and-nine patients with congenital structural
heart disease requiring surgery within 31 days of life were included.
Worst preoperative arterial lactate of the prenatally diagnosed group was
3.05 ±  0.35 versus 6.08 ± 0.45 mmol/L in the postnatal group, indicating a
significant difference in favor of the prenatally diagnosed group (P<0.001).
No significant differences in pH or base excess were found. Normalization
of preoperative lactate values occurred on average 21.5 hours after admis-
sion. The pH normalized 5.3 hours and base excess 0.41 hours after admis-
sion. Of the patients without a prenatal diagnosis 22.3% had a worst pre-
operative lactate greater than 7.5 mmol/L, while none of the patients with
a prenatal diagnosis had a worst lactate greater than 7.5 mmol/L (P=0.026).
Prenatal diagnosis, therefore, results in a better condition of the infants at
surgery and might also result in a decrease of the risk of cerebral damage,
since high lactate values (> 7.5 mmol/L) are correlated with cerebral dama-
ge and neurodevelopmental complications.
Normalization of lactate values takes significantly more time than normali-
zation of either pH or base excess, since titration of bicarbonate will almost
immediately normalize pH and base excess. The extend of the hypoxia and
the severity of the resulting acidosis threatening the neonatal brain, seem
therefore to be better reflected by lactate values. Several studies suggest a
predictive role of serum lactate measurements for adverse outcome, since
elevated lactate levels reflect tissue hypoperfusion and hypoxemia. Arterial
pH and base excess are poorer predictors of the outcome.
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Our study shows that the prenatal diagnosis of congenital heart disease
has a role in the prevention of lactate acidemia in the preoperative period
by optimizing direct neonatal therapy. In theory this should result in a bet-
ter longterm neurological outcome. A diagnosis of the cardiac lesion before
birth will allow physicians to initiate therapy immediately after birth and
help to prevent these problems.
In chapter 4 the correlations between prenatal detection of congenital
heart disease, preoperative indicators of acidosis and short and longterm
developmental outcome were investigated. One-hundred-and-seventeen
patients with congenital structural heart disease requiring surgery within
31 days of life were included in this study. In 15 cases (13%) a prenatal diag-
nosis was established, while 102 patients (87%) had a postnatal diagnosis
of the structural heart disease.
Preoperative values of lactate, pH and base excess levels were retrieved
from all patients and the occurrence of disturbed developmental outcome
at the age range of two to eight years was documented. Data were extra-
polated to a standardized and validated Dutch developmental scale. An
underperformance of more than 10% from the P90 was defined as disturbed
development. Patients were split into groups with extreme values of para-
meters of acidosis. Receiver Operating Characteristic (ROC) curves were
used for determining cut-off values for pH, base excess and lactate.
No significant differences in developmental outcome were found using
values for pH or base excess as a cut-off level. However, preoperative
lactate values exceeding 6.1 mmol/L resulted in a significant increase in
impaired developmental outcome. Of the children with a preoperative lac-
tate lower than 6.1 mmol/L, 15% had subsequent developmental problems
compared to 41% of the children with a lactate exceeding 6.1 mmol/L
(P=0.03; OR=3.88). Disturbed developmental outcome was encountered in
25.4% of the children in the postnatally diagnosed group compared to
13.3% in the prenatal group (P=0.50).
The purpose of this study was to investigate the prognostic values of diffe-
rent preoperative parameters concerning patients with congenital heart
disease. Worst preoperative lactate values appeared to be of prognostic
significance on developmental outcome, and 41% of the patients with a lac-
tate over 6.1 mmol/L had a disturbed development. The limited prognostic
value of pH can be explained, just as in the previous study, by the fact that
pH is easily and rapidly corrected with bicarbonate infusion, while lactate
better reflects the total oxygen debt experienced by the patient with con-
genital heart disease. Base excess is also not as good as lactate as a marker
156
Chapter 11
of tissue hypoxia, since its value is also dependent on the Pco2, thus exag-
gerating any metabolic acidosis. Lactate on the other hand is the end pro-
duct of anaerobic metabolism and is therefore an ideal parameter of pro-
longed hypoxia.
Chapters 2 and 3 show that prenatal diagnosis does help preventing the
development of severe acidosis and in chapter 4 a significant correlation
between preoperative lactate values and disturbed developmental outcome
has been documented. Therefore a positive effect of a prenatal diagnosis of
congenital heart disease on developmental outcome might be expected if
larger numbers would be analyzed.
Chapter 5 concerns a retrospective study on the management and outcome
of prenatally diagnosed cases of hypoplastic left heart syndrome (HLHS). At
an estimated prevalence of 1 to 4 per 10.000 life births the HLHS accounts
for 7 to 8% of congenital heart disease (CHD) and is the most common
cause of death due to heart disease in the newborn period. Hypoplastic left
heart syndrome is readily detectable before 20 weeks gestation by echocar-
diographic examination of the four-chamber view. It is the most serious of
structural cardiac malformations diagnosed prenatally and is characterized
by severe underdevelopment of the structures in the heart-aorta complex,
including the left ventricular cavity and mass.
In this descriptive paper we present the experience with HLHS in the
Wilhelmina Children’s Hospital over a period of 13 years and compare its
management strategy with that of centers in the United Kingdom (UK) and
United States (US). The percentages of the intention-to-treat group are 34%
(our study) versus 36% (Andrews et al.; UK). There was a slight difference in
the choice of termination of pregnancy (50% vs 60%) and more so for com-
passionate care (16% vs 3.5%) between our study and that of the UK respec-
tively. If we compare both European studies with the study by Allan et al.
from the United States, a striking difference is encountered in the distribu-
tion of the various treatment options (P<0.05). In the USA study the inten-
tion-to-treat group constitutes 67% of all patients, whereas the group of
parents that opt for termination of pregnancy constitutes only 13%. In 20%
of all cases parents declined treatment.
Prenatal diagnosis of the HLHS provides opportunities to get patients in
optimal preoperative condition when surgery is offered. It also facilitates
in-depth counseling of the parents on this severe malformation.
The parents of our Dutch study population faced with the difficult decision
of possible termination of pregnancy, compassionate care or surgical
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strategy, choose in a minority for surgical treatment. The different parental
approach to this structural cardiac anomaly may be attributed to different
socioreligious opinions on the management of this type of lesion as well as
to differences in counseling of the parents. Apparently clinicians and
parents in Europe are more concerned with the longterm psychoneurologi-
cal outcome which is grim in these patients and the prospective quality of
life. This policy might well change in the future since survival rates of the
Norwood procedure are improving, although the poor longterm neurophy-
siological outcome remains a major issue. The difference in early survival
between the surgical groups with and without a prenatal diagnosis of the
anomaly is likely based on the more stable preoperative clinical condition
of the prenatally diagnosed patients.
Chapter 6 deals with the experience of prenatally diagnosed Ebstein’s ano-
maly. A review of the literature on Ebstein’s anomaly is performed and the
cases encountered at the Wilhelmina Children’s Hospital are described.
While HLHS forms one extreme of the spectrum of CHD, dysplastic malfor-
mations of the tricuspid valve form the other extreme. They range from
deformation of the leaflets and the tension apparatus without downward
displacement (primarily described as dysplasia) to lesions in which the pri-
mary lesion is a downward displacement of the proximal attachment of
the posterior and septal leaflets, known as Ebstein’s malformation.
The prevalence, fetal and maternal risk factors and echocardiographical
features are described. Moreover, the occurrence of associated anomalies
is portrayed.
Once the crucial neonatal phase is survived and pulmonary problems have
been overcome, the outlook of these newborns becomes favorable and
comparable to that of older children and adults in whom this diagnosis is
made in later life. This is emphasized and furthermore the literature is
reviewed for the intrauterine course and postnatal interventions and out-
come. In our series prenatal diagnosis of isolated Ebstein’s anomaly was
established in four patients. Of these four fetuses two died in utero; in one
case the parents opted for compassionate care and one infant is alive 9
years after operation.
We conclude that Ebstein’s anomaly remains a severe and frequently fatal
disorder in the fetus with gross echocardiographic abnormalities, readily
detectable by routine obstetrical ultrasound. In general, the earlier the
patient presents with the malformation, the poorer the prognosis. Fetal
and neonatal presentation is typically associated with a dismal outcome
secondary to the almost always occurring pulmonary hypoplasia. This ‘early
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group’ constitutes a specific entity and cannot be compared with patients
in whom the anomaly is detected later in life. Parental counseling of these
patients therefore can not be based upon the natural history of this disea-
se in older patients. Surgical procedures of tricuspid valve repair or replace-
ment may be offered, but this option is almost exclusively possible in
patients who are older, i.e. after the neonatal period. Unfortunately only
very few patients with a prenatal diagnosis of Ebstein's disease survive the
perinatal period. For some congenital heart defects (e.g. hypoplastic left
heart syndrome, transposition of the great arteries and coarctation of the
aorta) prenatal diagnosis will frequently lead to a better outcome.
Ebstein's anomaly is an example of CHD that is easily detectable in utero
because of the severity of the lesion but still has an unfavorable outcome
compared to cases that present in later life.
In chapter 7 we have investigated patients with congenital heart disease
who were diagnosed prenatally in the Utrecht area and analyzed the
management and outcome of this disease after prenatal detection. In addi-
tion we analyzed all patients requiring surgery for congenital heart disease
in the newborn period and assessed the overlap between both groups.
One-hundred-and-seventy patients with a prenatal diagnosis of congenital
heart disease were included. Spontaneous intrauterine death occurred in 23
patients. Parents chose to terminate the pregnancy in 56 cases. Over half of
the patients with a prenatal diagnosis (n=91) were born alive. In 29
patients parents declined treatment and 24 patients were operated on in
the neonatal period. The other 38 patients underwent elective surgery after
the neonatal period or did not need surgery at all. In the same period 191
patients were operated on for congenital heart disease; only 24 (13%) of
them had a prenatal diagnosis of their cardiac defect and formed the over-
lap with the prenatal group.
Unfortunately within the surgery group of 167 patients without a previous
prenatal diagnosis a mismatch existed between the efforts to diagnose the
majority of congenital heart disease and the actual percentage of prenatal-
ly diagnosed cases. It is regrettable that a large number of patients had
numerous prenatal ultrasound studies which were reported as normal,
while the defect should have been visible on the four-chamber view. It is in
this group that improvement is necessary in view of the positive effects of
prenatal diagnosis on the prevention and deterioration of the acid-base-
equilibrium. An increased emphasis on the evaluation fetal cardiac structu-
res by gynecologists and echographists is required. Better training provided
by pediatric cardiologists seems to be crucial to achieve this goal. A discre-
pancy exists between the supposed potential of the ultrasound
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examination of the fetal heart and the actual situation in the Netherlands.
There is room for improvement.
Rhythm disorder
Chapter 8 concerns a study which was conducted to demonstrate that pre-
natal diagnosis may also have beneficial effects for rhythm disorders. This
study focuses on the in utero diagnosis and treatment of a specific form of
fetal tachycardia as a primary condition: fetal atrial flutter (AF). Atrial flut-
ter occurs in approximately 0.2% of all pregnancies. The atrial rate is more
than 250 beats per minute with a fixed or variable AV block, resulting in a
variable ventricular response.
In this multi-center study we investigated the management of a popula-
tion of 44 cases diagnosed prenatally. Since the management and outcome
of the AF appeared to be influenced by the presence of fetal hydrops, the
study population was divided into a hydropic (n=20) and nonhydropic
(n=24) group. The conversion rate to sinus rhythm in utero among the
pharmacologically treated fetuses was slightly better for the nonhydropic
(n=17) than for the hydropic (n=18) group with 89% (n=16) and 65% (n=11)
respectively. Despite adequate treatment, recurrence of AF occurred fre-
quently at birth, namely 24% in the hydropic group (n=4) and 11% in the
nonhydropic group (n=2). More importantly fetal hydrops was associated
with neurological morbidity in 4 cases (3 cerebral hypoxic-ischemic lesions
and one hemorrhagic lesion) and with mortality in 3 cases.
This study shows that patients with hydrops are more difficult to treat
than those without any signs of hydrops fetalis. The decision to initiate
pharmacological intervention in the case of AF seems clear but can be
inferred based on several factors, i.e. age at presentation, state of fetal lung
maturation and existence of hydrops or associated structural heart disease.
This must be weighed against possible maternal and/or fetal adverse
effects inherent to the use of antiarrhythmics. In this retrospective study
the drug of first choice was digoxin. Although digoxin had shown to be
successful in most patients in our study, we have abandoned this drug as
the drug of first choice due to the requirement of high maternal serum
levels to reach therapeutic levels in the fetus. In the presence of fetal
hydrops this drug has a slow and only partial transplacental transfer.
The safety and efficacy of sotalol (a noncardioselective beta-adrenergic-
blocking agent and its class III antiarrhythmic properties) have led to the
use of this drug as the drug of first choice, especially since no recurrence of
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AF was detected at birth after use of sotalol in 8 cases treated thus far.
Digoxin is a second-line drug since it may have a positive inotropic effect
on the compromised function of the fetal heart, besides its antiarrhythmic
properties.
In conclusion a prenatal diagnosis of the arrhythmia is beneficial for the
fetus as undiagnosed cases may deteriorate into a hemodynamic unfavora-
ble situation which may lead to neurological damage or even intrauterine
death. Just as in structural heart disease (chapter 4) fetuses with sustained
AF at birth may be compromised requiring direct intervention at birth to
restore sinus rhythm and prevent cerebral damage or neonatal death.
Diabetic pregnancies and congenital heart disease
As gravid diabetic patients form the single largest maternal referral popu-
lation for prenatal cardiac investigation, we have investigated both the
morphological and the physiological impact of this disease on the fetal
cardiovascular system. In chapter 9 we describe a multi-center study which
aim was to study the pattern of cardiac anomalies among offspring of
pregnancies complicated by type-1 diabetes mellitus. Assessment of peri-
conceptional glycemic control, reflected by glycosylated hemoglobin
(HbA1c) levels during the first trimester is also important.
We studied the incidence and the spectrum of congenital cardiac malfor-
mations among fetuses and neonates born to mothers with type-1 diabetes
mellitus in two Dutch and one American populationgroups and combined
our data with those reported in the literature. These combined data were
compared to the incidence and pattern encountered among the offspring
of unselected women from the EUROCAT Registry Northern Netherlands.
Combining the cardiac anomalies encountered in our study population
with those in the literature shows that a quarter of all anomalies could be
defined as conotruncal malformations (CTM): transposition of the great
arteries (TGA) accounted for 49% of the CTM, followed by tetralogy of
Fallot (TOF) with 25%, persistent truncus arteriosus (PTA) with 15% and dou-
ble-outlet right ventricle (DORV) with 2.6%. When we compared these data
with that of EUROCAT, a significant increased incidence was found for TGA,
PTA, single ventricle and visceral heterotaxia. First trimester HbA1c values
of diabetic pregnancies complicated by CHD were higher than those resul-
ting in the birth of a healthy infant.
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Our study reveals a high incidence of complex anomalies of laterality and
looping, and of conotruncal malformations among the offspring of type-1
diabetes pregnancies. The high incidence of conotruncal septation defects
suggests a profound teratogenic effect during the first weeks of gestation.
These anomalies are ductal-dependent for sustained pulmonary and syste-
mic blood flow and are particularly amenable to early medical and surgical
intervention.
The data for the Netherlands show that also with only slightly increased
HbA1c values, the incidence of CHD is still increased. Near normoglycemia
apparently is not good enough. These children might hopefully have an
improved outlook when periconceptional care in these pregnancies is fur-
ther optimized but till then one should benefit from an in utero diagnosis
of the CHD. In conclusion these findings stress the importance of adequate
diabetes control, prenatal diagnosis of CHD and sophisticated neonatal
care.
In chapter 10 anatomically normal fetuses of women with type-1 diabetes
were studied to evaluate the impact of the disease on the fetal circulation.
Longitudinal data were obtained on blood flow over the AV orifices. Blood
flow velocities through mitral and tricuspid valve orifices were measured
and blood flow volumes were calculated and compared to those of control
fetuses.
Mean and maximum temporal velocities over the fetal AV orifices and the
combined ventricular output were significantly higher in the diabetic preg-
nancies. These changes in fetal circulation might be a compensatory reac-
tion to the existence of a chronic hypoxemic situation caused by a relative
immaturity of the placenta, with an increased distance over which oxygen
diffusion has to occur from maternal to fetal side. Contrary to the control
group, in the diabetic group a decrease of the ratio of right to left ventricu-
lar output did not occur in the course of gestation. This indicates that a
dominant role for the right ventricle remains until the end of gestation in
diabetic pregnancies. The reason for this right ventricle dominance might
be the fact that more blood has to be transported to the immature placen-
ta, for which the right ventricle is responsible and that the head of fetuses
of women with diabetes is relatively smaller than the body. We conclude
that these data indicate significant differences in the fetal circulation
between normal pregnancy and well-controlled type-1 diabetic pregnancies
and suggest the existence of a compensatory mechanism that increases
cardiac output.
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In conclusion, we can state that prenatal diagnosis of heart disease, both
morphological and functional, may influence management of pregnancy
and outcome of affected fetuses. It is the most important positive effect of
prenatal diagnosis that the sequence of planned delivery in a center, equip-
ped to treat this type of patients and the immediate installment of
appropriate therapy may lead to an improved longterm outcome. Lactate
levels reflecting the overall oxygen deficiency experienced seem to be a
good indicator to measure this possible positive effect. Planned delivery
and immediate therapy may keep lactate levels of affected fetuses below
6.1 mmol/L, providing a safe starting point for surgical intervention with
better chances of a normal neurophysiological development.
The two extreme sides of the spectrum of prenatally encountered congeni-
tal heart disease described in this thesis, the hypoplastic left heart syndro-
me and Ebstein’s anomaly, indicate that in these cases morphology might
dominate outcome in a negative manner. This implies that even in the best
managed pregnancies, delivery and immediate care of these patients do
not assure a favorable longterm outcome.
Finally the data concerning the well-controlled diabetic pregnancies show
that this maternal disease infringes on both the fetal cardiac anatomy and
circulation. The higher incidence of congenital heart disease is predomi-
nantly located in the conotruncal region. The circulatory changes encoun-
tered in the structurally normal heart occur later in gestation and suggest
being adaptive to ensure an increased cardiac output.
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Prenatale diagnostiek van hartafwijkingen
De toename van het gebruik van geavanceerde ultrasound technologie
heeft het mogelijk gemaakt om een steeds groter aantal vormen van car-
diale problematiek van de foetus reeds voor de geboorte te diagnosticeren.
De positieve bijdrage hiervan is gelokaliseerd in het optimaliseren van het
management van deze patiënten tijdens de zwangerschap, de bevalling en
in de neonatale periode, teneinde ze in een zo goed mogelijke conditie aan
het cardiale behandeltraject te laten beginnen. In dit promotie-onderzoek
worden achtereenvolgens een aantal aspecten van deze prenatale diagnos-
tiek beschreven.
Structurele hartafwijkingen
Aangeboren hartafwijkingen worden in toenemende mate voor de geboor-
te vastgesteld en vormen een zeer belangrijke groep prenataal gediagnos-
ticeerde aandoeningen. Hoewel al het mogelijke in het werk gesteld wordt
om deze patiënten een optimale behandeling te bieden, eindigt toch nog
altijd een relatief groot aantal van deze zwangerschappen in een intra-ute-
riene vruchtdood. In dergelijke gevallen is het enige voordeel van de prena-
tale diagnose dat de ouders voorbereid waren op de mogelijk slechte uit-
komst en dat ze geadviseerd kunnen worden met betrekking tot eventueel
volgende zwangerschappen.
Daarnaast is er de groep patiënten bij wie een zeer ernstige hartafwijking
voor de geboorte wordt vastgesteld en bij wie – door de ernst van de afwij-
king – geen vooruitzichten zijn op een aanvaardbare kwaliteit van leven na
de geboorte. In zulke gevallen kunnen de ouders besluiten de zwanger-
schap af te laten breken. Wanneer de ouders niet voor een abortus kiezen
of wanneer de diagnose van de zeer ernstige afwijking na de 24e zwanger-
schapsweek wordt gesteld, kunnen ze eveneens besluiten over te gaan tot
een abstinerend beleid na de geboorte. In deze gevallen voorkomt de pre-
natale diagnostiek een langdurige en intensieve behandeling na de
geboorte; een behandeling, die voor alle betrokken partijen traumatisch
kan zijn.
Het belangrijkste voordeel van de prenatale diagnostiek ligt echter bij de
groep die na de geboorte met spoed een chirurgische ingreep dient te
ondergaan in verband met een aangeboren hartafwijking. Bij deze patiën-
ten biedt prenatale diagnostiek de mogelijkheid om direct na de geboorte
met de juiste therapie te starten, waardoor mogelijk de uiteindelijke prog-
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nose gunstig beïnvloed wordt. Daarom hebben wij in hoofdstuk 2 in een
retrospectief multi-center onderzoek de invloed van prenatale diagnostiek
op behandeling en uiteindelijke uitkomst bestudeerd bij patiënten met een
aangeboren hartafwijking. Het optreden van een verstoring van het zuur-
base evenwicht werd daarbij als uitkomstparameter gehanteerd bij patiën-
ten met en zonder prenatale diagnose.
Eerdere studies hebben een lagere mortaliteit aangetoond bij een prenata-
le diagnose van een aantal goed omschreven diagnoses. Ons onderzoek
heeft zich specifiek gericht op de preoperatieve conditie van een brede
range van patiënten met aangeboren hartafwijkingen, waarbij werd uitge-
gaan van de slechtste preoperatieve waarden. In dit onderzoek werd een
significant verschil in het optreden van ernstige acidose gevonden in het
voordeel van patiënten met een prenatale diagnose. Zowel het preoperatie-
ve base excess als de preoperatieve pH was significant lager in de groep
waarbij de diagnose pas na de geboorte werd gesteld. In dit onderzoek was
het gehele spectrum van ernstige aangeboren hartafwijkingen vertegen-
woordigd. De resultaten wijzen erop dat een prenatale diagnose en aan-
sluitend anticiperend neonataal ingrijpen ervoor kunnen zorgen dat het
zuur-base evenwicht gestabiliseerd wordt en een ernstige verzuring voor-
komen wordt.
De patiënten werden tevens onderverdeeld in groepen met al dan niet duc-
tus-afhankelijke aandoeningen. Bij de groep afwijkingen, waarbij de circu-
latie afhankelijk was van het persisteren van de ductus Botalli, werden sig-
nificante verschillen in base excess en pH gevonden in het voordeel van de
prenataal gediagnosticeerde groep, terwijl bij patiënten met niet-ductus-
afhankelijke aandoeningen alleen de base excess significant verschilde.
Deze resultaten suggereren dat vooral de onmiddellijke toediening van
Prostaglandine E1 (PGE1) in de ductus-afhankelijke groep een positief effect
heeft op het voorkomen van metabole acidose. Daarnaast tonen de resulta-
ten in de niet-ductus-afhankelijke groep dat ook bij patiënten die niet
gebaat zijn bij een PGE1 behandeling, de snelle en goed gecoördineerde
start van de juiste zorg een positieve invloed heeft.
Concluderend tonen de resultaten beschreven in hoofdstuk 2 een positieve
invloed van prenatale diagnostiek van aangeboren hartafwijkingen op het
voorkomen van ernstige acidose tijdens de preoperatieve periode. Het is te
verwachten dat prenatale diagnostiek en de daarbij behorende handhaving
van het zuur-base evenwicht op de lange termijn tot een betere uitkomst
van deze kwetsbare patiëntenpopulatie zullen leiden met vooral een afna-
me van de incidentie van hersenbeschadiging als gevolg.
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In hoofdstuk 3 wordt een deel van de patiëntenpopulatie uit hoofdstuk 2
opnieuw onderzocht en wordt het optreden van lactaatacidose verder uit-
gediept. Aangezien lactaatmetingen alleen in de Nederlandse populatie als
standaard verricht werden, werden de twee Amerikaanse populaties uit het
vorige hoofdstuk niet in deze studie betrokken. Er werden 209 patiënten
geïncludeerd, die in de neonatale periode chirurgie nodig hadden voor hun
aangeboren hartafwijking. De slechtste preoperatieve lactaatwaarden
waren in de groep met een prenatale diagnose aanmerkelijk minder ernstig
dan in de groep zonder prenatale diagnose, respectievelijk 3.05 ± 0.35 en
6.08 ± 0.45 mmol/L (P<0.001). De verschillen tussen beide groepen voor
wat betreft base excess en pH waren niet significant. De preoperatieve lac-
taatwaarden waren gemiddeld 21.5 uur na opname weer normaal, terwijl
dit bij de pH al na 5.3 uur en bij het base excess na 0.4 uur het geval was.
Een slechtste preoperatieve lactaatwaarde van meer dan 7.5 mmol/L kwam
voor bij 22% van de patiënten bij wie de diagnose na de geboorte gesteld
was en bij geen van de patiënten met een prenatale diagnose (P=0.026).
Extreme lactaatwaarden (>7.5 mmol/L) zijn gecorreleerd met hersenschade,
neurologische complicaties en ontwikkelingsachterstand.
Titratie van bicarbonaat normaliseert vrijwel onmiddellijk de waarden van
base excess en pH. Het duurt veel langer voordat de waarden van lactaat
gecorrigeerd zijn. De ernst van de hypoxie en de daaruit voortkomende aci-
dose worden dan ook het beste weergegeven door bepaling van het lac-
taatgehalte. Lactaatwaarden weerspiegelen de doorgemaakte hypoxie en
hypoperfusie van het weefsel en hebben een grotere prognostische beteke-
nis met betrekking tot mortaliteit en morbiditeit dan pH en base excess.
De studie, die in dit hoofdstuk beschreven wordt, toont aan dat een prena-
tale diagnose mogelijkheden biedt om patiënten met een ernstige conge-
nitale hartafwijking zodanig te stabiliseren dat een lactaatacidose in de
preoperatieve periode voorkomen wordt. Door de onmiddellijke start van
de benodigde therapie kan hierdoor mogelijk neurologische schade beperkt
worden.
Aangezien de operatiemortaliteit van veel aangeboren hartaandoeningen
tegenwoordig laag is, is de aandacht langzaam verschoven van korte ter-
mijn naar lange termijn resultaten, zoals het al dan niet optreden van her-
senbeschadiging of van een ontwikkelingsachterstand bij kinderen met een
aangeboren hartafwijking. Daarom wordt in hoofdstuk 4 de relatie onder-
zocht tussen prenatale diagnostiek, preoperatieve parameters van acidose
en het optreden van een ontwikkelingsachterstand op latere leeftijd. In
deze studie werden 117 patiënten geïncludeerd die in de neonatale periode
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chirurgie nodig hadden voor hun aangeboren hartafwijking. Vijftien van
deze patiënten (13%) waren reeds prenataal gediagnosticeerd, terwijl in 102
gevallen (87%) de diagnose pas na de geboorte gesteld werd. Van al deze
patiënten werden de preoperatieve waarden van lactaat, base excess en pH
verzameld en werd onderzocht of er een samenhang was met het optreden
van een ontwikkelingsachterstand op de leeftijd van 2 tot 8 jaar.
Retrospectieve gegevens werden geëxtrapoleerd naar het Van Wiechen ont-
wikkelingsschema. Een ontwikkelingsachterstand werd in deze studie
gedefinieerd als een achterstand in ontwikkeling van tenminste 10% op de
P90 volgens het Van Wiechen ontwikkelingsschema. Door gebruik te maken
van de verschillende parameters voor acidose werden de patiënten in groe-
pen onderverdeeld. Met behulp van Receiver Operating Characteristic cur-
ves werden de afkapwaarden voor lactaat, base excess en pH gevonden
met de beste combinatie van sensitiviteit en specificiteit.
De preoperatieve pH en base excess waren niet gerelateerd aan het optre-
den van een ontwikkelingsachterstand. Preoperatieve lactaatwaarden
boven 6.1 mmol/L leidden daarentegen significant vaker tot een ontwikke-
lingsachterstand op latere leeftijd. Van de patiënten met een preoperatief
lactaat boven 6.1 mmol/L kreeg op kinderleeftijd 41% te maken met een
ontwikkelingsachterstand ten opzichte van 15% bij de groep met een lac-
taat onder 6.1 mmol/L (P=0.03; OR=3.88). In de groep waarbij de diagnose
voor de geboorte werd gesteld, ontstond in 13% van de gevallen een ont-
wikkelingsachterstand in vergelijking met 25% in de groep waarbij pas na
de geboorte de diagnose gesteld werd (P=0.50).
Concluderend was alleen een hoog lactaatgehalte gecorreleerd met een
significant hogere kans op het ontstaan van een ontwikkelingsachterstand.
Dat lactaat een betere voorspellende waarde heeft dan pH en base excess
kan verklaard worden door het feit dat de pH snel en gemakkelijk door
titratie van bicarbonaat gecorrigeerd kan worden en dat base excess behal-
ve van de mate van verzuring ook van de Pco2 afhankelijk is, waardoor
mogelijk al aanwezige verzuring versterkt en overdreven wordt. Lactaat,
daarentegen, is het eindproduct van de anaërobe verbranding en daarmee
een goede parameter van doorgemaakte hypoxie.
In de hoofdstukken 2 en 3 is aangetoond dat het voor de geboorte vaststel-
len van een aangeboren hartafwijking leidt tot het voorkomen van versto-
ringen van het zuur-base evenwicht na de geboorte. In hoofdstuk 4 wordt
de invloed van hoge lactaatwaarden op het ontstaan van een ontwikke-
lingsachterstand op latere leeftijd aangetoond. Daarmee is een gunstig
effect van prenatale diagnostiek van aangeboren hartafwijkingen op het
ontstaan van een ontwikkelingsachterstand aannemelijk gemaakt.
169
Nederlandse samenvatting
In hoofdstuk 5 wordt de behandelingsstrategie bij een prenataal vastge-
steld hypoplastisch linker hart syndroom (HLHS) beschreven. Deze afwij-
king wordt gekarakteriseerd door een ernstige onderontwikkeling van het
linkerventrikel- en aortasysteem. Met een geschatte incidentie van 1 tot 4
per 10.000 levendgeborenen, omvat het HLHS 7 tot 8 procent van alle aan-
geboren hartafwijkingen en is het de meest voorkomende oorzaak van
sterfte als gevolg van hartziekte in het eerste levensjaar. Het HLHS is door
middel van echoscopie goed te herkennen in de eerste helft van de zwan-
gerschap (<20 weken). Het is een van de meest ernstige vormen van hartaf-
wijkingen die prenataal gediagnosticeerd kunnen worden.
In dit onderzoek beschrijven wij de ervaring met het prenataal vastgestel-
de HLHS bij patiënten die behandeld zijn in het Wilhelmina Kinder-
ziekenhuis over een tijdsperiode van 13 jaar en vergelijken wij de verschil-
lende behandelstrategieën met die van kinderhartcentra in het Verenigd
Koningrijk (VK) en de Verenigde Staten (VS).
Het percentage kinderen, bij wie gekozen werd voor operatief ingrijpen
(‘intention-to-treat’) bedroeg in onze studie 34 procent en dat kwam goed
overeen met dat van een onderzoek in het VK (36%). De keuze voor zwan-
gerschapsafbreking verschilde slechts in geringe mate tussen onze popula-
tie en die van het VK (50% en 60% respectievelijk), terwijl in onze populatie
vaker sprake was van een abstinerend beleid na de geboorte (16% en 3,5%).
De behandelingsstrategie in het Amerikaanse onderzoek was echter aan-
zienlijk anders: in 67 procent van de gevallen werd daar gekozen voor een
chirurgische behandeling, in 13 procent voor zwangerschapsafbreking en in
20 procent voor een abstinerend beleid.
Vroegtijdige diagnose van het HLHS schept dus niet alleen de mogelijkheid
tot het verlenen van optimale perinatale zorg om de pasgeborene in de
preoperatieve periode in goede conditie te houden, maar verschaft ook tijd
voor advisering en begeleiding van de ouders zonder dat de medische en
emotionele aspecten tijdens de acute neonatale situatie een goede beslis-
sing in de weg staan. De ouders in onze populatie kozen in een minderheid
voor een postnataal chirurgisch beleid. De verschillende benadering van
deze ernstige hartafwijking kan mogelijk toegeschreven worden aan ver-
schillen in sociale of religieuze gevoelens over het omgaan met deze aan-
doening, maar ook aan een andere manier van informeren en adviseren van
de ouders. Blijkbaar leggen de ouders en artsen in Europa momenteel meer
de nadruk op de slechte lange termijn prognose van deze kinderen en zien
daarom vaker af van een operatieve behandeling. Dit kan in de toekomst
170
Chapter 12
veranderen aangezien de overlevingskansen na de chirurgische ‘Norwood’
procedure lijken te verbeteren, hoewel de lange termijn neurologische
prognose nog zeer twijfelachtig blijft.
In hoofdstuk 6 wordt de ervaring met de prenataal gediagnosticeerde
Ebstein’s malformatie (EM) beschreven en worden enkele aspecten van
deze aandoening nader toegelicht. De Ebstein’s malformatie is een dysplas-
tische afwijking van de tricuspidalis klep (TK), die gekenmerkt wordt door
een apicale verplaatsing van de proximale aanhechting van de achterste en
septale klepbladen. Naast de Ebstein’s malformatie is er nog een andere –
en minder ernstige – vorm van primaire dysplasie, waarbij de dysplastische
afwijking van de tricuspidalis klep niet gepaard gaat met een apicale ver-
plaatsing.
Wij beschrijven vier patiënten bij wie de Ebstein’s malformatie prenataal in
het Wilhelmina Kinderziekenhuis vastgesteld werd. Van deze vier kinderen
stierven er twee intra-uterien, kozen de ouders in een casus voor een absti-
nerend beleid en is een kind 9 jaar na operatieve interventie in leven.
Wij concluderen op basis van onze gegevens en van die van de literatuur
dat de Ebstein’s malformatie in de foetale periode een zeer ernstige en
vaak letale hartafwijking is. Presentatie in utero gaat vaak gepaard met de
aanwezigheid van longhypoplasie en daarom ook met een slechtere prog-
nose. Indien de patiënt echter de cruciale neonatale periode overleeft en
longcomplicaties vermeden kunnen worden, verbetert de prognose voor de
pasgeborene aanzienlijk. Deze is dan zelfs te vergelijken met de prognose
van kinderen en volwassenen, bij wie de aandoening op latere leeftijd werd
vastgesteld.
Wanneer deze aandoening prenataal wordt vastgesteld, dan mag, bij het
informeren en adviseren van ouders, het advies niet gebaseerd zijn op het
beloop zoals we dat kennen bij oudere patiënten, maar dient het grote risi-
co op sterfte in utero en in de neonatale periode aan bod te komen.
Aangezien slechts enkele patiënten met een prenatale diagnose van
Ebstein’s malformatie de perinatale periode overleven, moet ouders duide-
lijk gemaakt worden dat chirurgische behandeling of vervanging van de tri-
cuspidalisklep alleen aangeboden kan worden aan oudere kinderen die de
risicovolle neonatale periode overleven. In tegenstelling tot veel andere
structurele hartafwijkingen, leidt prenatale diagnostiek van Ebstein’s mal-
formatie helaas niet tot een betere overleving.
In hoofdstuk 7 is bij de Utrechtse patiëntenpopulatie bij wie prenataal
een aangeboren hartafwijking werd vastgesteld, gekeken naar de
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behandelingsmodaliteiten en de uiteindelijke uitkomst. Deze populatie is
vervolgens vergeleken met het totale aantal kinderen dat in de neonatale
periode geopereerd werd in verband met een aangeboren hartafwijking.
De bijdrage van prenatale diagnostiek op het verloop van de aandoening
en op het tijdig chirurgisch aanbieden van de patiënten werd daarmee
geïnventariseerd.
Honderdenzeventig patiënten met een prenataal vastgestelde aangeboren
hartafwijking werden geïncludeerd. Bij 23 van hen eindigde de zwanger-
schap in een intra-uteriene vruchtdood en in 56 gevallen werd door de
ouders besloten de zwangerschap af te laten breken. Meer dan de helft van
de kinderen (n=91) werd levend geboren. Bij deze kinderen werd in 29
gevallen voor een abstinerend beleid gekozen en werden 24 patiënten in de
neonatale periode geopereerd. Bij de overige 38 patiënten hoefde niet chi-
rurgisch ingegrepen te worden. In dezelfde periode werden in totaal 191
patiënten in de neonatale periode geopereerd aan een aangeboren hartaf-
wijking. Bij slechts 24 van hen (13%) was dus sprake van een diagnose voor
de geboorte.
Helaas is er derhalve sprake van een 'mismatch' tussen de pogingen om bij
zoveel mogelijk patiënten de diagnose voor de geboorte te stellen en het
percentage prenataal gediagnosticeerde patiënten dat na de geboorte een
operatie behoefde. Bij verreweg de meeste patiënten die geopereerd wer-
den was de diagnose pas na de geboorte gesteld, terwijl bij een groot aan-
tal van hen prenataal wel echoscopisch onderzoek was verricht. Doorgaans
was hierbij de hartafwijking niet onderkend, terwijl deze in veel gevallen
toch goed zichtbaar geweest moet zijn op het vierkamerbeeld. Eerder is
reeds gewezen op de voordelen van prenatale diagnostiek van hartafwij-
kingen. Een grotere nadruk op eventuele cardiale problematiek van de foe-
tus lijkt bij de opleiding van echoscopisten en gynaecologen dan ook
gewenst om de grote discrepantie tussen de potentie van prenatale echo-
scopie van aangeboren hartafwijkingen en de huidige praktijk in Nederland
te verkleinen.
In hoofdstuk 8 wordt de betekenis van prenatale diagnostiek op het ver-
loop van hartritmestoornissen geïllustreerd aan de hand van een specifieke
ritmestoornis, de boezemflutter. Deze foetale hartritmestoornis komt voor
bij ongeveer 0,2 procent van alle zwangerschappen. De frequentie van de
atria (boezems) bedraagt bij deze aandoening meer dan 250 slagen/min,
met een vast of variabel atrioventriculair (AV) blok, resulterend in een 
wisselende respons van de kamers.
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In een multi-center studie evalueerden wij de behandeling van 44 kinderen
bij wie de diagnose voor de geboorte gesteld was. Aangezien de behande-
ling en uitkomst van de boezemflutter sterk beïnvloed worden door het al
dan niet aanwezig zijn van foetale hydrops, werd de studiepopulatie onder-
verdeeld in een hydropische (n=20) en een nonhydropische (n=24) groep.
Bij 35 patiënten, waarbij werd getracht het hartritme door pharmaco-
therapeutisch ingrijpen te corrigeren, blijkt de conversie-ratio naar een
normaal sinus ritme beter te zijn voor de nonhydropische (n=16/18; 89%)
dan voor de hydropische groep (n=11/17; 65%). Ondanks zorgvuldige behan-
deling, vond zowel in de hydropische groep (24%) als in de nonhydropische
groep (11%) een terugval in de ritmestoornis plaats rond de partus.
Drie van de hydropische kinderen overleden in de perinatale periode terwijl
bij vier sprake was van ernstige neurologische morbiditeit (hypoxisch-
ischemische hersenlaesie bij drie kinderen en hemorrhagische hersenlaesie
bij een pasgeborene).
Dit onderzoek toont aan dat hydropische patiënten moeilijker te behande-
len zijn dan patiënten zonder tekenen van hydrops foetalis. Prenatale phar-
macotherapeutische interventie is vooral van belang om foetale hydrops te
voorkomen. Besluit tot deze interventie is echter ook afhankelijk van facto-
ren als zwangerschapsduur, foetale longrijpheid, de aanwezigheid van
hydrops foetalis of andere structurele hartafwijkingen en (mogelijke)
maternale en/of foetale bijwerkingen van anti-arrhythmica.
In dit retrospectieve onderzoek was digoxine het medicament van eerste
keus. Hoewel digoxine bewezen effectief is bij de behandeling van deze
foetale ritmestoornis, heeft de noodzaak van het verkrijgen van hoge, door-
gaans subtoxische bloedspiegels bij de moeder om een therapeutisch
effect bij de foetus te behalen, ons doen besluiten een ander medicament
als eerste keus aan te raden. Dit is mede ingegeven door het feit dat dig-
oxine in aanwezigheid van hydrops slechts langzaam en in beperkte mate
de placenta passeert. Onze huidige eerste keus is sotalol. Dit is een veilig
en effectief, niet-cardioselectief anti-beta-adrenergicum met klasse III anti-
aritmische eigenschappen. Tot dusverre zagen wij tijdens het gebruik van
sotalol bij acht patiënten geen terugkeer van de boezemflutter vóór of bij
de geboorte. Digoxine wordt nog wel gebruikt als middel van tweede keus,
mede vanwege het positief inotropisch effect van dit middel op het niet
optimaal functionerende foetale hart.
Naar onze mening draagt tijdige prenatale diagnostiek en behandeling
van deze hartritmestoornis bij tot preventie van foetale hydrops en daar-
mee van neurologische schade en intra-uteriene sterfte. Net als bij de
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structurele hartafwijkingen hebben foetussen met boezemflutter bij de
geboorte baat bij de mogelijkheid van directe interventie om het sinusrit-
me te herstellen en daarmee hersenschade of sterfte te voorkomen.
Moederlijke diabetes en aangeboren hartafwijkingen
Zwangeren met diabetes vormen een grote verwijspopulatie voor prenatale
diagnostiek van hartafwijkingen. Daarom hebben wij de invloed van deze
metabole ziekte op zowel de morfologische als functionele ontwikkeling
van het hart bestudeerd. In hoofdstuk 9 beschrijven we een multi-center
studie waarin we de frequentie en het spectrum van aangeboren hartafwij-
kingen onderzochten bij kinderen van vrouwen met type-1 (insuline afhan-
kelijke) diabetes mellitus. Dit werd onderzocht in een Amerikaanse en twee
Nederlandse populaties. Deze data werden gecombineerd met gegevens uit
de literatuur. De gecombineerde gegevens werden vergeleken met de inci-
dentie en het patroon van aangeboren hartafwijkingen bij nakomelingen
van een ongeselecteerde populatie vrouwen uit de EUROCAT registratie in
Noord-Nederland.
Zowel in onze studiepopulatie als in de literatuur over diabetes en zwan-
gerschap, bleek dat een kwart van alle afwijkingen zijn oorsprong had in de
conotruncale (CT) regio: transpositie van de grote vaten (TGV) vormde 49%
van alle CT afwijkingen, gevolgd door tetralogie van Fallot (TOF; 25%), per-
sisterende truncus arteriosus (PTA; 15%) en double-outlet right ventricle
(DORV; 2,6%). Deze afwijkingen kwamen veel vaker voor dan in de normale
populatie (EUROCAT). In geval van een hartafwijking was bij onze studie-
populatie het HbA1c – als maat van de bloedglucoseregulatie in de vooraf-
gaande weken - in het eerste trimester significant hoger dan dat bij de
overige zwangeren met diabetes.
Dit onderzoek toont een hoge incidentie van complexe hartafwijkingen van
lateraliteit en looping en van conotruncale oorsprong bij kinderen van
vrouwen met type-1 diabetes. De hoge incidentie van conotruncale afwij-
kingen suggereert een sterk teratogeen effect tijdens de eerste weken van
de zwangerschap. Deze afwijkingen zijn voor een pulmonale en systemi-
sche circulatie doorgaans afhankelijk van de ductus Botalli, en daardoor is
directe instelling van prostaglandine medicatie en aansluitend operatief
ingrijpen vaak noodzakelijk.
De Nederlandse gegevens uit dit onderzoek tonen ook dat bij slechts
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gering verhoogde HbA1c waarden, de incidentie van aangeboren hartafwij-
kingen reeds toeneemt. Bijna-normale HbA1c waarden zijn blijkbaar niet
goed genoeg. Dit wijst er op dat de bloedsuikerregulatie rondom de con-
ceptie nog verder verbeterd moet worden. Prenatale diagnostiek blijft ech-
ter van belang.
In hoofdstuk 10 wordt de invloed van type-1 diabetes op de foetale circula-
tie bestudeerd. Bij 17 foetussen zonder structurele hartafwijkingen werden
de stroomsnelheid en het volume van de bloedstroom door de mitralis en
tricuspidalis openingen bepaald. De gegevens werden vergeleken met die
van een controlegroep.
Bij de zwangerschappen gecompliceerd door diabetes, was zowel de gemid-
delde en hoogste stroomsnelheid over de AV-kleppen, als de gecombineer-
de ventriculaire ‘output’ significant verhoogd. Deze veranderde foetale cir-
culatie kan een compensatie zijn voor de aanwezigheid van een toestand
van chronische hypoxie, die wordt veroorzaakt door de relatieve immaturi-
teit van de placenta, waarbij de diffusie-afstand tussen het maternale en
foetale bloed groter is. Bij de controlegroep daalde de verhouding tussen
de ‘output’ van de rechter harthelft en de linker harthelft in het verloop
van de zwangerschap ten gunste van links; bij de foetussen van moeders
met diabetes vond deze verandering niet plaats en bleef de verhouding
constant. Dit duidt erop dat de rechter harthelft bij deze laatste groep tot
aan het eind van de zwangerschap een dominante rol blijft spelen. De ver-
klaring voor deze rechtsdominantie is tweeledig. Enerzijds is er een ver-
hoogde bloedstroom in de richting van de immature placenta noodzakelijk,
waarvoor de rechter harthelft verantwoordelijk is en anderzijds is het
hoofd van kinderen van moeders met diabetes relatief klein ten opzichte
van het lichaam.
Concluderend kan gesteld worden dat de foetale circulatie bij moederlijke
type-1 diabetes aanzienlijk verschilt van die van ongecompliceerde zwan-
gerschappen. De veranderingen bij diabetes berusten mogelijk op een com-
pensatiemechanisme en op andere anatomische verhoudingen.
Als conclusie van dit proefschrift menen wij te kunnen stellen dat prenata-
le diagnostiek bij zowel morfologische als functionele hartafwijkingen een
positieve invloed kan hebben op de behandeling en de uiteindelijke uit-
komst van deze zwangerschappen. Het belangrijkste positieve effect van
een prenatale diagnose betreft anticipatie op postnatale opvang: een
bevalling in een ziekenhuis met een kinderhartcentrum, dat gespeciali-
seerd is in de behandeling van dit soort patiëntjes, waardoor onmiddellijk
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met de benodigde therapie gestart kan worden. Dit leidt in het algemeen
tot een betere preoperatieve conditie en in dit proefschrift werd ook een
betere lange termijn ontwikkeling gevonden.
In dit proefschrift werden twee extreme vormen van aangeboren hartafwij-
kingen beschreven, namelijk het hypoplastisch linker hartsyndroom en
Ebstein’s malformatie. In beide gevallen leidt prenatale diagnostiek in ons
onderzoek niet tot een betere uitkomst, aangezien de prognose van de
hartafwijking momenteel te slecht is.
Tenslotte tonen de gegevens van zwangeren met type-1 diabetes, dat deze
ziekte, zelfs wanneer deze goed gecontroleerd is, invloed heeft op zowel de
foetale cardiale anatomie als op de foetale circulatie. De hoge incidentie
hartafwijkingen bij deze groep blijkt vooral in de conotruncale regio gelo-
kaliseerd te zijn. De circulatieveranderingen bij foetussen met een normale
cardiale anatomie treden later in de zwangerschap op en lijken een com-
pensatie te zijn om voldoende ‘cardiac output’ te waarborgen.
Adviezen naar aanleiding van onze bevindingen:
1 Bij het prenataal echografisch onderzoek van de foetus verdient het aanbe-
veling het ritme en het vierkamerbeeld van het hart te evalueren teneinde
ernstige en levensbedreigende pathologie uit te sluiten.
2 Bij twijfel omtrent de aanwezigheid van een normaal hartritme of vierka-
merbeeld dient de patiënt naar een derdelijns diagnostisch centrum verwe-
zen te worden.
3 In aanwezigheid van een afwijkend hartritme of afwijkende intracardiale
anatomie verdient het aanbeveling de patiënt in een centrum te laten
bevallen waar directe cardiale evaluatie en behandelingsmogelijkheden
aanwezig zijn.
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